

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<u>http://bmjopen.bmj.com</u>).

If you have any questions on BMJ Open's open peer review process please email <u>info.bmjopen@bmj.com</u>

BMJ Open

BMJ Open

Health-related quality of life and wellbeing in people over 75 years of age with end-stage kidney disease managed with dialysis or comprehensive conservative care: a crosssectional study in the UK and Australia

Journal:	BMJ Open
Manuscript ID	bmjopen-2018-027776
Article Type:	Research
Date Submitted by the Author:	15-Nov-2018
Complete List of Authors:	Shah, Karan; NHMRC Clinical Trials Centre, Health Economics Murtagh, Fliss; Wolfson Palliative Care Research Centre, Hull York Medical School, University of Hull, UK, McGeechan, Kevin; The University of Sydney, School of Public Health; Crail, Su; Royal Adelaide Hospital Burns, Aine; Royal Free Hospital Tran, Anh; NHMRC Clinical Trials Centre Morton, Rachael; The University of Sydney, NHMRC Clinical Trials Centre
Keywords:	Chronic renal failure < NEPHROLOGY, Chronic renal insufficiency, Dialysis < NEPHROLOGY, PALLIATIVE CARE, HEALTH ECONOMICS, Quality of life

SCHOLARONE [™]	
Manuscripts	

 Title: Health-related quality of life and wellbeing in people over 75 years of age with endstage kidney disease managed with dialysis or comprehensive conservative care: a crosssectional study in the UK and Australia

Karan Shah, Fliss E M Murtagh, Kevin McGeechan, Su Crail, Aine Burns, Anh D Tran, Rachael L Morton

- National Health and Medical Research Council (NHMRC) Clinical Trials Centre, The University of Sydney, NSW, Australia
- Wolfson Palliative Care Research Centre, Hull York Medical School, University of Hull, UK

ien

- 3. School of Public Health, The University of Sydney, NSW, Australia
- 4. Royal Adelaide Hospital, SA, Australia
- 5. Royal Free Hospital, London NHS Foundation Trust, UK

Corresponding Author:

Karan Shah, MSc.

Health Economics, NHMRC Clinical Trials Centre,

The University of Sydney,

92-94 Parramatta Road, Camperdown NSW 2050, Australia

Tel: +61 2 9562 5030

Fax: +61 2 9562 5387

Email: karan.shah@ctc.usyd.edu.au

Word Count: 3358

ABSTRACT

Objective

 Decisions regarding treatment of older people with end-stage kidney disease need to be supported by information about the impact of dialysis on health-related quality of life (HRQoL) and wellbeing. Few data exist from patients aged 75 years of age or older.

Design

Prospective cross-sectional study.

Setting

3 renal units in the UK and Australia.

Participants

129 ESKD patients managed with dialysis or with an estimated glomerular filtration $(eGFR) \le 10 \text{ml/min}/1.73 \text{m}^2$ and managed with comprehensive conservative, non-dialytic care.

Outcome measures

HRQoL and wellbeing were assessed using Short-Form six dimensions (SF-6D, 0-1 scale); KDQOL-36 (0-100 scale) and Investigating Choice Experiments Capability Measure–Older people (ICECAP-O, 0-1 scale). Linear regression assessed associations between treatment, HRQoL and wellbeing. Pearson's correlation coefficient assessed convergent validity between instruments.

Results

Median age of 81 years [IQR 78–85], 65% males; 83(64%) were managed with dialysis and 46(36%) with conservative care. When adjusted for treatment type and sociodemographic variables, those managed on dialysis reported lower mean SF-6D utility (-0.05, 95%CI -0.12 to 0.01); lower KDQOL Physical component summary score (-3.17, 95%CI -7.61 to 1.27); lower Mental component summary score (-2.41, 95%CI -7.66 to 2.84); lower quality of life due to burden (-28.59, 95%CI -41.77 to -15.42); symptoms (-5.93, 95%CI -14.61 to 2.73), and

 effects of kidney disease (-16.49, 95%CI -25.98 to -6.99); and lower overall ICECAP-O wellbeing (-0.07, 95%CI -0.16 to 0.02) than those managed conservatively. Correlation between ICECAP-O wellbeing and SF-6D utility scores was strong overall, 0.65 (p<0.001), but weak to moderate at domain level.

Conclusions

Older people on dialysis report significantly higher burden and effects of kidney disease than those on conservative care. Lower HRQoL and wellbeing may be associated with dialysis treatment, and should inform shared decision making about treatment options.

Trial registration

UK (IRAS project ID: 134360 & REC reference 14/LO/0291) and Australia (R20140203 HREC/14/RAH/36).

KEYWORDS

Chronic Kidney Failure, Chronic Renal Insufficiency, Renal Dialysis, Quality Of Life, Palliative Care

STRENGTHS AND LIMITATIONS OF THIS STUDY

- The strengths of our study include a prospective assessment of HRQoL in people over 75 years of age, and the use of a novel measure to value wellbeing.
- This information is essential for doctors to discuss the relative benefits of dialysis compared with conservative care.
- The limitation of this study is that, the sample size may not have been sufficient to detect a statistically significant difference in mean scores if one existed.
- We did not have complete data on patient's comorbid conditions that may have impacted our ability to explore the associations between comorbid conditions and HRQoL or wellbeing.
- Considering the cross-sectional nature of the data, we were unable to analyse any changes relating to individuals' HRQoL or wellbeing over time, which might be captured in a longitudinal study.

INTRODUCTION

Comprehensive conservative care services were developed for people with end-stage kidney disease (ESKD) in the UK and Australia following the substantial increase in the number of older people aged \geq 75 years being referred to nephrologists for dialysis,[1]. Comprehensive conservative care includes interventions to delay the progression of kidney disease and minimise complications, as well as detailed communication, shared decision-making, advance care planning, and psychologic and family support, but does not include dialysis,[2]. For older patients who often have high levels of comorbidity (such as diabetes and heart disease) and poor functional status, the survival advantage of dialysis may be limited, and comprehensive conservative management may be considered; however, robust comparative evidence remains minimal,[2]. Considerations such as symptoms, quality of life, and hospital-free days are sometimes more important for patients and families, than expected length of survival,[2].

Traditionally, economists attempt to assist resource allocation decisions by focusing on measuring and valuing health (in its broadest sense), using health-related quality of life (HRQoL) measures and survival, in particular combined in the quality-adjusted life year (QALY),[3]. In QALY calculations, values (often referred to as utility scores) are assigned to different health states, which allows the quantification of health gains comprising both length and quality of life gains from medical interventions,[3, 4]. Utilities are preference weights, where preference can be equated with value or desirability,[5, 6]. The quality adjusted life years (QALYs) value is then calculated by combining the length of survival and the utility weights.

However, many healthcare interventions may impact more broadly on quality of life (assumed to encompass the broad range of factors that are important to people in living their lives) rather than just health (which centers on physical and mental health),[3]. These broad factors could

be related to health and non-health factors that may impact the overall quality of life of a patient,[4]. Measures that look only at health in assessing the impact of these interventions would be very likely to underestimate this impact,[3, 7].

Dialysis has a large impact on the quality of life of both patients and their families; however, traditional HRQoL measures, such as the Short Form 36 (SF-36) and Kidney Disease Quality of Life (KDQOL-36) surveys may be too narrowly focused to detect all of the critical aspects of dialysis that increase or decrease an individual's quality of life,[8]. KDQOL-36TM is a short form questionnaire that includes the SF-12, a generic quality of life questionnaire,[9, 10] plus disease-specific domains including the burden of kidney disease, symptoms/problems of kidney disease, and effects of kidney disease. For this purpose, broader HRQoL measures, often named wellbeing measures, could be used to capture more facets of peoples' lives than health status alone,[4].

New instruments have been developed that provide information across health and social care, rather than just across health,[3]. The recently developed "Investigating Choice Experiments Capability Measure (ICECAP)" family of instruments have been designed to incorporate such dimensions,[11]. These instruments have their theoretical grounding in Amartya Sen's work on the relationships between functioning and capability,[11, 12]. They seek to measure a conceptually different evaluative space through a focus on capabilities: that is, what a person is able to do and who they are able to be, rather than on functioning: what a person actually does and who they become,[13]. Capabilities refer to the potential to achieve certain states and perform certain actions,[4]. Having the capability to live life the way one desires is obviously important, also to older people, and reduction of this capability limits their wellbeing,[4, 14, 15]. There is little research on how the ICECAP-O is related to other conceptualisations of

BMJ Open

wellbeing, and the relationships between the ICECAP-O and measures of health (physical, psychological, and social) remain underexplored,[16].

The aims of the study were to measure HRQoL using SF-12 questionnaire, kidney disease quality of life using KDQOL-36TM questionnaire, and wellbeing using ICECAP-O questionnaire; to determine the association between treatment type and socio-demographic characteristics on these outcome measures; to assess the convergent validity between the ICECAP-O wellbeing and the SF-6D utility (derived from SF-12 questionnaire); and to assess the feasibility and acceptability of questionnaires in older ESKD patients.

MATERIALS AND METHODS

Study design

We conducted a cross-sectional study of patients with ESKD treated with dialysis or comprehensive conservative care in the UK and Australia between 2014 and 2017. The study was performed in accordance with the Australian National Statement on Ethical Conduct in Human Research (2007), and relevant guidance in the UK. Each renal unit participating in the study obtained the approval of their Institutional Research Boards UK (IRAS project ID: 134360 & REC reference 14/LO/0291) and Australia (R20140203 HREC/14/RAH/36). The study design conformed to the STROBE guidelines for observational studies (Item S1). Eligible subjects were fully informed about the purpose, benefits and risks of the study, and signed an approved participant consent form.

Setting and participants

The study was undertaken at three renal units in the UK and Australia. Included were males and females aged \geq 75 years with ESKD, managed with dialysis (facility hemodialysis, home hemodialysis, and peritoneal dialysis) or with an estimated glomerular filtration (eGFR) \leq 10ml/min/1.73m² and managed with comprehensive conservative, non-dialytic care. The exclusion criteria comprised cognitive impairment; patients unable to read English; and patients who were legally blind. To reduce selection bias, nephrologists and clinical nurses in each participating renal unit reviewed their clinic lists for all patients that met the eligibility criteria.

Patient and public involvement

The research question was developed from prior qualitative work with people with end-stage kidney disease and their carers,[17-19]. Patients were not directly involved in the design of this research study. Patients and their caregivers were informed of the study and invited to participate by the renal unit's research nurses. Participants were provided with an information sheet and consent from for them to read. If they were interested in participating they were asked to sign the consent form and then were provided with the surveys. Patients and their caregivers were assured that participation was entirely voluntary, that they did not have to participate and that their decision either way would not affect their clinical care.

Outcomes and variables

The key outcomes were SF-6D utilities derived from the SF-12 questions, KDQOL scores from the KDQOL-36 questions, ICECAP-O capability index derived from the ICECAP-O questions. Other outcomes were convergent validity between ICECAP-O wellbeing and the SF-6D utility instrument measured using the Pearson's correlation coefficient; and the feasibility and acceptability of the ICECAP-O and SF-12 questionnaires, assessed by response rate and specific items asking the patient whether the questionnaire was easy to complete, and whether it covered questions important to their quality of life and wellbeing.

Data sources/measurement

All eligible patients were invited to complete the KDQOL-36TM (Item S2) and the five-question ICECAP-O questionnaire (Item S3) while at their renal clinic. Relevant sociodemographic details such as age, sex, country, educational attainment, private health insurance and questions assessing feasibility and acceptability of the ICECAP-O and SF-12 questionnaire were collected (Item S4). Kidney treatment type (facility hemodialysis, home hemodialysis, peritoneal dialysis, and comprehensive conservative care), dialysis status (if currently on dialysis, and time of initiation) and renal transplant status were documented.

Health related quality of life questionnaire

The KDQOL-36 has 36 items: the SF-12 version 1 and another 24 kidney specific items,[20]. The SF-12 responses on the KDQOL-36 were transformed into HRQoL weights, known as utilities, using a published SF-6D algorithm,[21]. The SF-6D is a generic preference-based single measure of health used to generate utilities from six domains: physical, role, social, pain, mental, and vital (Item S5). The SF-6D utilities generated are measured on a 0 (death) to 1 (full health) scale, and were reported with mean and standard deviations (SDs) using UK population values,[21-23].

The SF-12 section of KDQOL-36 also yields PCS (Physical Component Summary) and MCS (Mental Component Summary) scores, both of which are scored on a T-score metric (mean = 50, SD = 10, for the US general population),[20, 24]. The three kidney specific scales assess Burden of Kidney Disease, Symptoms of Kidney Disease, and Effects of Kidney Disease. Each of these scales is scored by transforming all items to a 0 to 100 possible range and averaging across the items on each scale to create scale scores,[20]. KDQOL-36 items are all scaled so that higher scores indicate better HRQoL,[20, 25].

Wellbeing questionnaire

The ICECAP-O questionnaire measures capabilities and covers five domains of wellbeing, including attachment (love and friendship); security (thinking about the future without concern); role (doing things that make you feel valued); enjoyment (enjoyment and pleasure); and control (independence),[26]. It has four-level response options, representing four levels of capability: none, a little, a lot, and all. The responses on the ICECAP-O questions were transformed to a ICECAP-O capability index ranging from 0 (no capability) to 1 (full capability), and presented with mean and SDs using UK population weights,[3].

Quantitative variables

The SF-6D utilities, KDQOL scores, ICECAP-O capability index, and patients' age were treated as continuous, while patients' sex, treatment type (dialysis, conservative care), education (some high school or lower levels, completed high school or higher levels), private health insurance (yes, no), and health system (UK, Australia) were analysed as categorical variables. Age was also additionally dichotomised (less than or equal to, versus greater than the median age [81 years]).

Statistical methods

The analysis of data involved descriptive statistics assessing proportions and mean values of the SF-6D utilities, PCS, MCS, Burden of Kidney Disease, Symptoms of Kidney Disease, Effects of Kidney Disease scores, and the ICECAP-O capability index for the entire cohort. Hypothesis testing with a two-tailed Student's t-test was used to detect differences in the mean values of SF-6D utilities, KDQOL-36 scores, and ICECAP-O capability index for patients' treatment type and socio-demographic characteristics. We hypothesised that HRQoL and wellbeing measures in each treatment group would be equivalent.

BMJ Open

Linear regression with multivariable models was undertaken to determine the association between treatment type and patient characteristics on SF-6D utilities, KDQOL scores and ICECAP-O capability index. In the multivariable linear regression, age, sex, treatment type, education, private health insurance, and health system were included as covariates on the basis of *a priori* knowledge of their associations with the HRQoL and wellbeing measures.

Pearson's correlation coefficient was used to determine the convergent validity of the ICECAP-O wellbeing with the SF-6D utility instrument. The correlations were assessed for the overall ICECAP-O and SF-6D utility scores and their domains. We hypothesised, moderate to strong positive correlations because both these instruments measures some similar facets of quality of life. Correlations above 0.5 were considered strong, between 0.3 and 0.5 as moderate, and below 0.3 as weak,[16].

Complete case analysis was performed for all outcomes. All statistical analyses were performed with SAS Version 9.4 (SAS Institute, Cary, NC). A p-value of <0.05 was considered statistically significant.

RESULTS

A total of 129 patients were recruited, including 83 (64%) managed with dialysis and 46 (36%) patients managed with comprehensive conservative care. Overall, 65% were male, and the median age of the entire cohort was 81 years [IQR 75–78]. Patient characteristics are shown in Table 1.

Health-related quality of life SF-6D utilities

Of 129 patients, the mean utility for 116 patients with complete data was 0.62 (SD 0.14) (n = 13 missing values). The mean SF-6D utilities for the dialysis group were 0.61 (SD 0.13), and 0.65 (SD 0.15) for the conservative care group (Table S1). The "vitality" domain reported the highest average score, and was responsible for the highest decrement in utilities in both treatment groups (Table S2).

The mean SF-6D utilities were 0.07 (SD 0.14) lower for females than for males (p = 0.006); 0.06 (SD 0.14) lower for patients residing in the UK compared with those residing in Australia (p = 0.03); and 0.07 (SD 0.14) lower for patients without a private health insurance compared to patients with a private health insurance (p = 0.03) (Table S1). When adjusted for all variables, the mean SF-6D utilities were 0.09 lower for females compared to males (95 % lower CI = -0.14 and upper CI = -0.03, p = 0.002). There was no significant difference in the mean utilities observed between two treatments when adjusted for other variables (Table 2).

KDQOL scores

The mean KDQOL scores on the five domains for patients with complete data were as follows: PCS score of 32.41 (n = 115, SD 9.68); MCS score of 47.25 (n = 115, SD 11.34); Burden of Kidney Disease score of 44.46 (n = 127, SD 31.28); Symptom/Problems of Kidney Disease score of 72.78 (n = 125, SD 19.03); and Effects of Kidney Disease score of 70.24 (n = 127, SD 22.35).

In univariate analysis the PCS score was 5.46 points lower in females than males (p = 0.004) (i.e. lower physical health); the MCS score was 4.63 points lower in Australian versus UK patients (p = 0.03) (i.e. lower mental health) table S1 and table S3. The Burden of Kidney Disease score was 28.12 points lower in the dialysis group than the conservative care group (p

BMJ Open

< 0.001) (indicating a higher burden of disease and lower quality of life); 14.06 points lower in UK versus Australian patients (p = 0.01) (indicating higher burden of disease); 13.70 points lower in patients without private health insurance compared to those with private health insurance (p = 0.04) (indicating a higher burden of disease). The Effects of Kidney Disease score was 17.11 points lower in the dialysis group compared to the conservative care group (p< 0.001) (indicating higher effects of the disease and lower quality of life); 8.35 points lower in UK versus Australian patients (p = 0.03) (indicating higher effects of the disease).

The dialysis group reported a higher MCS score (47.67 vs 46.56), indicating marginally better mental health than the conservative care group. (Table S2).

When adjusted for other variables, the mean score for the Burden of Kidney Disease sub-scale was 28.59 lower (i.e. more burdensome) for patients on dialysis compared with patients on conservative care (p<0.001) (Table 2, Figure 1). The mean score for Effects of Kidney Disease when adjusted for all the other variables, was 16.49 lower (i.e. higher disease related effects) for patients on dialysis compared with patients on comprehensive conservative care (p<0.001) (Table 2, Figure 2). Adjusted scores were lower but not statistically, significantly different for PCS, MCS and Symptoms of Kidney Disease between the two treatment groups.

ICECAP-O capability index

The mean ICECAP-O capability index for 126 patients with complete data was 0.72 (SD 0.19) (n=3 missing values). In the dialysis group, the mean capability index was 0.71 (SD 0.19), and 0.76 (SD 0.20) for the conservative care group (Table S1), but not significantly different. Overall, the dialysis treatment group reported a lower wellbeing score on all five domains compared to the conservative care group. The "attachment" domain showed the highest average

score, and was responsible for the highest contribution to capabilities in both treatment groups (Table S2). When adjusted for other variables, there were no significant differences in the mean capability index observed between the two treatments (Table 2).

Convergent validity

For 114 observations the SF-6D utilities score and the pain domain of the SF-6D were strongly correlated with the overall ICECAP-O capability index with a Pearson's coefficient of 0.65 (p<0.001) and 0.56 (p<0.001) respectively. At the domain level, the role and control domains of the ICECAP-O questionnaire were strongly correlated with the pain domain of the SF-6D, with a Pearson's coefficient of 0.51 (p<0.001) and 0.53 (p<0.001) respectively. All other domains of the ICECAP-O were weakly or moderately correlated with SF-6D domains, values ranging from 0.02 to 0.49 (Table 3).

Feasibility and acceptability

115 of 129 patients completed the questionnaire, with 14 patients missing items for the ICECAP-O and 10 patients missing items for the SF-12. Overall, patients found both questionnaires easy to use and relevant to assessing their wellbeing. They responded with an average score of 1.78 out of 5 (1 = strongly agree, 5 = completely disagree) on questions assessing ease of use; and with an average score 1.77 and 1.79 out of 5 on the questions assessing the relevance of ICECAP-O and the SF-12 questions respectively.

DISCUSSION

This prospective cross-sectional study determined the mean SF-6D utilities, KDQOL scores and ICECAP-O capability index for patients with ESKD according to treatment, and sociodemographic variables. Our findings suggest females compared with males, patients residing

Page 15 of 48

BMJ Open

in the UK compared with those residing in Australia, and patients without private health insurance compared with those with private health insurance have significantly lower SF-6D utilities. However, when adjusted for the other variables, only females reported significantly lower utilities compared with males. Furthermore, the study determined the convergent validity between the ICECAP-O wellbeing and SF-6D utility instrument and assessed the feasibility and acceptability of the ICECAP-O wellbeing and SF-12 questionnaire in older people with ESKD.

The dialysis group reported 0.05 lower SF-6D utilities compared with the conservative care group reflecting a potentially clinically meaningful difference related to treatment, however, this difference was not statistically significant. Meaningful differences or the minimal important difference (MID) in utility-based HRQoL reported in 11 studies using the SF-6D utilities ranged from 0.011 to 0.097, with a mean MID of 0.041,[27]. It is therefore likely our study has detected a meaningful difference. In addition, a 0.05 difference in ICECAP-O wellbeing for dialysis patients may also represent a clinically meaningful difference, however, MIDs for ICECAP-O have not yet been published.

In our study, with the exception of a strong correlation between the "control" and "role" domain of the ICECAP-O with the "pain" domain on the SF-6D, most of the ICECAP-O domains were found to have weak to moderate correlations with the SF-6D corresponding domains. This indicates the newly developed capability instrument does measure different aspects of quality of life or wellbeing, and offers additional information when compared to measures of health, such as the SF-6D used in the conventional QALY approach. In addition, we observed a higher score for the feasibility and acceptability of the ICECAP-O questions indicating it to be acceptable and as relevant as SF-12 (an established HRQoL measure).

BMJ Open

There is debate in the health economics literature concerning the ways to apply the capability approach in economic evaluations with some suggesting that QALYs alone are adequate, while others argue this approach is too narrow, and that direct measures of capability or wellbeing provide a more extensive application of Sen's paradigm,[28]. Capability is empirically distinct from functioning and the content of capability instruments is not subsumed by the content of instruments used to capture changes in HRQoL for QALYs,[28].

Health economic analyses would benefit from the inclusion of individual capability measures; whether the focus should be only upon people's *achievements*—their "functioning"—or people's *capability to achieve* is contested,[28]. Sen's example of the fasting man versus the starving man serves as a key example for focusing on capability: two people, one of whom is starving and the other, who is fasting, have comparable functioning in terms of nourishment, but their capabilities to be nourished are notably different,[28]. The argument is that focusing on functioning alone would miss important distinctions, such as differences in freedom and choice between individuals,[28].

There are some limitations to this study. First, the sample size may not have been sufficient to detect a statistically significant difference in mean scores if one existed. Second, we did not have complete data on patient's comorbid conditions that may have impacted our ability to explore the associations between comorbid conditions and HRQoL or wellbeing. Third, considering the cross-sectional nature of the data, we were unable to analyse any changes relating to individuals' HRQoL or wellbeing over time, which might be captured in a longitudinal study. The strengths of our study include a prospective assessment of HRQoL in people over 75 years of age, and the use of a novel measure to value wellbeing. This

BMJ Open

information is essential for doctors to discuss the relative benefits of dialysis compared with conservative care.

In conclusion, we observed lower quality of life and wellbeing for older patients with ESKD managed on dialysis compared to comprehensive conservative care. Furthermore, measuring wellbeing using a capability index provides additional insights into the impact of dialysis on older people than HRQoL measurement alone and has potential to improve the economic evaluation of treatment for ESKD.

Topper textice on the o

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Acknowledgements

The authors gratefully acknowledge the patients who participated in this study; the research nurses from the UK and Australian renal units; and Dr Sherilyn Goldstone for proof reading the final version of the manuscript.

Authors' Contributions

Authors FM, KM, SC, AB, and RM designed the study. RM, SC and AB led the data collection. KS conducted the analysis and drafted the first version of the manuscript. RM, AT and KM supported the data analysis and interpretation of the results, and all authors revised the final version of the manuscript.

Funding

This work was supported by the NHMRC Early Career Researcher Fellowship and Sidney Sax – Public Health Overseas Fellowship (1054216) grant awarded to Rachael Morton for the conduct of the ICECAP-O study. Karan Shah is employed at the NHMRC Clinical Trials Centre, University of Sydney, and is fully funded by the institution. The remaining authors declare that they have no other relevant financial interests.

Competing interests

None of the authors declare a conflict of interest. The results presented in this paper have not been published previously elsewhere, either in whole or part, except in abstract format.

Ethics approval

The study was performed in accordance with the NHMRC National Statement on Ethical Conduct in Human Research (Commonwealth of Australia, 2007), and relevant guidance in the

UK. Each renal unit participating in the study obtained the approval of the Institutional Health Research Ethics Committee to conduct the study. The study approval numbers are as follow: UK (IRAS project ID: 134360 & REC reference 14/LO/0291) and Australia (R20140203 HREC/14/RAH/36).

Data sharing statement

Data for the study can be provided for specific research questions that are available from the corresponding author on request

Rectories only

Page 20 of 48

REFERENCES

 Morton RL, Turner RM, Howard K, et al. Patients who plan for conservative care rather than dialysis: a national observational study in Australia. Am J Kidney Dis. 2012;59(3):419-27.

 Murtagh FEM, Burns A, Moranne O, et al. Supportive Care: Comprehensive Conservative Care in End-Stage Kidney Disease. Clin J Am Soc Nephrol. 2016;11(10):1909-14.

3. Coast J, Flynn TN, Natarajan L, et al. Valuing the ICECAP capability index for older people. Soc Sci Med. 2008;67(5):874-82.

 Makai P, Beckebans F, van Exel J, et al. Quality of life of nursing home residents with dementia: validation of the German version of the ICECAP-O. PLoS One. 2014;9(3):e92016.

5. Weinstein MC, Torrance G, McGuire A. QALYs: the basics. Value Health. 2009;12:S5-S9.

6. Whitehead SJ, Ali S. Health outcomes in economic evaluation: the QALY and utilities. Br Med Bull. 2010;96(1):5-21.

7. Walker RC, Howard K, Tong A, et al. The economic considerations of patients and caregivers in choice of dialysis modality. Hemodialysis International. 2016;20(4):634-42.

 Murtagh FE, Marsh JE, Donohoe P, et al. Dialysis or not? A comparative survival study of patients over 75 years with chronic kidney disease stage 5. Nephrol Dial Transplant. 2007;22(7):1955-62.

 Ware Jr JE, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996;34(3):220-33.

BMJ Open

10. Wyld ML, Chadban SJ, Morton RL. Improving Our Understanding of Quality of Life in CKD. Am J Kidney Dis. 2016;67(6):820-1.

11. Chen G, Ratcliffe J, Kaambwa B, et al. Empirical Comparison Between Capability and Two Health-Related Quality of Life Measures. Soc Indic Res.1-16.

12. Al-Janabi H, Flynn TN, Coast J. Development of a self-report measure of capability wellbeing for adults: the ICECAP-A. Qual Life Res. 2012;21(1):167-76.

13. Coast J, Smith RD, Lorgelly P. Welfarism, extra-welfarism and capability: the spread of ideas in health economics. Soc Sci Med. 2008;67(7):1190-8.

14. Sen A. Choice, welfare, and measurement: Harvard University Press; 1997.

15. Grewal I, Lewis J, Flynn T, et al. Developing attributes for a generic quality of life measure for older people: preferences or capabilities? Soc Sci Med. 2006;62(8):1891-901.

Makai P, Koopmanschap MA, Brouwer WB, et al. A validation of the ICECAP-O in a population of post-hospitalized older people in the Netherlands. Health Qual Life Outcomes. 2013;11(1):57.

 Sellars M, Clayton JM, Morton RL, et al. An Interview Study of Patient and Caregiver Perspectives on Advance Care Planning in ESRD. Am J Kidney Dis.
 2018;71(2):216-24.

18. Walker RC, Howard K, Morton RL, et al. Patient and caregiver values, beliefs and experiences when considering home dialysis as a treatment option: a semi-structured interview study. Nephrol Dial Transplant. 2015;31(1):133-41.

 Morton RL, Tong A, Webster AC, et al. Characteristics of dialysis important to patients and family caregivers: a mixed methods approach. Nephrol Dial Transplant.
 2011;26(12):4038-46. **BMJ** Open

20. Peipert JD, Bentler PM, Klicko K, et al. Psychometric properties of the kidney disease quality of life 36-item short-form survey (KDQOL-36) in the United States. Am J Kidney Dis. 2018;71(4):461-8.

21. Brazier JE, Roberts J. The estimation of a preference-based measure of health from the SF-12. Med Care. 2004;42(9):851-9.

22. Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ. 2002;21(2):271-92.

23. Kharroubi SA, Brazier JE, Roberts J, et al. Modelling SF-6D health state preference data using a nonparametric Bayesian method. J Health Econ. 2007;26(3):597-612.

24. Ware JE, Keller SD, Kosinski M. SF-12: How to score the SF-12 physical and mental health summary scales: Health Institute, New England Medical Center; 1995.

25. Hays R, Spritzer K. KDQOL-36TM Scoring Program (v1. 0). 2000.

26. Flynn TN, Chan P, Coast J, et al. Assessing quality of life among British older people using the ICEPOP CAPability (ICECAP-O) measure. Appl Health Econ Health Policy.
2011;9(5):317-29.

27. Walters SJ, Brazier JE. Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D. Qual Life Res. 2005;14(6):1523-32.

28. Mitchell PM, Venkatapuram S, Richardson J, et al. Are Quality-Adjusted Life Years a Good Proxy Measure of Individual Capabilities? Pharmacoeconomics. 2017;35(6):637-46.

Patient Characteristics	Dialysis	Conservative	
	Diarysis	Care	Total
	n = 83	n = 46	n = 129
	n (%)	n (%)	n (%)
Dialysis			
Facility Haemodialysis	68 (82%)	-	68 (53%)
Home Haemodialysis	2 (2%)	-	2 (2%)
Peritoneal Dialysis	13 (16%)	-	13 (10%)
Median age (y)	81 [78-84]	83 [81-87]	81 [78-85
Age group			
≤81 years	50 (60%)	19 (41%)	69 (53%)
>81 years	33 (40%)	27 (59%)	60 (47%)
Sex			
Males	57 (69%)	27 (59%)	84 (65%)
Females	26 (31%)	19 (41%)	45 (35%)
Country			
United Kingdom	58 (70%)	9 (20%)	67 (52%)
Australia	25 (30%)	37 (80%)	62 (48%)
Education			
Primary school	26 (31%)	19 (41%)	45 (35%)
Some high school	35 (42%)	17 (37%)	52 (40%)
Completed high school	8 (10%)	3 (7%)	11 (9%)
Completed diploma	6 (7%)	3 (7%)	9 (7%)
Completed university degree	7 (8%)	3 (7%)	10 (8%)
Private Health Insurance			
Yes	15 (18%)	14 (30%)	29 (22%
No	65 (78%)	29 (63%)	94 (73%
Unknown	1 (1%)	1 (2%)	2 (2%)

Table 1: Patients characteristics according to treatment group

	Differences†	95 % Lower CI	95 % Upper CI	p value
SF-6D utilities	-0.05	-0.12	0.01	0.12
KDQOL-PCS	-3.17	-7.61	1.27	0.16
KDQOL-MCS	-2.41	-7.66	2.84	0.37
KDQOL-Burden of Disease	-28.59	-41.77	-15.42	<0.001*
KDQOL-Symptoms of Disease	-5.93	-14.61	2.73	0.18
KDQOL-Effects of Disease	-16.49	-25.98	-6.99	<0.001*
ICECAP-O capability index	-0.07	-0.16	0.02	0.12

Table 2: Adjusted Difference in SF-6D utilities, KDQOL-36 scores, and ICECAP-O capability index for dialysis compared with conservative care (fully adjusted)

 \dagger Difference in scores adjusted for age, gender, country, education, and health insurance status. * p < 0.001, statistical significance. CI - Confidence interval. KDQOL-36 - Kidney disease quality of life with 36 items. PCS - Physical Component Summary. MCS - Mental Component Summary.

Table 3: Convergent validity between ICECAP-O and SF-6D measures (n = 114)[†] using Pearson's correlation coefficient

ICECAP-O overall	ICECAP-O
-------------------------	----------

		domain				
		Attachment	Security	Role	Enjoyment	Control
SF-6D overall	0.65**	-	-	-	-	-
SF-6D domain						
Physical health	0.43**	0.08	0.31*	0.40**	0.32*	0.40**
Role limitations	0.30*	0.05	0.21*	0.28*	0.14	0.31*
Social functioning	0.41**	0.18	0.25*	0.34*	0.30*	0.35*
Pain	0.56**	0.17	0.29*	0.51**	0.43**	0.53**
Mental health	0.39**	0.19*	0.35*	0.30*	0.27*	0.27*
Vitality	0.44**	0.17	0.21*	0.41**	0.28*	0.42**

[†] Observations with missing values on either SF-12 or ICECAP-O questions were removed from the analysis (n = 15). * p < 0.05, statistical significance. ** p < 0.001, statistical significance.

Figure Legends

Figure 1- *Title:* KDQOL-36 Burden of Kidney Disease score according to treatment group. *Label:* (a) Dialysis group (n=83), (b) Conservative Care group (n=44).

Explanatory text: A higher score indicates lower burden of disease and better quality of life.

Figure 2- *Title:* KDQOL-36 Effects of Kidney Disease score according to treatment group.

Label: (a) Dialysis group (n=82), (b) Conservative Care group (n=45).

Explanatory text: A higher score indicates lower effects of disease and better quality of life.

beer teries only

BMJ Open

2 3 4 5	Supplementary Material
6 7	Supplementary Table 1 (Table S1): SF-6D utilities, SF-12 PCS and MCS scores, and
8 9 10	ICECAP-O capability index according to patient characteristics
10 11 12	Supplementary Table 2 (Table S2): Mean scores and weights of SF-6D, KDQOL-36 and
13 14	ICECAP-O according to treatment group
15 16 17	Supplementary Table 3 (Table S3): KDQOL-36 Burden of Kidney Disease, Symptoms of
18 19	Kidney Disease, and Effects of Kidney Disease scores according to patient characteristics
20 21	Supplementary Item 1 (Item S1): STROBE Statement: checklist of items that should be
22 23 24	included in reports of observational studies
25 26	Supplementary Item 2 (Item S2): KDQOL-36 Questionnaire (SF-12: Questions 1 – 12
27 28 29	(converted to SF-utilities), KDQOL scores (PCS and MCS scores: Questions 1 – 12, burden
30 31	of kidney disease: Questions $13 - 16$, effects of kidney disease: Questions $17 - 28$, symptoms of kidney disease: Questions $29 - 36$)
32 33 34	Supplementary Item 3 (Item S3): ICECAP-O Questionnaire
35 36	Supplementary Item 4 (Item S4): Background Questions
37 38	Supplementary Item 5 (Item S5): SF-6D domains
39 40 41	
42 43	
44 45 46	
47 48	
49 50 51	
52 53	
54 55	
56 57 58	
59	

BMJ Open





Figure 1: KDQOL-36 Burden of Kidney Disease score according to treatment group.

Page 29 of 48

BMJ Open



Characteristics	SF-6D (n = 116) \ddagger	$PCS (n = 115) \dagger \dagger$	MCS (n = 115)	ICECAP-O $(n = 126)$	
	Mean (95 % CI)	Mean (95 % CI)	Mean (95 % CI)	Mean (95 % CI)	
Age					
≤81 years	0.63 (0.60-0.67)	32.71 (30.31-35.10)	48.35 (45.51-51.19)	0.73 (0.69-0.78)	
>81 years	0.62 (0.58-0.65)	32.08 (29.33-34.84)	46.04 (42.89-49.20)	0.72 (0.67-0.77)	
Gender					
Males	0.65 (0.62-0.68)*	34.31 (32.00-36.62)*	47.92 (45.44-50.40)	0.73 (0.68-0.77)	
Females	0.58 (0.53-0.62)*	28.85 (26.31-31.39)*	45.98 (42.03-49.93)	0.72 (0.67-0.78)	
Treatment**					
Dialysis	0.61 (0.57-0.64)	31.22 (29.02-33.43)	47.67 (45.03-50.30)	0.71 (0.66-0.75)	
Conservative Care	0.65 (0.61-0.70)	34.32 (31.27-37.38)	46.56 (42.98-50.15)	0.76 (0.70-0.82)	
Country					
United Kingdom	0.60 (0.56-0.63)*	30.76 (28.30-33.22)	49.62 (46.66-52.58)*	0.72 (0.67-0.76)	
Australia	$0.65 \ (0.61 - 0.69)^{*}$	33.98 (31.38-36.57)	44.99 (42.06-47.92)*	0.73 (0.68-0.79)	В
Education §					M) C
Attended some high school	0.62 (0.59-0.65)	31.87 (29.84-33.91)	46.98 (44.43-49.53)	0.72 (0.68-0.76))pen
Completed high school or	$0.63\ (0.58-0.69)$	34.19 (30.22-38.17)	48.09 (44.21-51.97)	0.73 (0.66-0.80)	
tertiary education					
Private Health Insurance ¶					
Yes	0.68 (0.62-0.73)*	33.03 (29.55-36.50)	49.50 (44.82-54.18)	0.79 (0.73-0.85)	
No/Unknown	0.61 (0.58-0.64)*	32 25 (30 09-34 40)	46 77 (44 40-49 13)	0 71 (0 67-0 75)	

Specific SF-6D algorithms were used to convert the SF-12 scores to preference based SF-6D utilities for the UK and the Australian population. 13 out of 129 observations had missing values on SF-12 questionnaire and their SF-6D utilities were not calculated; the remaining had 2 observations missing value for education variable; 3 observations missing value for health insurance variable. 77 14 out of 129 observations had missing values on SF-12 questionnaire and their PCS score were not calculated; the remaining had 1 observation missing value for education variable; 2 observations missing value for health insurance variable. ‡ 14 out of 129 observations had missing values on SF-12 and their MCS score were not calculated; the remaining had 1 observation missing value for education variable; 2 observations missing value for health insurance variable. ‡‡ 3 out of 129 observations had missing values on ICECAP-O questionnaire and their capability index were not calculated; the remaining had 2 observations missing value for education variable; 4 observations missing value Completed A- levels/ University degree were merged into one category as "Completed high school or tertiary education". ¶ Individual responses to "No" and "Unknown" were merged into one category as "No/Unknown". CI - Confidence interval. SF-12 - Short form survey with 12 items. PCS - Physical Component Summary. MCS - Mental Component Summary. responses to Primary school/Some high school were merged into one category as "Attended some high school" and the responses to GCSEs/Completed high school/Diploma/TARE/ for health insurance variable. * p < 0.05, statistical significance. ** The dialysis group consist of Facility Haemodialysis, Home Haemodialysis and Peritoneal dialysis. § Individual

For peer review only - http://bmjopen.pmj.com/site/about/guidelines.xhtml

	Score	Weights	Score	Weights
		Mean (SD)	Mean (SD)	Mean (SD)
rnysical iuncuoning	2.47 (1.04)	-0.02 (0.02)	2.26 (0.68)	-0.018 (0.02)
Role limitations 3.22 (1.44)		-0.06 (0.02)	2.84 (1.28)	-0.05 (0.03)
Social functioning 3.33 (1.62)		-0.06 (0.03)	2.65 (1.25)	-0.06 (0.03)
Pain 3.29 (2.13)		-0.05 (0.05)	2.60 (1.37)	-0.04 (0.05)
Mental health 2.90 (1.92)		-0.05 (0.04)	2.33 (1.10)	-0.05 (0.04)
Vitality 3.86 (1.72)		-0.09 (0.02)	3.57 (1.13)	-0.09 (0.01)
KDQOL-36				
Physical Component Summary (PCS) 31.22 (9.32)	(9.32)		34.32 (10.05)	ı
Mental Component Summary (MCS) 47.67 (11.12	(11.12)		46.56 (11.78)	ı
Burden of Kidney Disease 34.71 (27.77	(27.77)	2	62.83 (29.45)	
Symptom of Kidney Disease 70.71 (18.74	(18.74)		76.61 (19.18)	
Effects of Kidney Disease 64.18 (20.27	(20.27)		81.29 (21.92)	ı
ICECAP-0#				
Attachment (love and friendship) 3.25 (0.87)	_	0.22 (0.06)	3.27 (0.81)	0.22 (0.05)
Security (thinking about future without concern) 2.42 (0.99)		0.09 (0.05)	2.71 (0.92)	0.10 (0.05)
Role (doing things that make you feel valued) 2.51 (0.82)		0.15 (0.04)	2.69 (0.85)	0.15 (0.05)
Enjoyment (enjoyment and pleasure) 2.52 (0.94)		0.13 (0.04)	2.80 (0.97)	0.14 (0.04)
Control (independence) 2.51 (0.94)		0.13 (0.08)	2.82 (1.01)	0.15 (0.09)
† 6 observations missing values on SF-6D Role limitation domain; 12 observations missing PCS and MCS score; 2 observations missing Symptoms of Kidney Disease score;	omain; 12	observations missing PCS and MCS score;	; 2 observations n	uissing Symptoms of Kidney Disease score; 1
observations missing Effects of Kidney Disease score; 2 observations missing values on ICECAP-O Attachment domain. †† 1 observation missing value on SF-6D Role limitation	rvations m	issing values on ICECAP-O Attachment do	omain. †† 1 obser	vation missing value on SF-6D Role limitation
domain; 2 observations missing KDQOL-36 PCS, MCS, Burden of Kidney Disease, and Symptoms of Kidney Disease score; 1 observation missing KDQOL-36 Effects of Kidney	den of Kid	ney Disease, and Symptoms of Kidney Dise	ease score; 1 obse	vation missing KDQOL-36 Effects of Kidney
Disease soore: 1 observation mission value on all ICECAD domains + SE 6D domain soores are weighted domeaners ++ ICECAD domain soores are weighted increments	Jamoine	+ CD ED domoin correct ore weighted deriv		1 D O damain comes are weighted increments

SD - Standard deviation. KDQOL-36 - Kidney disease quality of life with 36 items.

6 2 2 5 5 5 5 5 5 5 7 5 7 7 7 7 7 7 7 7 7	T-36 Burden of Kitiney Disease, Symponia L-36 Burden of Kitiney Disease, Symponia	5 5 5 5 5 5 5 5 7 5 1 1 1 1 1 1 1 1 1 1	1 1 0 6 8 2 9 5 7 8 5 1 1 2 2 2 5 5 5 5 5 5 5 5 5 5 5 5 5 5
Characteristics	Burden of Kidney Disease $(n = 127)$ [†]	Symptoms of Kidney Disease $(n = 125)$ ††	Effects of Kidney Disease $(n = 127)$
	Mean (95 % CI)	Mean (95 % CI)	Mean (95 % CI)
Age			
\leq 81 years	41.80 (34.47-49.12)	72.21 (67.15-77.27)	69.15 (63.05-75.25)
>81 years	47.16 (38.81-55.50)	73.35 (68.76-77.95)	71.35 (66.26-76.43)
Gender			
Males	44.43 (37.70-51.15)	74.00 (70.01-78.00)	71.48 (66.72-76.23)
Females	44.51 (34.62-54.39)	70.46 (64.13-76.79)	67.91 (60.77-75.05)
$Treatment^{**}$			
Dialysis	34.71 (28.65-40.78)*	70.71 (66.56-74.85)	64.18 (59.72-68.63)*
Conservative Care	62.83 (53.88-71.78)*	76.61 (70.78-82.44)	81.29 (74.70-87.88)*
Country			
United Kingdom	37.81 ($30.68-44.94$)*	71.97 (67.37-76.58)	66.29 (61.31-71.28)*
Australia	51.88 (43.59-60.16)*	73.72 (68.64-78.81)	74.65 (68.52-80.77)*
Education§			Oper
Attended some high school	45.32 (38.85-51.79)	71.42 (67.21-75.63)	70.93 (66.29-75.57)
Completed high school or tertiary educa-	43.53 (32.44-54.61)	76.87 (72.15-81.59)	68.92 (61.06-76.79)
tion			
Private Health Insurance¶			
Yes	55.32 (41.82-68.83)*	73.33 (65.11-81.54)	75.85 (67.67-84.02)
No/Unknown	41.62 (35.62-47.63)*	72.88 (69.03-76.73)	69.32 (64.80-73.84)
† 2 out of 129 observations had missing value	es on burden of disease questions and their s	† 2 out of 129 observations had missing values on burden of disease questions and their score was not calculated; the remaining had 2 observations missing value for education variable;	rvations missing value for education variable;
4 observations missing value for health insura	ance variable. †† 4 out of 129 observations	4 observations missing value for health insurance variable. †† 4 out of 129 observations had missing values on symptoms of disease questions and their score was not calculated; the	ons and their score was not calculated; the
remaining had 2 observations missing value f	for education variable; 4 observations missir	remaining had 2 observations missing value for education variable; 4 observations missing value for health insurance variable. ‡ 2 out of 129 observations had missing values on effects	29 observations had missing values on effects
of disease questions and their score was not c	calculated; the remaining had 2 observations	missing value for education variable; 4 observation	ons missing value for health insurance
variable. * $p < 0.05$, statistical significance. *	** The dialysis group consist of Facility Hae	smodialysis, Home Haemodialysis and Peritoneal	dialysis. § Individual responses to Primary
school/Some high school were merged into o	me category as "Attended some high school"	' and the responses to GCSEs/Completed high sch	ool/Diploma/TAFE/ Completed A- levels/
University degree were merged into one categ "No/Unknown". CI - Confidence interval. KI	gory as "Completed high school or tertiary e DQOL-36 - Kidney disease quality of life w	University degree were merged into one category as "Completed high school or tertiary education". ¶ Individual responses to "No" and "Unknown" were merged into one category as "No/Unknown". CI - Confidence interval. KDQOL-36 - Kidney disease quality of life with 36 items.	nknown" were merged into one category & 25 o
			⁵ 48

Supplementary Item 1 (Item S1): STROBE Statement: checklist of items that should be

included in reports of observational studies

	Item		Yes/No/NA
	No	Recommendation	
Title and abstract	1	(<i>a</i>) Indicate the study's design with a commonly used term in the title or the abstract	Yes
	0	(b) Provide in the abstract an informative and balanced summary of what was done and what was found	Yes
Introduction		0	
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	Yes
Objectives	3	State specific objectives, including any pre- specified hypotheses	Yes
Methods		2	
Study design	4	Present key elements of study design early in the paper	Yes
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow- up, and data collection	Yes
Participants	6	<i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	Yes

Variables	7	Clearly define all outcomes, exposures, predictors,	Yes
		potential confounders, and effect modifiers. Give	
		diagnostic criteria, if applicable	
Data sources/	8*	For each variable of interest, give sources of data	Yes
measurement		and details of methods of assessment	
		(measurement). Describe comparability of	
		assessment methods if there is more than one group	
Bias	9	Describe any efforts to address potential sources of	Yes
		bias	
Study size	10	Explain how the study size was arrived at	Yes
Quantitative variables	11	Explain how quantitative variables were handled in	Yes
		the analyses. If applicable, describe which	
		groupings were chosen and why	
Statistical methods	12	(a) Describe all statistical methods, including those	Yes
		used to control for confounding	
		(b) Describe any methods used to examine	Yes
		subgroups and interactions	
		(c) Explain how missing data were addressed	Yes
		Cross-sectional study—If applicable, describe	NA
		analytical methods taking account of sampling	
		strategy	
	1		

Participants	13*	(a) Report numbers of individuals at each stage of study—	No –
		e.g., numbers potentially eligible, examined for eligibility,	screening
		confirmed eligible, included in the study, completing	logs at eacl
		follow-up, and analysed	site were
			not
			available
		(b) Give reasons for non-participation at each stage	No
	Ċ	(c) Consider use of a flow diagram	NA
Descriptive data	14*	(a) Give characteristics of study participants (e.g.,	Yes
		demographic, clinical, social) and information on exposures	
		and potential confounders	
		(b) Indicate number of participants with missing data for	Yes
		each variable of interest	
		(c) Cohort study—Summarise follow-up time (e.g., average	NA
		and total amount)	
Outcome data	15*	Cross-sectional study—Report numbers of outcome events	Yes
		or summary measures	
Main results	16	(<i>a</i>) Give unadjusted estimates and, if applicable,	Yes
		confounder-adjusted estimates and their precision (e.g.,	
		95% confidence interval). Make clear which confounders	
		were adjusted for and why they were included	
		(b) Report category boundaries when continuous variables	Yes
		were categorised	
		(c) If relevant, consider translating estimates of relative risk	NA
		into absolute risk for a meaningful time period	

1	
2	
3	
4	
5	
5	
2 3 4 5 6 7 8 9 10	
7	
8	
0	
9	
10	
11	
12 13	
12	
13	
14 15 16 17 18	
15	
16	
17	
10	
18	
19	
20	
21	
21	
22	
23	
24	
25	
25	
20	
27	
28	
20 21 22 23 24 25 26 27 28 29 30 31 32 33 34	
30	
50	
31	
32	
33	
34	
24	
35	
35 36 37 38	
37	
20	
20	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
51	
52	
53	
54	
55	
56	
57	
58	
59	
60	

Other analyses	17	Report other analyses done—e.g., analyses of subgroups	Yes
		and interactions, and sensitivity analyses	
Discussion	1		
Key results	18	Summarise key results with reference to study objectives	Yes
Limitations	19	Discuss limitations of the study, taking into account sources	Yes
		of potential bias or imprecision. Discuss both direction and	
		magnitude of any potential bias	
Interpretation	20	Give a cautious overall interpretation of results considering	Yes
		objectives, limitations, multiplicity of analyses, results from	
		similar studies, and other relevant evidence	
Generalisability	21	Discuss the generalisability (external validity) of the study	Yes
		results	
Other information	on	2.	
Funding	22	Give the source of funding and the role of the funders for	Yes
		the present study and, if applicable, for the original study	
		on which the present article is based	
	1		1

Supplementary Item 2 (Item S2): KDQOL-36 Questionnaire (SF-12: Questions 1 – 12 (converted to SF-utilities), KDQOL scores (PCS and MCS scores: Questions 1 – 12, burden of kidney disease: Questions 13 – 16, effects of kidney disease: Questions 17 – 28, symptoms of kidney disease: Questions 29 – 36)

Your Health – and – Well-Being

Kidney Disease and Quality of Life (KDQOLTM-36)

This survey asks for your views about your health. This information will help keep track of how you feel and how well you are able to do your usual activities.



Thank you for completing these questions!

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Kidney Disease and Quality of Life™ (KDQOL™-36) English Version 1. Copyright © 2000 by RAND and the University of Arizona

Your Health

This survey includes a wide variety of questions about your health and your life. We are interested in how you feel about each of these issues.

1. In general, would you say your health is: [Mark an 🖂 in the one box that best describes your answer.]



The following items are about activities you might do during a typical day. <u>Does your health now limit</u> you in these activities? If so, how much? [Mark an 🔀 in a box on each line.]

		Yes, limited a lot	Yes, limited a little	No, not limited at all
2.	<u>Moderate activities</u> , such as moving a table, pushing a vacuum cleaner, bowling, or playing golf	. 🔲 i	2	🗌 3
3.	Climbing several flights of stairs		2	🗌 3

During the <u>past 4 weeks</u>, have you had any of the following problems with your work or other regular daily activities <u>as a result of your</u> <u>physical health</u>?

	Γ	Yes	No
4.	Accomplished less than you would like	<u> </u>	2
5.	Were limited in the <u>kind</u> of work or other activities	<u> </u>] 1

During the past 4 weeks, have you had any of the following problems with your work or other regular daily activities as a result of any emotional problems (such as feeling depressed or anxious)?

		Yes	No
6.	Accomplished less than you would like	<u> </u>] 1
7.	Didn't do work or other activities as <u>carefully</u> as usual	i	2

8. During the <u>past 4 weeks</u>, how much did <u>pain</u> interfere with your normal work (including both work outside the home and housework)?

Not at all	A little bit	Moderately	Quite a bit	Extremely
<u> </u>	2	3	4	s s

These questions are about how you feel and how things have been with you <u>during the past 4 weeks</u>. For each question, please give the one answer that comes closest to the way you have been feeling.

How much of the time during the past 4 weeks ...

	Γ			A good			
		All of the time	Most of the time	A good bit of the time	Some of the time	A little of the time	None of the time
9.	Have you felt calm and peaceful?	1	2	🔲 3		5	🗌 o
10.	Did you have a lot of energy?	1	2	🔲 3	4] s	🗌 6
11.	Have you felt downhearted and blue?	i	2	🔲 3		🚺 s	🗌 6

12. During the <u>past 4 weeks</u>, how much of the time has your <u>physical</u> <u>health or emotional problems</u> interfered with your social activities (like visiting with friends, relatives, etc.)?

All of the time	Most of the time	Some of the time	A little of the time	None of the time
<u> </u>	2	3	A	5

		Definitely	Mostly	Don't	Mostly	Definit
13.	My kidney disease interferes too much with my	true	true	know	false	fals
14.	life Too much of my time is spent	L_] I	······ 2 ····			
	dealing with my kidney disease	1	2	3		
15.	I feel frustrated dealing with my kidney disease	i	2	3		
16.	I feel like a burden on my family	<u> </u>	2			

2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
45 46
47
48
49
50
51
52
53
55 54
55
55 56
57
58
59

1

During the <u>past 4 weeks</u>, to what extent were you bothered by each of the following?

		Not at all bothered		Moderately bothered		
17.	Soreness in your muscles?	1	2	3		s
18.	Chest pain?	1		3	d	5
19.	Cramps?	i		3	4	5
20.	Itchy skin?	1		в з	4	5
21.	Dry skin?	i	2	B	4	5
22.	Shortness of breath?	<u> </u>	2	ē]	4	
23.	Faintness or dizziness?	1	2	î	4	s
24.	Lack of appetite?	<u> </u>		в з	4	
25.	Washed out or drained?	1	2	î	4	s
26.	Numbness in hands or feet?	1		3	4	5
27.	Nausea or upset stomach?	1	2	3		s
28 ^a .	(Hemodialysis patie	nt only)				
	Problems with your access site?		2	3	4	5
28 ^b .	(Peritoneal dialysis)	patient only)			
	Problems with your catheter site?	[] i	2	£ 🗍		s

Effects of Kidney Disease on Your Daily Life

Some people are bothered by the effects of kidney disease on their daily life, while others are not. How much does kidney disease <u>bother</u> you in each of the following areas?


		Not at all bothered	Somewhat bothered	Moderately bothered	Very much bothered	Extremely bothered
29.	Fluid restriction?	🔲 ı		3		5
30.	Dietary restriction?	1		î	4	s
31.	Your ability to work around the house?	1	2			5
32.	Your ability to travel?	[] 1	2	î		5
33.	Being dependent on doctors and other medical staff?	<u> </u>	2	2	4	S
34.	Stress or worries caused by kidney disease?	1	2	2	4	5
35.	Your sex life?	<u> </u>		3	4	5
36.	Your personal appearance?	<u> </u>		3	4	5


BMJ Open

Supplementary Item 3 (Item S3): ICECAP-O Questionnaire

ABOUT YOUR QUALITY OF LIFE

By placing a tick (\checkmark) in ONE box in EACH group below, please indicate which statement best describes your quality of life at the moment.





Q1.	What is your full name?	
Q2.	What is your date of birth?	(dd/mm/yyyy)
Q3.	Gender (please tick one)	
	Male 🗆	
	Female 🗆	
Q4.	What is your main residential postcode	?
Q5.	What was your country of birth?	
Q6.	What is the highest level of education y	ou have completed? (please ti
	box that best describes you)	
	Primary school	
	Some high school	
	Completed high school	
	Completed Diploma/ TAFE course	
	Completed University Degree	
Q7.	Do you have private health insurance? (please tick one)
	Yes	
	No 🗆	
	Don't know	
Q8.	What type of kidney treatment are you	c urrently having? (please tick
	Hemodialysis (satellite or hospital)	
	Hemodialysis at home	
	Peritoneal dialysis	
	Non-dialysis renal supportive care	

Q9. If you are currently on dialysis when did you first start dialysis?

_____(mm/yyyy)

Q10. Have you ever had a kidney transplant before? (*please tick one*)

Yes \Box No \Box

Q11. The next two questions are about the **ICECAP-O survey.** On the scale below please rate how easy this survey was to complete *(circle a number between 1)*

and 5)

Very easy	Somewhat	Neutral	Somewhat	Very
	easy		difficult	difficult
1	2	3	4	5

Q12. Did this survey measure the things that you consider <u>important</u> to your quality of life? *(circle a number between 1 and 5)*

Completely	Somewhat	Neutral	Somewhat	Completely
agree	agree	0	disagree	disagree
1	2	3	4	5

Q13. If you responded with 'somewhat disagree' or 'completely disagree,' would you like to tell us what you think the **ICECAP-O survey** was missing?

Q14. The next two questions are about the SF-12 survey. On the scale below please rate

how <u>easy</u> this survey was to complete (circle a number between 1 and 5)

Very easy	Somewhat	Neutral	Somewhat	Very
	easy		difficult	difficult
1	2	3	4	5

Q15. Did this survey measure the things that you consider <u>important</u> to your quality of life? *(circle a number between 1 and 5)*

disagree disagree
4 5

Q16. If you responded with 'somewhat disagree' or 'completely disagree,' would

you like to tell us what you think the SF-12 survey was missing?

Supplementary Item 5 (Item S5): SF-6D domains

Level	SF-6D				
	Physical Functioning				
1	Your health does not limit you in vigorous activities				
2					
$\frac{2}{3}$	Your health limits you a little in vigorous activities				
	Your health limits you a little in moderate activities				
4	Your health limits you a lot in moderate activities				
5	Your health limits you a little in bathing and dressing				
6	Your health limits you a lot in bathing and dressing				
	Role limitations				
1	You have no problems with your work or other regular				
1					
	daily activities as a result of your physical health or any				
	emotional problems				
2	You are limited in the kind of work or other activities as a				
	result of your physical health				
3	You accomplish less than you would like as a result of				
	emotional problems				
4	You are limited in the kind of work or other activities as a				
3. Kor	result of your physical health and accomplish less than				
	you would like as a result of emotional problems				
	you would like as a result of emotional problems				
	Social functioning				
1	Your health limits your social activities <i>none of the time</i>				
2	Your health limits your social activities a little of the time				
3	Your health limits your social activities some of the time				
4	Your health limits your social activities most of the time				
5	Your health limits your social activities <i>all of the time</i>				
5					
	Pain				
1	You have no pain				
2	You have pain but it does not interfere with your normal				
	work (both outside the home and housework)				
3	You have pain that interferes with your normal work				
	(both outside the home and housework) a little bit				
4	You have pain that interferes with your normal work				
7	(both outside the home and housework) <i>moderately</i>				
-					
5	You have pain that interferes with your normal work				
~	(both outside the home and housework) quite a bit				
6	You have pain that interferes with your normal work				
	(both outside the home and housework) <i>extremely</i> Mental health				
1	You feel tense or downhearted and low <i>none of the time</i>				
2					
	You feel tense or downhearted and low a little of the time				
3	You feel tense or downhearted and low some of the time				
4	You feel tense or downhearted and low most of the time				
5	You feel tense or downhearted and low all of the time				
1	Vitality You have a lot of energy all of the time				
2					
	You have a lot of energy most of the time				
3	You have a lot of energy some of the time				
4	You have a lot of energy a little of the time				
5	You have a lot of energy <i>none of the time</i>				

Copyright © 2004 John Wiley & Sons, Ltd.

BMJ Open

BMJ Open

Health-related quality of life and wellbeing in people over 75 years of age with end-stage kidney disease managed with dialysis or comprehensive conservative care: a crosssectional study in the UK and Australia

Journal:	BMJ Open
Manuscript ID	bmjopen-2018-027776.R1
Article Type:	Research
Date Submitted by the Author:	26-Feb-2019
Complete List of Authors:	Shah, Karan; The University of Sydney, NHMRC Clinical Trials Centre, Health Economics Murtagh, Fliss; Wolfson Palliative Care Research Centre, Hull York Medical School, University of Hull, UK McGeechan, Kevin; The University of Sydney, School of Public Health Crail, Su; Royal Adelaide Hospital Burns, Aine; Royal Free Hospital Tran, Anh; The University of Sydney, NHMRC Clinical Trials Centre, Health Economics Morton, Rachael; The University of Sydney, NHMRC Clinical Trials Centre, Health Economics
Primary Subject Heading :	Health economics
Secondary Subject Heading:	Health services research, Qualitative research, Renal medicine, Research methods
Keywords:	Chronic renal failure < NEPHROLOGY, Chronic renal insufficiency, Dialysis < NEPHROLOGY, PALLIATIVE CARE, HEALTH ECONOMICS, Quality of life



Title: Health-related quality of life and wellbeing in people over 75 years of age with endstage kidney disease managed with dialysis or comprehensive conservative care: a crosssectional study in the UK and Australia

Karan Shah¹, Fliss E M Murtagh², Kevin McGeechan³, Su Crail⁴, Aine Burns⁵, Anh D

Tran¹, Rachael L Morton¹

- National Health and Medical Research Council (NHMRC) Clinical Trials Centre, The University of Sydney, NSW, Australia
- Wolfson Palliative Care Research Centre, Hull York Medical School, University of Hull, UK

ien

- 3. School of Public Health, The University of Sydney, NSW, Australia
- 4. Royal Adelaide Hospital, SA, Australia
- 5. Royal Free Hospital, London NHS Foundation Trust, UK

Corresponding Author:

Karan Shah, MSc.

Health Economics, NHMRC Clinical Trials Centre,

The University of Sydney,

92-94 Parramatta Road, Camperdown NSW 2050, Australia

Tel: +61 2 9562 5030

Fax: +61 2 9562 5387

Email: karan.shah@ctc.usyd.edu.au

Word Count: 3454

ABSTRACT

Objective

Decisions regarding treatment of older people with end-stage kidney disease need to be supported by information about the impact of dialysis on health-related quality of life (HRQoL) and wellbeing. Few data exist from patients aged 75 years of age or older.

Design

Prospective cross-sectional study.

Setting

3 renal units in the UK and Australia.

Participants

129 ESKD patients managed with dialysis or with an estimated glomerular filtration $(eGFR) \le 10 \text{ml/min}/1.73 \text{m}^2$ and managed with comprehensive conservative, non-dialytic care.

Outcome measures

HRQoL and wellbeing were assessed using Short-Form six dimensions (SF-6D, 0-1 scale); KDQOL-36 (0-100 scale) and Investigating Choice Experiments Capability Measure–Older people (ICECAP-O, 0-1 scale). Linear regression assessed associations between treatment, HRQoL and wellbeing. Pearson's correlation coefficient assessed convergent validity between instruments.

Results

Median age of 81 years [IQR 78–85], 65% males; 83(64%) were managed with dialysis and 46(36%) with conservative care. When adjusted for treatment type and sociodemographic variables, those managed on dialysis reported lower mean SF-6D utility (-0.05, 95%CI -0.12 to 0.01); lower KDQOL Physical component summary score (-3.17, 95%CI -7.61 to 1.27); lower Mental component summary score (-2.41, 95%CI -7.66 to 2.84); lower quality of life due to burden (-28.59, 95%CI -41.77 to -15.42); symptoms (-5.93, 95%CI -14.61 to 2.73), and

 effects of kidney disease (-16.49, 95%CI -25.98 to -6.99); and lower overall ICECAP-O wellbeing (-0.07, 95%CI -0.16 to 0.02) than those managed conservatively. Correlation between ICECAP-O wellbeing and SF-6D utility scores was strong overall, 0.65 (p<0.001), but weak to moderate at domain level.

Conclusions

Older people on dialysis report significantly higher burden and effects of kidney disease than those on conservative care. Lower HRQoL and wellbeing may be associated with dialysis treatment, and should inform shared decision making about treatment options.

Trial registration

UK (IRAS project ID: 134360 & REC reference 14/LO/0291) and Australia (R20140203 HREC/14/RAH/36).

KEYWORDS

Chronic Kidney Failure, Chronic Renal Insufficiency, Renal Dialysis, Quality Of Life, Palliative Care

STRENGTHS AND LIMITATIONS OF THIS STUDY

- The strengths of our study include a prospective assessment of HRQoL in people over 75 years of age, and the use of a novel measure to value wellbeing.
- This information is essential for doctors to discuss the relative benefits of dialysis compared with conservative care.
- The limitation of this study is that, the sample size may not have been sufficient to detect a statistically significant difference in mean scores if one existed.
- We did not have complete data on patient's comorbid conditions that may have impacted our ability to explore the associations between comorbid conditions and HRQoL or wellbeing.
- Considering the cross-sectional nature of the data, we were unable to analyse any changes relating to individuals' HRQoL or wellbeing over time, which might be captured in a longitudinal study.

INTRODUCTION

Comprehensive conservative care services were developed for people with end-stage kidney disease (ESKD) in the UK and Australia following the substantial increase in the number of older people aged \geq 75 years being referred to nephrologists for dialysis,[1]. Comprehensive conservative care includes interventions to delay the progression of kidney disease and minimise complications, as well as detailed communication, shared decision-making, advance care planning, and psychologic and family support, but does not include dialysis,[2]. For older patients who often have high levels of comorbidity (such as diabetes and heart disease) and poor functional status, the survival advantage of dialysis may be limited, and comprehensive conservative management may be considered; however, robust comparative evidence remains minimal,[2]. Considerations such as symptoms, quality of life, and hospital-free days are sometimes more important for patients and families, than expected length of survival,[2].

Traditionally, economists attempt to assist resource allocation decisions by focusing on measuring and valuing health (in its broadest sense), using health-related quality of life (HRQoL) measures and survival, in particular combined in the quality-adjusted life year (QALY),[3]. In QALY calculations, values (often referred to as utility scores) are assigned to different health states, which allows the quantification of health gains comprising both length and quality of life gains from medical interventions,[3, 4]. Utilities are preference weights, where preference can be equated with value or desirability,[5, 6]. The quality adjusted life years (QALYs) value is then calculated by combining the length of survival and the utility weights.

However, many healthcare interventions may impact more broadly on quality of life (assumed to encompass the broad range of factors that are important to people in living their lives) rather than just health (which centers on physical and mental health),[3]. These broad factors could

be related to health and non-health factors that may impact the overall quality of life of a patient,[4]. Measures that look only at health in assessing the impact of these interventions would be very likely to underestimate this impact,[3, 7].

Dialysis has a large impact on the quality of life of both patients and their families; however, traditional HRQoL measures, such as the Short Form 36 (SF-36) and Kidney Disease Quality of Life (KDQOL-36) surveys may be too narrowly focused to detect all of the critical aspects of dialysis that increase or decrease an individual's quality of life,[8]. KDQOL-36TM is a short form questionnaire that includes the SF-12, a generic quality of life questionnaire,[9, 10] plus disease-specific domains including the burden of kidney disease, symptoms/problems of kidney disease, and effects of kidney disease. For this purpose, broader HRQoL measures, often named wellbeing measures, could be used to capture more facets of peoples' lives than health status alone,[4].

New instruments have been developed that provide information across health and social care, rather than just across health,[3]. The recently developed "Investigating Choice Experiments Capability Measure (ICECAP)" family of instruments have been designed to incorporate such dimensions,[11]. These instruments have their theoretical grounding in Amartya Sen's work on the relationships between functioning and capability,[11, 12]. They seek to measure a conceptually different evaluative space through a focus on capabilities: that is, what a person is able to do and who they are able to be, rather than on functioning: what a person actually does and who they become,[13]. Capabilities refer to the potential to achieve certain states and perform certain actions,[4]. Having the capability to live life the way one desires is obviously important, also to older people, and reduction of this capability limits their wellbeing,[4, 14, 15]. The ICECAP-O instrument was specifically developed to measure capability in older

BMJ Open

people. There is little research on how the ICECAP-O is related to other conceptualisations of wellbeing, and the relationships between the ICECAP-O and measures of health (physical, psychological, and social) remain underexplored,[16].

The aims of the study were to measure HRQoL using SF-12 questionnaire, kidney disease quality of life using KDQOL-36TM questionnaire, and wellbeing using ICECAP-O questionnaire; to determine the association between treatment type and socio-demographic characteristics on these outcome measures; to assess the convergent validity between the ICECAP-O wellbeing and the SF-6D utility (derived from SF-12 questionnaire); and to assess the feasibility and acceptability of questionnaires in older ESKD patients.

MATERIALS AND METHODS

Study design

We conducted a cross-sectional study of patients with ESKD treated with dialysis or comprehensive conservative care in the UK and Australia between 2014 and 2017. The study was performed in accordance with the Australian National Statement on Ethical Conduct in Human Research (2007), and relevant guidance in the UK. Each renal unit participating in the study obtained the approval of their Institutional Research Boards UK (IRAS project ID: 134360 & REC reference 14/LO/0291) and Australia (R20140203 HREC/14/RAH/36). The study design conformed to the STROBE guidelines for observational studies (Item S1),[17]. Eligible subjects were fully informed about the purpose, benefits and risks of the study, and signed an approved participant consent form.

Setting and participants

The study was undertaken at three renal units in the UK and Australia. Included were males and females aged \geq 75 years with ESKD, managed with dialysis (facility hemodialysis, home

hemodialysis, and peritoneal dialysis) or with an estimated glomerular filtration (eGFR) $\leq 10 \text{ml/min/1.73m}^2$ and managed with comprehensive conservative, non-dialytic care. The exclusion criteria comprised cognitive impairment; patients unable to read English; and patients who were legally blind. To reduce selection bias, nephrologists and clinical nurses in each participating renal unit reviewed their clinic lists for all patients that met the eligibility criteria.

Patient and public involvement

The research question was developed from prior qualitative work with people with end-stage kidney disease and their carers,[18-20]. Patients were not directly involved in the design of this research study. Patients and their caregivers were informed of the study and invited to participate by the renal unit's research nurses. Participants were provided with an information sheet and consent from for them to read. If they were interested in participating they were asked to sign the consent form and then were provided with two surveys contained in the one booklet, (the ICECAP-O survey and the standard KDQOL-36TM) while at their renal clinic. Patients and their caregivers were assured that participation was voluntary, that they did not have to participate and that their decision either way would not affect their clinical care.

Outcomes and variables

The key outcomes were SF-6D utilities derived from the SF-12 questions, KDQOL scores from the KDQOL-36 questions, ICECAP-O capability index derived from the ICECAP-O questions. Other outcomes were convergent validity between ICECAP-O wellbeing and the SF-6D utility instrument measured using the Pearson's correlation coefficient; and the feasibility and acceptability of the ICECAP-O and SF-12 questionnaires, assessed by response rate and

 BMJ Open

specific items asking the patient whether the questionnaire was easy to complete, and whether it covered questions important to their quality of life and wellbeing.

Data sources/measurement

All eligible patients were invited to complete the KDQOL-36TM (Item S2) and the five-question ICECAP-O questionnaire (Item S3) while at their renal clinic. Relevant sociodemographic details such as age, sex, country, educational attainment, private health insurance and questions assessing feasibility and acceptability of the ICECAP-O and SF-12 questionnaire were collected (Item S4). Kidney treatment type (facility hemodialysis, home hemodialysis, peritoneal dialysis, and comprehensive conservative care), dialysis status (if currently on dialysis, and time of initiation) and renal transplant status were documented.

Health related quality of life questionnaire

The KDQOL-36 has 36 items: the SF-12 version 1 and another 24 kidney specific items,[21]. The SF-12 responses on the KDQOL-36 were transformed into HRQoL weights, known as utilities, using a published SF-6D algorithm,[22]. The SF-6D is a generic preference-based single measure of health used to generate utilities from six domains: physical, role, social, pain, mental, and vital (Item S5). The SF-6D utilities generated are measured on a 0 (death) to 1 (full health) scale, and were reported with mean and standard deviations (SDs) using UK population values,[22-24].

The SF-12 section of KDQOL-36 also yields PCS (Physical Component Summary) and MCS (Mental Component Summary) scores, both of which are scored on a T-score metric (mean = 50, SD = 10, for the US general population),[21, 25]. The three kidney specific scales assess Burden of Kidney Disease, Symptoms of Kidney Disease, and Effects of Kidney Disease. Each

of these scales is scored by transforming all items to a 0 to 100 possible range and averaging across the items on each scale to create scale scores,[21]. KDQOL-36 items are all scaled so that higher scores indicate better HRQoL,[21, 26].

Wellbeing questionnaire

 The ICECAP-O questionnaire measures capabilities and covers five domains of wellbeing, including attachment (love and friendship); security (thinking about the future without concern); role (doing things that make you feel valued); enjoyment (enjoyment and pleasure); and control (independence),[27]. It has four-level response options, representing four levels of capability: none, a little, a lot, and all. The responses on the ICECAP-O questions were transformed to a ICECAP-O capability index ranging from 0 (no capability) to 1 (full capability), and presented with mean and SDs using UK population weights,[3].

Quantitative variables

The SF-6D utilities, KDQOL scores, ICECAP-O capability index, and patients' age were treated as continuous, while patients' sex, treatment type (dialysis, conservative care), education (some high school or lower levels, completed high school or higher levels), private health insurance (yes, no), and health system (UK, Australia) were analysed as categorical variables. Age was also additionally dichotomised (less than or equal to, versus greater than the median age [81 years]).

Statistical methods

The analysis of data involved descriptive statistics assessing proportions and mean values of the SF-6D utilities, PCS, MCS, Burden of Kidney Disease, Symptoms of Kidney Disease, Effects of Kidney Disease scores, and the ICECAP-O capability index for the entire cohort.

BMJ Open

Hypothesis testing with a two-tailed Student's t-test was used to detect differences in the mean values of SF-6D utilities, KDQOL-36 scores, and ICECAP-O capability index for patients' treatment type and socio-demographic characteristics. We hypothesised that HRQoL and wellbeing measures in each treatment group would be equivalent. Linear regression with multivariable models was undertaken to determine the association between treatment type and patient characteristics on SF-6D utilities, KDQOL scores and ICECAP-O capability index. In the multivariable linear regression, age, sex, treatment type, education, private health insurance, and health system were included as covariates on the basis of *a priori* knowledge of their associations with the HRQoL and wellbeing measures.

Pearson's correlation coefficient was used to determine the convergent validity of the ICECAP-O wellbeing with the SF-6D utility instrument. The correlations were assessed for the overall ICECAP-O and SF-6D utility scores and their domains. We hypothesised, moderate to strong positive correlations because both these instruments measures some similar facets of quality of life. Correlations above 0.5 were considered strong, between 0.3 and 0.5 as moderate, and below 0.3 as weak,[16].

Complete case analysis was performed for all outcomes. All statistical analyses were performed with SAS Version 9.4 (SAS Institute, Cary, NC). A p-value of <0.05 was considered statistically significant.

RESULTS

A total of 129 patients were recruited, including 83 (64%) managed with dialysis and 46 (36%) patients managed with comprehensive conservative care. Overall, 65% were male, and the

median age of the entire cohort was 81 years [IQR 75–78]. Patient characteristics are shown in Table 1.

Health-related quality of life SF-6D utilities

Of 129 patients, the mean utility for 116 patients with complete data was $0.62 \text{ (SD } 0.14) \text{ (n = 13} missing values)}$. The mean SF-6D utilities for the dialysis group were 0.61 (SD 0.13), and 0.65 (SD 0.15) for the conservative care group (Table S1). The "vitality" domain reported the highest average score, and was responsible for the highest decrement in utilities in both treatment groups (Table S2).

The mean SF-6D utilities were 0.07 (SD 0.14) lower for females than for males (p = 0.006); 0.06 (SD 0.14) lower for patients residing in the UK compared with those residing in Australia (p = 0.03); and 0.07 (SD 0.14) lower for patients without a private health insurance compared to patients with a private health insurance (p = 0.03) (Table S1). When adjusted for all variables, the mean SF-6D utilities were 0.09 lower for females compared to males (95 % lower CI = -0.14 and upper CI = -0.03, p = 0.002). There was no significant difference in the mean utilities observed between two treatments when adjusted for other variables (Table 2).

KDQOL scores

The mean KDQOL scores on the five domains for patients with complete data were as follows: PCS score of 32.41 (n = 115, SD 9.68); MCS score of 47.25 (n = 115, SD 11.34); Burden of Kidney Disease score of 44.46 (n = 127, SD 31.28); Symptom/Problems of Kidney Disease score of 72.78 (n = 125, SD 19.03); and Effects of Kidney Disease score of 70.24 (n = 127, SD 22.35).

BMJ Open

In univariate analysis the PCS score was 5.46 points lower in females than males (p = 0.004) (i.e. lower physical health); the MCS score was 4.63 points lower in Australian versus UK patients (p = 0.03) (i.e. lower mental health) table S1 and table S3. The Burden of Kidney Disease score was 28.12 points lower in the dialysis group than the conservative care group (p < 0.001) (indicating a higher burden of disease and lower quality of life); 14.06 points lower in UK versus Australian patients (p = 0.01) (indicating higher burden of disease); 13.70 points lower in patients without private health insurance compared to those with private health insurance (p = 0.04) (indicating a higher burden of disease). The Effects of Kidney Disease score was 17.11 points lower in the dialysis group compared to the conservative care group (p < 0.001) (indicating higher effects of the disease and lower quality of life); 8.35 points lower in UK versus Australian patients (p = 0.03) (indicating higher effects of the disease).

The dialysis group reported a higher MCS score (47.67 vs 46.56), indicating marginally better mental health than the conservative care group. (Table S2).

When adjusted for other variables, the mean score for the Burden of Kidney Disease sub-scale was 28.59 lower (i.e. more burdensome) for patients on dialysis compared with patients on conservative care (p<0.001) (Table 2, Figure 1 and Figure 2). The mean score for Effects of Kidney Disease when adjusted for all the other variables, was 16.49 lower (i.e. higher disease related effects) for patients on dialysis compared with patients on comprehensive conservative care (p<0.001) (Table 2, Figure 3 and 4). Adjusted scores were lower but not statistically, significantly different for PCS, MCS and Symptoms of Kidney Disease between the two treatment groups.

ICECAP-O capability index

The mean ICECAP-O capability index for 126 patients with complete data was 0.72 (SD 0.19) (n=3 missing values). In the dialysis group, the mean capability index was 0.71 (SD 0.19), and 0.76 (SD 0.20) for the conservative care group (Table S1), but not significantly different. Overall, the dialysis treatment group reported a lower wellbeing score on all five domains compared to the conservative care group. The "attachment" domain showed the highest average score, and was responsible for the highest contribution to capabilities in both treatment groups (Table S2). When adjusted for other variables, there were no significant differences in the mean capability index observed between the two treatments (Table 2).

Convergent validity

For 114 observations the SF-6D utilities score and the pain domain of the SF-6D were strongly correlated with the overall ICECAP-O capability index with a Pearson's coefficient of 0.65 (p<0.001) and 0.56 (p<0.001) respectively. At the domain level, the role and control domains of the ICECAP-O questionnaire were strongly correlated with the pain domain of the SF-6D, with a Pearson's coefficient of 0.51 (p<0.001) and 0.53 (p<0.001) respectively. All other domains of the ICECAP-O were weakly or moderately correlated with SF-6D domains, values ranging from 0.02 to 0.49 (Table 3).

Feasibility and acceptability

115 of 129 patients completed the questionnaire, with 14 patients missing items for the ICECAP-O and 10 patients missing items for the SF-12. Overall, patients found both questionnaires easy to use and relevant to assessing their wellbeing. They responded with an average score of 1.78 out of 5 (1 = strongly agree, 5 = completely disagree) on questions assessing ease of use; and with an average score 1.77 and 1.79 out of 5 on the questions assessing the relevance of ICECAP-O and the SF-12 questions respectively.

DISCUSSION

This prospective cross-sectional study determined the mean SF-6D utilities, KDQOL scores and ICECAP-O capability index for patients with ESKD according to treatment, and sociodemographic variables. Our findings suggest females compared with males, patients residing in the UK compared with those residing in Australia, and patients without private health insurance compared with those with private health insurance have significantly lower SF-6D utilities. However, when adjusted for the other variables, only females reported significantly lower utilities compared with males. Furthermore, the study determined the convergent validity between the ICECAP-O wellbeing and SF-6D utility instrument and assessed the feasibility and acceptability of the ICECAP-O wellbeing and SF-12 questionnaire in older people with ESKD.

The dialysis group reported 0.05 lower SF-6D utilities compared with the conservative care group reflecting a potentially clinically meaningful difference related to treatment, however, this difference was not statistically significant. Meaningful differences or the minimal important difference (MID) in utility-based HRQoL reported in 11 studies using the SF-6D utilities ranged from 0.011 to 0.097, with a mean MID of 0.041,[28]. It is therefore likely our study has detected a meaningful difference. In addition, a 0.05 difference in ICECAP-O wellbeing for dialysis patients may also represent a clinically meaningful difference, however, MIDs for ICECAP-O have not yet been published. Similarly, the KDQOL-36[™] instrument identified a higher burden of disease, and greater effects of the disease for those on dialysis. This finding needs to be explored further in a larger sample size to investigate the potential detrimental effects of dialysis on HRQoL.

BMJ Open

In our study, with the exception of a strong correlation between the "control" and "role" domain of the ICECAP-O with the "pain" domain on the SF-6D, most of the ICECAP-O domains were found to have weak to moderate correlations with the SF-6D corresponding domains. This indicates the newly developed capability instrument does measure different aspects of quality of life or wellbeing, and offers additional information when compared to measures of health, such as the SF-6D used in the conventional QALY approach. In addition, we observed a higher score for the feasibility and acceptability of the ICECAP-O questions indicating it to be acceptable and as relevant as SF-12 (an established HRQoL measure).

There is debate in the health economics literature concerning the ways to apply the capability approach in economic evaluations with some suggesting that QALYs alone are adequate, while others argue this approach is too narrow, and that direct measures of capability or wellbeing provide a more extensive application of Sen's paradigm,[29]. Capability is empirically distinct from functioning and the content of capability instruments is not subsumed by the content of instruments used to capture changes in HRQoL for QALYs,[29].

Health economic analyses would benefit from the inclusion of individual capability measures; whether the focus should be only upon people's *achievements*—their "functioning"—or people's *capability to achieve* is contested,[29]. Sen's example of the fasting man versus the starving man serves as a key example for focusing on capability: two people, one of whom is starving and the other, who is fasting, have comparable functioning in terms of nourishment, but their capabilities to be nourished are notably different,[29]. The argument is that focusing on functioning alone would miss important distinctions, such as differences in freedom and choice between individuals,[29].

BMJ Open

There are some limitations to this study. First, the sample size may not have been sufficient to detect a statistically significant difference in mean scores if one existed. Second, our observational study of older patients with end-stage kidney disease may not have perfectly matched the two groups with respect to co-morbid conditions. We did not have complete data on comorbidities and this may have impacted our ability to explore the associations between treatment type, HRQoL or wellbeing. Third, considering the cross-sectional nature of the data, we were unable to analyse any changes relating to individuals' HRQoL or wellbeing over time, which might be captured in a longitudinal study. The strengths of our study include a prospective assessment of HRQoL in people over 75 years of age, and the use of a novel measure to value wellbeing. This information is essential for doctors to discuss the relative benefits of dialysis compared with conservative care.

In conclusion, we observed lower quality of life and wellbeing for older patients with ESKD managed on dialysis compared to comprehensive conservative care. Furthermore, measuring wellbeing using a capability index provides additional insights into the impact of dialysis on older people than HRQoL measurement alone and has potential to improve the economic evaluation of treatment for ESKD.

Acknowledgements

The authors gratefully acknowledge the patients who participated in this study; the research nurses from the UK and Australian renal units; and Dr Sherilyn Goldstone for proof reading the final version of the manuscript.

Authors' Contributions

Authors FM, KM, SC, AB, and RM designed the study. RM, SC and AB led the data collection. KS conducted the analysis and drafted the first version of the manuscript. RM, AT and KM supported the data analysis and interpretation of the results, and all authors revised the final version of the manuscript.

Funding

This work was supported by the NHMRC Early Career Researcher Fellowship and Sidney Sax – Public Health Overseas Fellowship (1054216) grant awarded to Rachael Morton for the conduct of the ICECAP-O study. Karan Shah is employed at the NHMRC Clinical Trials Centre, University of Sydney, and is fully funded by the institution. The remaining authors declare that they have no other relevant financial interests.

Competing interests

None of the authors declare a conflict of interest. The results presented in this paper have not been published previously elsewhere, either in whole or part, except in abstract format.

Ethics approval

The study was performed in accordance with the NHMRC National Statement on Ethical Conduct in Human Research (Commonwealth of Australia, 2007), and relevant guidance in the

UK. Each renal unit participating in the study obtained the approval of the Institutional Health Research Ethics Committee to conduct the study. The study approval numbers are as follow: UK (IRAS project ID: 134360 & REC reference 14/LO/0291) and Australia (R20140203 HREC/14/RAH/36).

Data sharing statement

Data for the study can be provided for specific research questions that are available from the corresponding author on request

Recteries only

REFERENCES

1. Morton RL, Turner RM, Howard K, et al. Patients who plan for conservative care rather than dialysis: a national observational study in Australia. Am J Kidney Dis. 2012;59(3):419-27.

2. Murtagh FEM, Burns A, Moranne O, et al. Supportive Care: Comprehensive Conservative Care in End-Stage Kidney Disease. Clin J Am Soc Nephrol. 2016;11(10):1909-14.

3. Coast J, Flynn TN, Natarajan L, et al. Valuing the ICECAP capability index for older people. Soc Sci Med. 2008;67(5):874-82.

4. Makai P, Beckebans F, van Exel J, et al. Quality of life of nursing home residents with dementia: validation of the German version of the ICECAP-O. PLoS One. 2014;9(3):e92016.

5. Weinstein MC, Torrance G, McGuire A. QALYs: the basics. Value Health. 2009;12:S5-S9.

6. Whitehead SJ, Ali S. Health outcomes in economic evaluation: the QALY and utilities. Br Med Bull. 2010;96(1):5-21.

7. Walker RC, Howard K, Tong A, et al. The economic considerations of patients and caregivers in choice of dialysis modality. Hemodialysis International. 2016;20(4):634-42.

8. Murtagh FE, Marsh JE, Donohoe P, et al. Dialysis or not? A comparative survival study of patients over 75 years with chronic kidney disease stage 5. Nephrol Dial Transplant. 2007;22(7):1955-62.

9. Ware Jr JE, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996;34(3):220-33.

10. Wyld ML, Chadban SJ, Morton RL. Improving Our Understanding of Quality of Life in CKD. Am J Kidney Dis. 2016;67(6):820-1.

11. Chen G, Ratcliffe J, Kaambwa B, et al. Empirical Comparison Between Capability and Two Health-Related Quality of Life Measures. Soc Indic Res.1-16.

12. Al-Janabi H, Flynn TN, Coast J. Development of a self-report measure of capability wellbeing for adults: the ICECAP-A. Qual Life Res. 2012;21(1):167-76.

13. Coast J, Smith RD, Lorgelly P. Welfarism, extra-welfarism and capability: the spread of ideas in health economics. Soc Sci Med. 2008;67(7):1190-8.

14. Sen A. Choice, welfare, and measurement: Harvard University Press; 1997.

15. Grewal I, Lewis J, Flynn T, et al. Developing attributes for a generic quality of life measure for older people: preferences or capabilities? Soc Sci Med. 2006;62(8):1891-901.

16. Makai P, Koopmanschap MA, Brouwer WB, et al. A validation of the ICECAP-O in a population of post-hospitalized older people in the Netherlands. Health Qual Life Outcomes. 2013;11(1):57.

17. Vandenbroucke JP, von Elm E, Altman DG, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and Elaboration. PLoS Med. 2007;4(10):e297.

18. Sellars M, Clayton JM, Morton RL, et al. An Interview Study of Patient and Caregiver Perspectives on Advance Care Planning in ESRD. Am J Kidney Dis. 2018;71(2):216-24.

19. Walker RC, Howard K, Morton RL, et al. Patient and caregiver values, beliefs and experiences when considering home dialysis as a treatment option: a semi-structured interview study. Nephrol Dial Transplant. 2015;31(1):133-41.

BMJ Open

20. Morton RL, Tong A, Webster AC, et al. Characteristics of dialysis important to patients and family caregivers: a mixed methods approach. Nephrol Dial Transplant. 2011;26(12):4038-46.

21. Peipert JD, Bentler PM, Klicko K, et al. Psychometric properties of the kidney disease quality of life 36-item short-form survey (KDQOL-36) in the United States. Am J Kidney Dis. 2018;71(4):461-8.

22. Brazier JE, Roberts J. The estimation of a preference-based measure of health from the SF-12. Med Care. 2004;42(9):851-9.

23. Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ. 2002;21(2):271-92.

24. Kharroubi SA, Brazier JE, Roberts J, et al. Modelling SF-6D health state preference data using a nonparametric Bayesian method. J Health Econ. 2007;26(3):597-612.

25. Ware JE, Keller SD, Kosinski M. SF-12: How to score the SF-12 physical and mental health summary scales: Health Institute, New England Medical Center; 1995.

26. Hays R, Spritzer K. KDQOL-36[™] Scoring Program (v1. 0). 2000.

27. Flynn TN, Chan P, Coast J, et al. Assessing quality of life among British older people using the ICEPOP CAPability (ICECAP-O) measure. Appl Health Econ Health Policy. 2011;9(5):317-29.

28. Walters SJ, Brazier JE. Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D. Qual Life Res. 2005;14(6):1523-32.

29. Mitchell PM, Venkatapuram S, Richardson J, et al. Are Quality-Adjusted Life Years a Good Proxy Measure of Individual Capabilities? Pharmacoeconomics. 2017;35(6):637-46.



Patient Characteristics	Dialysis	Conservative	
	Dialysis	Care	Total
	n = 83	n = 46	n = 129
	n (%)	n (%)	n (%)
Dialysis			
Facility Haemodialysis	68 (82%)	-	68 (53%)
Home Haemodialysis	2 (2%)	-	2 (2%)
Peritoneal Dialysis	13 (16%)	-	13 (10%)
Median age (y)	81 [78-84]	83 [81-87]	81 [78-85]
Age group			
≤81 years	50 (60%)	19 (41%)	69 (53%)
>81 years	33 (40%)	27 (59%)	60 (47%)
Sex			
Males	57 (69%)	27 (59%)	84 (65%)
Females	26 (31%)	19 (41%)	45 (35%)
Country			
United Kingdom	58 (70%)	9 (20%)	67 (52%)
Australia	25 (30%)	37 (80%)	62 (48%)
Education			
Primary school	26 (31%)	19 (41%)	45 (35%)
Some high school	35 (42%)	17 (37%)	52 (40%)
Completed high school	8 (10%)	3 (7%)	11 (9%)
Completed diploma	6 (7%)	3 (7%)	9 (7%)
Completed university degree	7 (8%)	3 (7%)	10 (8%)
Private Health Insurance			
Yes	15 (18%)	14 (30%)	29 (22%)
No	65 (78%)	29 (63%)	94 (73%)
Unknown	1 (1%)	1 (2%)	2 (2%)

Table 1: Patients characteristics according to treatment group

	Differences†	95 % Lower CI	95 % Upper CI	p value
SF-6D utilities	-0.05	-0.12	0.01	0.12
KDQOL-PCS	-3.17	-7.61	1.27	0.16
KDQOL-MCS	-2.41	-7.66	2.84	0.37
KDQOL-Burden of Disease	-28.59	-41.77	-15.42	<0.001*
KDQOL-Symptoms of Disease	-5.93	-14.61	2.73	0.18
KDQOL-Effects of Disease	-16.49	-25.98	-6.99	<0.001*
ICECAP-O capability index	-0.07	-0.16	0.02	0.12

Table 2: Adjusted Difference in SF-6D utilities, KDQOL-36 scores, and ICECAP-O capability index for dialysis compared with conservative care (fully adjusted)

Difference in scores adjusted for age, gender, country, education, and health insurance status. * p < 0.001, statistical significance. CI - Confidence interval. KDQOL-36 - Kidney disease quality of life with 36 items. PCS - Physical Component Summary. MCS - Mental Component Summary.

Table 3: Convergent validity between ICECAP-O and SF-6D measures (n = 114)[†] using Pearson's correlation coefficient

	ICECAP-O overall	ICECAP-O				
		domain				
		Attachment	Security	Role	Enjoyment	Control
SF-6D overall	0.65**	-	-	-	-	-
SF-6D domain						
Physical health	0.43**	0.08	0.31*	0.40**	0.32*	0.40**
Role limitations	0.30*	0.05	0.21*	0.28*	0.14	0.31*
Social functioning	0.41**	0.18	0.25*	0.34*	0.30*	0.35*
Pain	0.56**	0.17	0.29*	0.51**	0.43**	0.53**
Mental health	0.39**	0.19*	0.35*	0.30*	0.27*	0.27*
Vitality	0.44**	0.17	0.21*	0.41**	0.28*	0.42**

[†] Observations with missing values on either SF-12 or ICECAP-O questions were removed from the analysis (n = 15). * p < 0.05, statistical significance. ** p < 0.001, statistical significance.

Figure Legends

Figure 1- *Title:* KDQOL-36 Burden of Kidney Disease score for Dialysis group (n = 83).

Explanatory text: A higher score indicates lower burden of disease and better quality of life.

Figure 2- *Title:* KDQOL-36 Burden of Kidney Disease score Conservative Care group (n = 44).

Explanatory text: A higher score indicates lower burden of disease and better quality of life.

Figure 3- *Title:* KDQOL-36 Effects of Kidney Disease score for Dialysis group (n = 82).

Explanatory text: A higher score indicates lower effects of disease and better quality of life.

Figure 4- Title: KDQOL-36 Effects of Kidney Disease score for Conservative Care group (n

= 45).

Explanatory text: A higher score indicates lower effects of disease and better quality of life.

Supplementary Material

Supplementary Table 1 (Table S1): SF-6D utilities, SF-12 PCS and MCS scores, and ICECAP-O capability index according to patient characteristics

Supplementary Table 2 (Table S2): Mean scores and weights of SF-6D, KDQOL-36 and ICECAP-O according to treatment group


Supplementary Table 3 (Table S3): KDQOL-36 Burden of Kidney Disease, Symptoms of Kidney Disease, and Effects of Kidney Disease scores according to patient characteristics Supplementary Item 1 (Item S1): STROBE Statement: checklist of items that should be included in reports of observational studies

Supplementary Item 2 (Item S2): KDQOL-36 Questionnaire (SF-12: Questions 1 - 12 (converted to SF-utilities), KDQOL scores (PCS and MCS scores: Questions 1 - 12, burden of kidney disease: Questions 13 - 16, effects of kidney disease: Questions 17 - 28, symptoms of kidney disease: Questions 29 - 36)

Supplementary Item 3 (Item S3): ICECAP-O Questionnaire

Supplementary Item 4 (Item S4): Background Questions

Supplementary Item 5 (Item S5): SF-6D domains







Figure 1: KDQOL-36 Burden of Kidney Disease score for Dialysis group (n = 83). A higher score indicates lower burden of disease and better quality of life.









Figure 2: KDQOL-36 Burden of Kidney Disease score for Conservative Care group (n = 44). A higher score indicates lower burden of disease and better quality of life.










Figure 4: KDQOL-36 Effects of Kidney Disease score for Conservative Care group (n = 45). A higher score indicates lower effects of disease and better quality of life.

Characteristics	SF-6D ($n = 116$) [†]	$PCS (n = 115) \ddagger \ddagger$	MCS (n = 115);	ICECAP-O $(n = 126)$	e 31
	Mean (95 % CI)	Mean (95 % CI)	Mean (95 % CI)	Mean (95 % CI)	of 49
Age					•
≤81 years	0.63 (0.60-0.67)	32.71 (30.31-35.10)	48.35 (45.51-51.19)	0.73 (0.69-0.78)	
>81 years	0.62 (0.58-0.65)	32.08 (29.33-34.84)	46.04 (42.89-49.20)	0.72 (0.67-0.77)	
Gender					
Males	0.65 (0.62-0.68)*	34.31 (32.00-36.62)*	47.92 (45.44-50.40)	0.73 (0.68-0.77)	
Females	0.58 (0.53-0.62)*	28.85 (26.31-31.39)*	45.98 (42.03-49.93)	0.72 (0.67-0.78)	
$Treatment^{**}$					
Dialysis	0.61 (0.57-0.64)	31.22 (29.02-33.43)	47.67 (45.03-50.30)	0.71 (0.66-0.75)	
Conservative Care	0.65 (0.61-0.70)	34.32 (31.27-37.38)	46.56 (42.98-50.15)	0.76 (0.70-0.82)	
Country					
United Kingdom	0.60 (0.56-0.63)*	30.76 (28.30-33.22)	49.62 (46.66-52.58)*	0.72 (0.67-0.76)	
Australia	0.65 (0.61-0.69)*	33.98 (31.38-36.57)	44.99 (42.06-47.92)*	0.73 (0.68 - 0.79)	B
Education §					M) C
Attended some high school	0.62 (0.59-0.65)	31.87 (29.84-33.91)	46.98 (44.43-49.53)	0.72 (0.68-0.76))pen
Completed high school or	$0.63\ (0.58-0.69)$	34.19 (30.22-38.17)	48.09 (44.21-51.97)	0.73 (0.66-0.80)	
tertiary education					
Private Health Insurance ¶					
Yes	0.68 (0.62-0.73)*	33.03 (29.55-36.50)	49.50 (44.82-54.18)	0.79 (0.73-0.85)	
No/Unknown	0.61 (0.58-0.64)*	32.25 (30.09-34.40)	46.77 (44.40-49.13)	0.71 (0.67 - 0.75)	

Specific SF-6D algorithms were used to convert the SF-12 scores to preference based SF-6D utilities for the UK and the Australian population. 13 out of 129 observations had missing values on SF-12 questionnaire and their SF-6D utilities were not calculated; the remaining had 2 observations missing value for education variable; 3 observations missing value for health insurance variable. 77 14 out of 129 observations had missing values on SF-12 questionnaire and their PCS score were not calculated; the remaining had 1 observation missing value for education variable; 2 observations missing value for health insurance variable. ‡ 14 out of 129 observations had missing values on SF-12 and their MCS score were not calculated; the remaining had 1 observation missing value for education variable; 2 observations missing value for health insurance variable. ‡‡ 3 out of 129 observations had missing values on ICECAP-O questionnaire and their capability index were not calculated; the remaining had 2 observations missing value for education variable; 4 observations missing value for health insurance variable. * p < 0.05, statistical significance. ** The dialysis group consist of Facility Haemodialysis, Home Haemodialysis and Peritoneal dialysis. § Individual responses to Primary school/Some high school were merged into one category as "Attended some high school" and the responses to GCSEs/Completed high school/Diploma/TAFE/ Completed A- levels/ University degree were merged into one category as "Completed high school or tertiary education". I Individual responses to "No" and "Unknown" were merged into one category as "No/Unknown". CI - Confidence interval. SF-12 - Short form survey with 12 items. PCS - Physical Component Summary. MCS - Mental Component Summary.

For peer review only - http://bmjopen.pmj.com/site/about/guidelines.xhtml

Instrument	Score	Weights	Score	Weights
	Mean (SD)	Mean (SD)	Mean (SD)	Mean (SD)
SF-6D‡				
Physical functioning	2.47 (1.04)	-0.02 (0.02)	2.26 (0.68)	-0.018 (0.02)
Role limitations	3.22 (1.44)	-0.06 (0.02)	2.84 (1.28)	-0.05 (0.03)
Social functioning	3.33 (1.62)	-0.06 (0.03)	2.65 (1.25)	-0.06 (0.03)
Pain	3.29 (2.13)	-0.05 (0.05)	2.60 (1.37)	-0.04 (0.05)
Mental health	2.90 (1.92)	-0.05 (0.04)	2.33 (1.10)	-0.05 (0.04)
Vitality	3.86 (1.72)	-0.09 (0.02)	3.57 (1.13)	-0.09 (0.01)
KDQOL-36				
Physical Component Summary (PCS)	31.22 (9.32)	-	34.32 (10.05)	,
Mental Component Summary (MCS)	47.67 (11.12)		46.56 (11.78)	
Burden of Kidney Disease	34.71 (27.77)	2	62.83 (29.45)	
Symptom of Kidney Disease	70.71 (18.74)	0	76.61 (19.18)	
Effects of Kidney Disease	64.18 (20.27)		81.29 (21.92)	ı
ICECAP-0#				
Attachment (love and friendship)	3.25 (0.87)	0.22 (0.06)	3.27 (0.81)	0.22 (0.05)
Security (thinking about future without concern)	2.42 (0.99)	0.09 (0.05)	2.71 (0.92)	0.10 (0.05)
Role (doing things that make you feel valued)	2.51 (0.82)	0.15(0.04)	2.69 (0.85)	0.15 (0.05)
Enjoyment (enjoyment and pleasure)	2.52 (0.94)	0.13 (0.04)	2.80 (0.97)	0.14 (0.04)
Control (independence)	2.51 (0.94)	0.13 (0.08)	2.82 (1.01)	0.15 (0.09)
† 6 observations missing values on SF-6D Role limitation domain; 12 observations missing PCS and MCS score; 2 observations missing Symptoms of Kidney Disease score; 1	tation domain; 1	2 observations missing PCS and M	CS score; 2 observations r	nissing Symptoms of Kidney Disease score
observations missing Effects of Kidney Disease score; 2 observations missing values on ICECAP-O Attachment domain. 77 1 observation missing value on SF-6D Role limitation	:; 2 observations	missing values on ICECAP-O Atta	chment domain. †† 1 obser	vation missing value on SF-6D Role limitati
domain; 2 observations missing KDQOL-36 PCS, MCS, Burden of Kidney Disease, and Symptoms of Kidney Disease score; 1 observation missing KDQOL-36 Effects of Kidney	CS, Burden of K	idney Disease, and Symptoms of K	idney Disease score; 1 obse	rvation missing KDQOL-36 Effects of Kidr
Disease score: 1 absentiation missing value on all ICECAD O domains				
Disease score, I ouser valion mussing value on all ICL		S. \ddagger SF-0U domain scores are weight	Died decrements. ## ICEC	. 7 Sr-6D domain scores are weighted decrements. 77 ICECAP-O domain scores are weighted increments.

6 2 5 5 5 5 5 5 5 5 7 7 7 7 7 7 7 7 7 7 7	50 Burden of KYdney Disease, Symponic	s s s s s s s s s s s s s s s b b b b b	Page 3: 1 2 3 4 5 6 7 8 9 10 2 8 scores according to patient
Characteristics	Burden of Kidney Disease (n = 127) \ddagger	Symptoms of Kidney Disease $(n = 125)$ ††	Effects of Kidney Disease $(n = 127)$
	Mean (95 % CI)	Mean (95 % CI)	ි Mean (95 % CI)
Age			
\leq 81 years	41.80 (34.47-49.12)	72.21 (67.15-77.27)	69.15 (63.05-75.25)
>81 years	47.16 (38.81-55.50)	73.35 (68.76-77.95)	71.35 (66.26-76.43)
Gender			
Males	44.43 (37.70-51.15)	74.00 (70.01-78.00)	71.48 (66.72-76.23)
Females	44.51 (34.62-54.39)	70.46 (64.13-76.79)	67.91 (60.77-75.05)
Treatment**			
Dialysis	34.71 (28.65-40.78)*	70.71 (66.56-74.85)	64.18 (59.72-68.63)*
Conservative Care	62.83 (53.88-71.78)*	76.61 (70.78-82.44)	81.29 (74.70-87.88)*
Country			
United Kingdom	37.81 (30.68-44.94)*	71.97 (67.37-76.58)	66.29 (61.31-71.28)*
Australia	51.88 (43.59-60.16)*	73.72 (68.64-78.81)	74.65 (68.52-80.77)*
Education§			Dpen
Attended some high school	45.32 (38.85-51.79)	71.42 (67.21-75.63)	70.93 (66.29-75.57)
Completed high school or tertiary educa-	43.53 (32.44-54.61)	76.87 (72.15-81.59)	68.92 (61.06-76.79)
tion			
Private Health Insurance¶			
Yes	55.32 (41.82-68.83)*	73.33 (65.11-81.54)	75.85 (67.67-84.02)
No/Unknown	41.62 (35.62-47.63)*	72.88 (69.03-76.73)	69.32 (64.80-73.84)
† 2 out of 129 observations had missing values	s on burden of disease questions and their s	† 2 out of 129 observations had missing values on burden of disease questions and their score was not calculated; the remaining had 2 observations missing value for education variable;	rvations missing value for education variable;
4 observations missing value for health insurar	nce variable. $\ddagger \ddagger 4$ out of 129 observations	4 observations missing value for health insurance variable. †† 4 out of 129 observations had missing values on symptoms of disease questions and their score was not calculated; the	ons and their score was not calculated; the
remaining had 2 observations missing value fo	or education variable; 4 observations missir	remaining had 2 observations missing value for education variable; 4 observations missing value for health insurance variable. ‡ 2 out of 129 observations had missing values on effects	29 observations had missing values on effects
of disease questions and their score was not calculated; the remaining had		2 observations missing value for education variable; 4 observations missing value for health insurance	ons missing value for health insurance
variable. * p < 0.05, statistical significance. ** The dialysis group consist		of Facility Haemodialysis, Home Haemodialysis and Peritoneal dialysis. § Individual responses to Primary	lialysis. § Individual responses to Primary
school/Some high school were merged into on	le category as "Attended some high school"	school/Some high school were merged into one category as "Attended some high school" and the responses to GCSEs/Completed high school/Diploma/TAFE/ Completed A- levels/	ool/Diploma/TAFE/ Completed A- levels/
University degree were merged into one catego	ory as "Completed high school or tertiary ϵ	University degree were merged into one category as "Completed high school or tertiary education". I Individual responses to "No" and "Unknown" were merged into one category as	nknown" were merged into one category as

"No/Unknown". CI - Confidence interval. KDQOL-36 - Kidney disease quality of life with 36 items.

Supplementary Item 1 (Item S1): STROBE Statement: checklist of items that should be

included in reports of observational studies

	Item		Yes/No/NA,
	No	Recommendation	Page No.
Title and abstract	1	(<i>a</i>) Indicate the study's design with a commonly	Yes, page 1-
		used term in the title or the abstract	2
		(b) Provide in the abstract an informative and	Yes, Page
		balanced summary of what was done and what was	2-3
		found	
Introduction			
Background/rationale	2	Explain the scientific background and rationale for	Yes, Page
		the investigation being reported	4-7
Objectives	3	State specific objectives, including any pre-	Yes, Page 7
		specified hypotheses	
Methods		2	
Study design	4	Present key elements of study design early in the	Yes, Page 7
		paper	
Setting	5	Describe the setting, locations, and relevant dates,	Yes, Page
		including periods of recruitment, exposure, follow-	7-8
		up, and data collection	
Participants	6	<i>Cross-sectional study</i> —Give the eligibility criteria,	Yes, Page
		and the sources and methods of selection of	7-8
		participants	

Variables	7	Clearly define all outcomes, exposures, predictors,	Yes, Page
		potential confounders, and effect modifiers. Give	8-9
		diagnostic criteria, if applicable	
Data sources/	8*	For each variable of interest, give sources of data	Yes, Page
measurement		and details of methods of assessment	9-10
		(measurement). Describe comparability of	
		assessment methods if there is more than one	
	D.	group	
Bias	9	Describe any efforts to address potential sources of	Yes, Page
		bias	
Study size	10	Explain how the study size was arrived at	Yes,
			Protocol
		Ċ,	Page 7
Quantitative variables	11	Explain how quantitative variables were handled in	Yes, Page
		the analyses. If applicable, describe which	10
		groupings were chosen and why	
Statistical methods	12	(a) Describe all statistical methods, including those	Yes, Page
		used to control for confounding	10-11
		(b) Describe any methods used to examine	Yes, Page
		subgroups and interactions	10-11
		(c) Explain how missing data were addressed	Yes, Page
			10-11
		Cross-sectional study—If applicable, describe	NA
		analytical methods taking account of sampling	
		strategy	

		(<u>e</u>) Describe any sensitivity analyses	NA
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—	No –
		e.g., numbers potentially eligible, examined for eligibility,	screening
		confirmed eligible, included in the study, completing	logs at each
		follow-up, and analysed	site were
			not
	C		available
		(b) Give reasons for non-participation at each stage	No
		(c) Consider use of a flow diagram	NA
Descriptive data	14*	(a) Give characteristics of study participants (e.g.,	Yes, Page
		demographic, clinical, social) and information on	7-8, 22
		exposures and potential confounders	
		(b) Indicate number of participants with missing data for	Yes, Page
		each variable of interest	12-14, 24
		(c) Cohort study—Summarise follow-up time (e.g.,	NA
		average and total amount)	
Outcome data	15*	Cross-sectional study—Report numbers of outcome events	Yes, Page
		or summary measures	11-14
Main results	16	(a) Give unadjusted estimates and, if applicable,	Yes, Page
		confounder-adjusted estimates and their precision (e.g.,	11-14, 23-
		95% confidence interval). Make clear which confounders	24
		were adjusted for and why they were included	

		(b) Report category boundaries when continuous variables	Yes, Page
		were categorised	11-14, 23
			24
		(<i>c</i>) If relevant, consider translating estimates of relative	NA
		risk into absolute risk for a meaningful time period	
Other analyses	17	Report other analyses done—e.g., analyses of subgroups	Yes, Page
		and interactions, and sensitivity analyses	11-14
Discussion		2	
Key results	18	Summarise key results with reference to study objectives	Yes, Page
		R	15-16
Limitations	19	Discuss limitations of the study, taking into account	Yes, Page
		sources of potential bias or imprecision. Discuss both	17
		direction and magnitude of any potential bias	
Interpretation	20	Give a cautious overall interpretation of results considering	Yes, Page
		objectives, limitations, multiplicity of analyses, results	17
		from similar studies, and other relevant evidence	
Generalisability	21	Discuss the generalisability (external validity) of the study	Yes, Page
		results	17
Other informati	on	·	
Funding	22	Give the source of funding and the role of the funders for	Yes, Page
		the present study and, if applicable, for the original study	18
		on which the present article is based	

Supplementary Item 2 (Item S2): KDQOL-36 Questionnaire (SF-12: Questions 1 – 12 (converted to SF-utilities), KDQOL scores (PCS and MCS scores: Questions 1 – 12, burden of kidney disease: Questions 13 – 16, effects of kidney disease: Questions 17 – 28, symptoms of kidney disease: Questions 29 – 36)

Your Health – and – Well-Being

Kidney Disease and Quality of Life (KDQOLTM-36)

This survey asks for your views about your health. This information will help keep track of how you feel and how well you are able to do your usual activities.



Thank you for completing these questions!

Kidney Disease and Quality of Life™ (KDQOL™-36) English Version 1. Copyright © 2000 by RAND and the University of Arizona

Your Health

This survey includes a wide variety of questions about your health and your life. We are interested in how you feel about each of these issues.

1. In general, would you say your health is: [Mark an 🖂 in the one box that best describes your answer.]



The following items are about activities you might do during a typical day. <u>Does your health now limit</u> you in these activities? If so, how much? [Mark an 🔀 in a box on each line.]

		Yes, limited a lot	Yes, limited a little	No, not limited at all
2.	<u>Moderate activities</u> , such as moving a table, pushing a vacuum cleaner, bowling, or playing golf	. 🔲 ı	2	🔲 3
3.	Climbing several flights of stairs		2	3

During the <u>past 4 weeks</u>, have you had any of the following problems with your work or other regular daily activities <u>as a result of your</u> <u>physical health</u>?

		Yes	No
4.	Accomplished less than you would like	1	
5.	Were limited in the <u>kind</u> of work or other activities	1	

During the past 4 weeks, have you had any of the following problems with your work or other regular daily activities as a result of any emotional problems (such as feeling depressed or anxious)?

		Yes	No
6.	Accomplished less than you would like	<u> </u>	
7.	Didn't do work or other activities as <u>carefully</u> as usual	1	

8. During the <u>past 4 weeks</u>, how much did <u>pain</u> interfere with your normal work (including both work outside the home and housework)?

Not at all	A little bit	Moderately	Quite a bit	Extremely
1	2	3	4	5

These questions are about how you feel and how things have been with you <u>during the past 4 weeks</u>. For each question, please give the one answer that comes closest to the way you have been feeling.

How much of the time during the past 4 weeks ...

	_						
		All of the time	Most of the time	A good bit of the time	Some of the time	A little of the time	None of the time
9.	Have you felt calm and peaceful?	1	2	🔲 3		5	🔲 õ
10.	Did you have a lot of energy?	i	2	🔲 3		5	б
11.	Have you felt downhearted and blue? .	i	2	🔲 3	4	5	6

12. During the <u>past 4 weeks</u>, how much of the time has your <u>physical</u> <u>health or emotional problems</u> interfered with your social activities (like visiting with friends, relatives, etc.)?

All	Most	Some	A little	None
of the time				
t	2	3	4	5

Your Kidney Disease

How true or false is each of the following statements for you?

		Definitely true	Mostly true	Don't know	Mostly false	Definitely false
13.	My kidney disease interferes too much with my life	<u> </u>	2	3		3
14.	Too much of my time is spent dealing with my kidney disease	1	2	3	4	3
15.	I feel frustrated dealing with my kidney disease	<u> </u>	2	3		5
16.	I feel like a burden on my family	1	2	3		5

		Not at all bothered	Somewhat bothered	Moderately bothered	Very much bothered	Extremely bothered
17.	Soreness in your muscles?	1	2	3	4	s
18.	Chest pain?	i		3	4	5
19.	Cramps?	1		3	4	s
20.	Itchy skin?	<u> </u>		3	4	5
21.	Dry skin?	1	2	B 3	4	5
22.	Shortness of breath?	<u> </u>	2	3		
23.	Faintness or dizziness?	1	2	2	4	s
24.	Lack of appetite?	1	2	3	4	5
25.	Washed out or drained?	1	2]	4	5
26.	Numbness in hands or feet?	t	2	3	4	
27.	Nausea or upset stomach?	<u> </u>	2	2	4	5
28 ^a .	(Hemodialysis patie	nt only)				
	Problems with your access site?	1	2	3	4	5
28 ^b .	(Peritoneal dialysis j	patient only))			
	Problems with your catheter site?	1	2	3	4	s

Effects of Kidney Disease on Your Daily Life


Some people are bothered by the effects of kidney disease on their daily life, while others are not. How much does kidney disease <u>bother</u> you in each of the following areas?

		Not at all bothered		Moderately bothered	Very much bothered	Extremely bothered
29.	Fluid restriction?	1	2	3		5
30.	Dietary restriction?	1	2	3	4	🗖 s
31.	Your ability to work around the house?	1	2	2	4	🔲 s
32.	Your ability to travel?	1	2	3	4	5
33.	Being dependent on doctors and other medical staff?	1	2	2	4	S
34.	Stress or worries caused by kidney disease?	, 🗌 1	2	£ 3	4	s
35.	Your sex life?	1	2	3	4	5
36.	Your personal appearance?	1		3	4	5

Supplementary Item 3 (Item S3): ICECAP-O Questionnaire

ABOUT YOUR QUALITY OF LIFE

By placing a tick (\checkmark) in ONE box in EACH group below, please indicate which statement best describes your quality of life at the moment.



© Joanna Coast & Terry Flynn

2	
2	
4	
5	
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29	
7	
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	
26	
27	
28	
29	
30 31 32 33 34 35 36 37 38	
31	
32	
33	
34	
35	
36	
3/	
38 39	
39 40	
40 41	
41	
42	
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
56	
57	
58	
50	

1

Supplementary Item 4 (Item S4): Background Questions

Q1.	What is your full name?	
Q2.	What is your date of birth?(<i>dd/mm/yyyy</i>)	
Q3.	Gender (please tick one)	
	Male	
	Female 🗆	
Q4.	What is your main residential postcode?	
Q5.	What was your country of birth?	
Q6.	What is the highest level of education you have completed? (please tick th	е
	box that best describes you)	
	Primary school	
	Some high school	
	Completed high school	
	Completed Diploma/ TAFE course	
	Completed University Degree	
Q7.	Do you have private health insurance? (please tick one)	
	Yes 🗆	
	No 🗆	
	Don't know	
Q8.	What type of kidney treatment are you <i>currently</i> having? (<i>please tick one</i>)	
	Hemodialysis (satellite or hospital)	
	Hemodialysis at home	
	Peritoneal dialysis	
	Non-dialysis renal supportive care	

Q9.	If you	If you are currently on dialysis when did you first start dialysis?				
		(mm/yyyy)				
Q10.	Have	Have you ever had a kidney transplant before? (please tick one)				
	Yes	□ № □				
Q11.	The n	ext two questions a	are about the ICE	CAP-O survey. Or	n the scale below	
	please	e rate how <u>easy</u> this	s survey was to co	mplete (circle a nu	mber between 1	
and 5)						
Very	y easy	Somewhat	Neutral	Somewhat	Very	
		easy		difficult	difficult	

Q12. Did this survey measure the things that you consider <u>important</u> to your quality of life? *(circle a number between 1 and 5)*

Completely	Somewhat	Neutral	Somewhat	Completely
agree	agree	102	disagree	disagree
1	2	3	4	5

Q13. If you responded with 'somewhat disagree' or 'completely disagree,' would

you like to tell us what you think the ICECAP-O survey was missing?

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Q14. The next two questions are about the SF-12 survey. On the scale below please rate

Very easy	Somewhat	Neutral	Somewhat	Very
	easy		difficult	difficult
1	2	3	4	5

how <u>easy</u> this survey was to complete (circle a number between 1 and 5)

Q15. Did this survey measure the things that you consider <u>important</u> to your quality of life? *(circle a number between 1 and 5)*

Completely	Somewhat	Neutral	Somewhat	Completely
agree	agree		disagree	disagree
1	2	3	4	5
		6		

Q16. If you responded with 'somewhat disagree' or 'completely disagree,' would

you like to tell us what you think the SF-12 survey was missing?

_ L

Supplementary Item 5 (Item S5): SF-6D domains

Level	SF-6D		
	Physical Functioning		
1	Your health does not limit you in vigorous activities		
2	Your health limits you a little in vigorous activities		
3	Your health limits you a little in <i>moderate activities</i>		
4	Your health limits you a lot in moderate activities		
5	Your health limits you a little in bathing and dressing		
6	Your health limits you a lot in bathing and dressing		
	Role limitations		
1	You have <i>no</i> problems with your work or other regular		
1	daily activities as a result of your physical health or any emotional problems		
~			
2	You are limited in the kind of work or other activities as a result of your physical health		
3	You accomplish less than you would like as a result of		
	emotional problems		
4	You are limited in the kind of work or other activities as a result of your physical health and accomplish less than		
	you would like as a result of emotional problems		
	Social functioning		
1	Your health limits your social activities none of the time		
2			
	Your health limits your social activities a little of the time		
3	Your health limits your social activities some of the time		
4	Your health limits your social activities most of the time		
5	Your health limits your social activities all of the time		
	Pain		
1	You have no pain		
2	You have pain but it does not interfere with your normal		
	work (both outside the home and housework)		
3	You have pain that interferes with your normal work		
	(both outside the home and housework) a little bit		
4	You have pain that interferes with your normal work		
-	(both outside the home and housework) <i>moderately</i>		
F			
5	You have pain that interferes with your normal work		
~	(both outside the home and housework) quite a bit		
6	You have pain that interferes with your normal work		
	(both outside the home and housework) extremely		
	Mental health		
1	You feel tense or downhearted and low none of the time		
2	You feel tense or downhearted and low a little of the time		
3	You feel tense or downhearted and low some of the time		
4	You feel tense or downhearted and low most of the time		
5	You feel tense or downhearted and low all of the time		
14	Vitality		
1	You have a lot of energy all of the time		
2	You have a lot of energy most of the time		
3	You have a lot of energy some of the time		
4	You have a lot of energy a little of the time		
5	You have a lot of energy none of the time		
	Tou have a for or energy none of the time		

Copyright © 2004 John Wiley & Sons, Ltd.

BMJ Open

BMJ Open

Health-related quality of life and wellbeing in people over 75 years of age with end-stage kidney disease managed with dialysis or comprehensive conservative care: a crosssectional study in the UK and Australia

Journal:	BMJ Open		
Manuscript ID	bmjopen-2018-027776.R2		
Article Type:	Research		
Date Submitted by the Author:	08-Apr-2019		
Complete List of Authors:	Shah, Karan; The University of Sydney, NHMRC Clinical Trials Centre, Health Economics Murtagh, Fliss; Wolfson Palliative Care Research Centre, Hull York Medical School, University of Hull, UK McGeechan, Kevin; The University of Sydney, School of Public Health Crail, Su; Royal Adelaide Hospital Burns, Aine; Royal Free Hospital Tran, Anh; The University of Sydney, NHMRC Clinical Trials Centre, Health Economics Morton, Rachael; The University of Sydney, NHMRC Clinical Trials Centre, Health Economics		
Primary Subject Heading :	Health economics		
Secondary Subject Heading:	Health services research, Qualitative research, Renal medicine, Research methods		
Keywords:	Chronic renal failure < NEPHROLOGY, Chronic renal insufficiency, Dialysis < NEPHROLOGY, PALLIATIVE CARE, HEALTH ECONOMICS, Quality of life		



Title: Health-related quality of life and wellbeing in people over 75 years of age with endstage kidney disease managed with dialysis or comprehensive conservative care: a crosssectional study in the UK and Australia

Karan K Shah¹, Fliss E M Murtagh², Kevin McGeechan³, Su Crail⁴, Aine Burns⁵, Anh D Tran¹, Rachael L Morton¹

- National Health and Medical Research Council (NHMRC) Clinical Trials Centre, The University of Sydney, NSW, Australia
- Wolfson Palliative Care Research Centre, Hull York Medical School, University of Hull, UK

ien

- 3. School of Public Health, The University of Sydney, NSW, Australia
- 4. Royal Adelaide Hospital, SA, Australia
- 5. Royal Free Hospital, London NHS Foundation Trust, UK

Corresponding Author:

Karan K Shah, MSc.

Health Economics, NHMRC Clinical Trials Centre,

The University of Sydney,

92-94 Parramatta Road, Camperdown NSW 2050, Australia

Tel: +61 2 9562 5030

Fax: +61 2 9562 5387

Email: karan.shah@ctc.usyd.edu.au

Word Count: 3550

ABSTRACT

Objective

To measure HRQoL and wellbeing in older people with end stage kidney disease and to determine the association between treatment type and socio-demographic characteristics on these outcome measures. In addition, to assess the convergent validity between the HRQoL and wellbeing measure and their feasibility and acceptability in this population.

Design

Prospective cross-sectional study.

Setting

3 renal units in the UK and Australia.

Participants

129 ESKD patients managed with dialysis or with an estimated glomerular filtration $(eGFR) \le 10 \text{ml/min}/1.73 \text{m}^2$ and managed with comprehensive conservative, non-dialytic care.

Outcome measures

HRQoL and wellbeing were assessed using Short-Form six dimensions (SF-6D, 0-1 scale); KDQOL-36 (0-100 scale) and Investigating Choice Experiments Capability Measure–Older people (ICECAP-O, 0-1 scale). Linear regression assessed associations between treatment, HRQoL and wellbeing. Pearson's correlation coefficient assessed convergent validity between instruments.

Results

Median age of 81 years [IQR 78–85], 65% males; 83(64%) were managed with dialysis and 46(36%) with conservative care. When adjusted for treatment type and sociodemographic variables, those managed on dialysis reported lower mean SF-6D utility (-0.05, 95%CI -0.12 to 0.01); lower KDQOL Physical Component Summary score (-3.17, 95%CI -7.61 to 1.27); lower Mental Component Summary score (-2.41, 95%CI -7.66 to 2.84); lower quality of life

BMJ Open

due to Burden (-28.59, 95%CI -41.77 to -15.42); Symptoms (-5.93, 95%CI -14.61 to 2.73), and Effects of Kidney Disease (-16.49, 95%CI -25.98 to -6.99); and lower overall ICECAP-O wellbeing (-0.07, 95%CI -0.16 to 0.02) than those managed conservatively. Correlation between ICECAP-O wellbeing and SF-6D utility scores was strong overall, 0.65 (p<0.001), but weak to moderate at domain level.

Conclusions

Older people on dialysis report significantly higher burden and effects of kidney disease than those on conservative care. Lower HRQoL and wellbeing may be associated with dialysis treatment, and should inform shared decision making about treatment options.

Trial registration

UK (IRAS project ID: 134360 & REC reference 14/LO/0291) and Australia (R20140203 HREC/14/RAH/36).

KEYWORDS

Chronic Kidney Failure, Chronic Renal Insufficiency, Renal Dialysis, Quality Of Life, Palliative Care

STRENGTHS AND LIMITATIONS OF THIS STUDY

- The strengths of our study include a prospective assessment of HRQoL in people over 75 years of age, and the use of a novel measure to value wellbeing.
- This information is essential for doctors to discuss the relative benefits of dialysis compared with conservative care.
- The limitation of this study is that, the sample size may not have been sufficient to detect a statistically significant difference in mean scores if one existed.
- We did not have complete data on patient's comorbid conditions that may have impacted our ability to explore the associations between comorbid conditions and HRQoL or wellbeing.
- Considering the cross-sectional nature of the data, we were unable to analyse any changes relating to individuals' HRQoL or wellbeing over time, which might be captured in a longitudinal study.

INTRODUCTION

Comprehensive conservative care services were developed for people with end-stage kidney disease (ESKD) in the UK and Australia following the substantial increase in the number of older people aged \geq 75 years being referred to nephrologists for dialysis,[1]. Comprehensive conservative care includes interventions to delay the progression of kidney disease and minimise complications, as well as detailed communication, shared decision-making, advance care planning, and psychologic and family support, but does not include dialysis,[2]. For older patients who often have high levels of comorbidity (such as diabetes and heart disease) and poor functional status, the survival advantage of dialysis may be limited, and comprehensive conservative management may be considered; however, robust comparative evidence remains minimal,[2]. Considerations such as symptoms, quality of life, and hospital-free days are sometimes more important for patients and families, than expected length of survival,[2].

Traditionally, economists attempt to assist resource allocation decisions by focusing on measuring and valuing health (in its broadest sense), using health-related quality of life (HRQoL) measures and survival, in particular combined in the quality-adjusted life year (QALY),[3]. In QALY calculations, values (often referred to as utility scores) are assigned to different health states, which allows the quantification of health gains comprising both length and quality of life gains from medical interventions,[3, 4]. Utilities are preference weights, where preference can be equated with value or desirability,[5, 6]. The quality adjusted life years (QALYs) value is then calculated by combining the length of survival and the utility weights.

However, many healthcare interventions may impact more broadly on quality of life (assumed to encompass the broad range of factors that are important to people in living their lives) rather than just health (which centers on physical and mental health),[3]. These broad factors could

be related to health and non-health factors that may impact the overall quality of life of a patient,[4]. Measures that look only at health in assessing the impact of these interventions would be very likely to underestimate this impact,[3, 7].

Dialysis has a large impact on the quality of life of both patients and their families; however, traditional HRQoL measures, such as the Short Form 36 (SF-36) and Kidney Disease Quality of Life (KDQOL-36) surveys may be too narrowly focused to detect all of the critical aspects of dialysis that increase or decrease an individual's quality of life,[8]. KDQOL-36TM is a short form questionnaire that includes the SF-12, a generic quality of life questionnaire,[9, 10] plus disease-specific domains including the burden of kidney disease, symptoms/problems of kidney disease, and effects of kidney disease. For this purpose, broader HRQoL measures, often named wellbeing measures, could be used to capture more facets of peoples' lives than health status alone,[4].

New instruments have been developed that provide information across health and social care, rather than just across health,[3]. The recently developed "Investigating Choice Experiments Capability Measure (ICECAP)" family of instruments have been designed to incorporate such dimensions,[11]. These instruments have their theoretical grounding in Amartya Sen's work on the relationships between functioning and capability,[11, 12]. They seek to measure a conceptually different evaluative space through a focus on capabilities: that is, what a person is able to do and who they are able to be, rather than on functioning: what a person actually does and who they become,[13]. Capabilities refer to the potential to achieve certain states and perform certain actions,[4]. Having the capability to live life the way one desires is obviously important, also to older people, and reduction of this capability limits their wellbeing,[4, 14, 15]. The ICECAP-O instrument was specifically developed to measure capability in older

BMJ Open

people. There is little research on how the ICECAP-O is related to other conceptualisations of wellbeing, and the relationships between the ICECAP-O and measures of health (physical, psychological, and social) remain underexplored,[16].

The aims of the study were to measure HRQoL using SF-12 questionnaire, kidney disease quality of life using KDQOL-36TM questionnaire, and wellbeing using ICECAP-O questionnaire; to determine the association between treatment type and socio-demographic characteristics on these outcome measures; to assess the convergent validity between the ICECAP-O wellbeing and the SF-6D utility (derived from SF-12 questionnaire); and to assess the feasibility and acceptability of questionnaires in older ESKD patients.

MATERIALS AND METHODS

Study design

We conducted a cross-sectional study of patients with ESKD treated with dialysis or comprehensive conservative care in the UK and Australia between 2014 and 2017. The study was performed in accordance with the Australian National Statement on Ethical Conduct in Human Research (2007), and relevant guidance in the UK. Each renal unit participating in the study obtained the approval of their Institutional Research Boards UK (IRAS project ID: 134360 & REC reference 14/LO/0291) and Australia (R20140203 HREC/14/RAH/36). The study was reported using STROBE guidelines for observational studies (Item S1),[17]. Eligible subjects were fully informed about the purpose, benefits and risks of the study, and signed an approved participant consent form.

Setting and participants

The study was undertaken at three renal units in the UK and Australia. Included were males and females aged \geq 75 years with ESKD, managed with dialysis (facility haemodialysis, home

haemodialysis, and peritoneal dialysis) or with an estimated glomerular filtration (eGFR) ≤ 10 ml/min/1.73m² and managed with comprehensive conservative, non-dialytic care. The exclusion criteria comprised cognitive impairment; patients unable to read English; and patients who were legally blind. To reduce selection bias, nephrologists and clinical nurses in each participating renal unit reviewed their clinic lists for all patients that met the eligibility criteria.

Sample size calculation

As per the study protocol, a sample size of 194 patients (97 on dialysis, 97 on comprehensive conservative care) was calculated to detect a mean difference of 0.05 in the outcomes with 80% power and 95% confidence.

Patient and public involvement

The research question was developed from prior qualitative work with people with end-stage kidney disease and their carers,[18-20]. Patients were not directly involved in the design of this research study. Patients and their caregivers were informed of the study and invited to participate by the renal unit's research nurses. Participants were provided with an information sheet and consent form for them to read. If they were interested in participating they were asked to sign the consent form and then were provided with two surveys contained in the one booklet, (the ICECAP-O survey and the standard KDQOL-36TM) while at their renal clinic. Patients and their caregivers were assured that participation was voluntary, that they did not have to participate and that their decision either way would not affect their clinical care.

Outcomes and variables

BMJ Open

The key outcomes were SF-6D utilities derived from the SF-12 questions, KDQOL scores from the KDQOL-36 questions, ICECAP-O capability index derived from the ICECAP-O questions. Other outcomes were convergent validity between ICECAP-O wellbeing and the SF-6D utility instrument measured using the Pearson's correlation coefficient; and the feasibility and acceptability of the ICECAP-O and SF-12 questionnaires, assessed by response rate and specific items asking the patient whether the questionnaire was easy to complete, and whether it covered questions important to their quality of life and wellbeing.

Data sources/measurement

All eligible patients were invited to complete the KDQOL-36TM (Item S2) and the five-question ICECAP-O questionnaire (Item S3) while at their renal clinic. Relevant sociodemographic details such as age, sex, country, educational attainment, private health insurance and questions assessing feasibility and acceptability of the ICECAP-O and SF-12 questionnaire were collected (Item S4). Kidney treatment type (facility haemodialysis, home haemodialysis, peritoneal dialysis, and comprehensive conservative care), dialysis status (if currently on dialysis, and time of initiation) and renal transplant status were documented.

Health related quality of life questionnaire

The KDQOL-36 has 36 items: the SF-12 version 1 and another 24 kidney specific items,[21]. The SF-12 responses on the KDQOL-36 were transformed into HRQoL weights, known as utilities, using a published SF-6D algorithm,[22]. The SF-6D is a generic preference-based single measure of health used to generate utilities from six domains: physical, role, social, pain, mental, and vital (Item S5). The SF-6D utilities generated are measured on a 0 (death) to 1 (full health) scale, and were reported with mean and standard deviations (SDs) using UK population values,[22-24].

The SF-12 section of KDQOL-36 also yields PCS (Physical Component Summary) and MCS (Mental Component Summary) scores, both of which are scored on a T-score metric (mean = 50, SD = 10, for the US general population),[21, 25]. The three kidney specific scales assess Burden of Kidney Disease, Symptoms of Kidney Disease, and Effects of Kidney Disease. Each of these scales is scored by transforming all items to a 0 to 100 possible range and averaging across the items on each scale to create scale scores,[21]. KDQOL-36 items are all scaled so that higher scores indicate better HRQoL,[21, 26].

Wellbeing questionnaire

The ICECAP-O questionnaire measures capabilities and covers five domains of wellbeing, including attachment (love and friendship); security (thinking about the future without concern); role (doing things that make you feel valued); enjoyment (enjoyment and pleasure); and control (independence),[27]. It has four-level response options, representing four levels of capability: none, a little, a lot, and all. The responses on the ICECAP-O questions were transformed to a ICECAP-O capability index ranging from 0 (no capability) to 1 (full capability), and presented with mean and SDs using UK population weights,[3].

Quantitative variables

The SF-6D utilities, KDQOL scores, ICECAP-O capability index, and patients' age were treated as continuous, while patients' sex, treatment type (dialysis, conservative care), education (some high school or lower levels, completed high school or higher levels), private health insurance (yes, no), and health system (UK, Australia) were analysed as categorical variables. Age was also additionally dichotomised (less than or equal to, versus greater than the median age [81 years]).

Statistical methods

The analysis of data involved descriptive statistics assessing proportions and mean values of the SF-6D utilities, PCS, MCS, Burden of Kidney Disease, Symptoms of Kidney Disease, Effects of Kidney Disease scores, and the ICECAP-O capability index for the entire cohort. Hypothesis testing with a two-tailed Student's t-test was used to detect differences in the mean values of SF-6D utilities, KDQOL-36 scores, and ICECAP-O capability index for patients' treatment type and socio-demographic characteristics. We hypothesised that HRQoL and wellbeing measures in each treatment group would be equivalent.

Linear regression with multivariable models was undertaken to determine the association between treatment type and patient characteristics on SF-6D utilities, KDQOL scores and ICECAP-O capability index. In the multivariable linear regression, age, sex, treatment type, education, private health insurance, and health system were included as covariates on the basis of *a priori* knowledge of their associations with the HRQoL and wellbeing measures.

Pearson's correlation coefficient was used to determine the convergent validity of the ICECAP-O wellbeing with the SF-6D utility instrument. The correlations were assessed for the overall ICECAP-O and SF-6D utility scores and their domains. We hypothesised, moderate to strong positive correlations because both these instruments measures some similar facets of quality of life. Correlations above 0.5 were considered strong, between 0.3 and 0.5 as moderate, and below 0.3 as weak,[16].

Complete case analysis was performed for all outcomes. All statistical analyses were performed with SAS Version 9.4 (SAS Institute, Cary, NC). A p-value of <0.05 was considered statistically significant.

RESULTS

A total of 129 patients were recruited, including 83 (64%) managed with dialysis and 46 (36%) patients managed with comprehensive conservative care. The majority of conservatively treated patients were from Australia (n = 37), and most treated with dialysis were from the UK (n = 58). Overall, 65% were male, and the median age of the entire cohort was 81 years [IQR 78–85]. Patient characteristics are shown in Table 1.

Health-related quality of life SF-6D utilities

Of 129 patients, the mean utility for 116 patients with complete data was 0.62 (SD 0.14) (n = 13 missing values). The mean SF-6D utilities for the dialysis group were 0.61 (SD 0.13), and 0.65 (SD 0.15) for the conservative care group (Table S1). The "vitality" domain reported the highest average score, and was responsible for the highest decrement in utilities in both treatment groups (Table S2).

The mean SF-6D utilities were 0.07 (SD 0.14) lower for females than for males (p = 0.006); 0.06 (SD 0.14) lower for patients residing in the UK compared with those residing in Australia (p = 0.03); and 0.07 (SD 0.14) lower for patients without a private health insurance compared to patients with a private health insurance (p = 0.03) (Table S1). When adjusted for all variables, the mean SF-6D utilities were 0.09 lower for females compared to males (95 % lower CI = -0.14 and upper CI = -0.03, p = 0.002). There was no significant difference in the mean utilities observed between two treatments when adjusted for other variables (Table 2).

KDQOL scores

The mean KDQOL scores on the five domains for patients with complete data were as follows: PCS score of 32.41 (n = 115, SD 9.68); MCS score of 47.25 (n = 115, SD 11.34); Burden of Kidney Disease score of 44.46 (n = 127, SD 31.28); Symptom/Problems of Kidney Disease score of 72.78 (n = 125, SD 19.03); and Effects of Kidney Disease score of 70.24 (n = 127, SD 22.35).

In univariate analysis the PCS score was 5.46 points lower in females than males (p = 0.004) (i.e. lower physical health); the MCS score was 4.63 points lower in Australian versus UK patients (p = 0.03) (i.e. lower mental health) table S1 and table S3. The Burden of Kidney Disease score was 28.12 points lower in the dialysis group than the conservative care group (p < 0.001) (indicating a higher burden of disease and lower quality of life) (Figure 1 and Figure 2); 14.06 points lower in UK versus Australian patients (p = 0.01) (indicating higher burden of disease); 13.70 points lower in patients without private health insurance compared to those with private health insurance (p = 0.04) (indicating a higher burden of disease). The Effects of Kidney Disease score was 17.11 points lower in the dialysis group compared to the conservative care group (p < 0.001) (indicating higher effects of the disease and lower quality of life) (Figure 3, Figure 4); 8.35 points lower in UK versus Australian patients (p = 0.03) (indicating higher effects of the disease).

The dialysis group reported a higher MCS score (47.67 vs 46.56), indicating marginally better mental health than the conservative care group. (Table S2).

BMJ Open

When adjusted for other variables, the mean score for the Burden of Kidney Disease sub-scale was 28.59 lower (i.e. more burdensome) for patients on dialysis compared with patients on conservative care (p<0.001) (Table 2). The mean score for Effects of Kidney Disease when adjusted for all the other variables, was 16.49 lower (i.e. higher disease related effects) for patients on dialysis compared with patients on comprehensive conservative care (p<0.001) (Table 2). Adjusted scores were lower but not statistically, significantly different for PCS, MCS and Symptoms of Kidney Disease between the two treatment groups.

ICECAP-O capability index

The mean ICECAP-O capability index for 126 patients with complete data was 0.72 (SD 0.19) (n=3 missing values). In the dialysis group, the mean capability index was 0.71 (SD 0.19), and 0.76 (SD 0.20) for the conservative care group (Table S1), but not significantly different. Overall, the dialysis treatment group reported a lower wellbeing score on all five domains compared to the conservative care group. The "attachment" domain showed the highest average score, and was responsible for the highest contribution to capabilities in both treatment groups (Table S2). When adjusted for other variables, there were no significant differences in the mean capability index observed between the two treatments (Table 2).

Convergent validity

For 114 observations the SF-6D utilities score and the pain domain of the SF-6D were strongly correlated with the overall ICECAP-O capability index with a Pearson's coefficient of 0.65 (p<0.001) and 0.56 (p<0.001) respectively. At the domain level, the role and control domains of the ICECAP-O questionnaire were strongly correlated with the pain domain of the SF-6D, with a Pearson's coefficient of 0.51 (p<0.001) and 0.53 (p<0.001) respectively. All other

 domains of the ICECAP-O were weakly or moderately correlated with SF-6D domains, values ranging from 0.02 to 0.49 (Table 3).

Feasibility and acceptability

115 of 129 patients completed the questionnaire, with 14 patients missing items for the ICECAP-O and 10 patients missing items for the SF-12. Overall, patients found both questionnaires easy to use and relevant to assessing their wellbeing. They responded with an average score of 1.78 out of 5 (1 = strongly agree, 5 = completely disagree) on questions assessing ease of use; and with an average score 1.77 and 1.79 out of 5 on the questions assessing the relevance of ICECAP-O and the SF-12 questions respectively.

DISCUSSION

This prospective cross-sectional study determined the mean SF-6D utilities, KDQOL scores and ICECAP-O capability index for patients with ESKD according to treatment, and sociodemographic variables. Our findings suggest females compared with males, patients residing in the UK compared with those residing in Australia, and patients without private health insurance compared with those with private health insurance have significantly lower SF-6D utilities. However, when adjusted for the other variables, only females reported significantly lower utilities compared with males. Furthermore, the study determined the convergent validity between the ICECAP-O wellbeing and SF-6D utility instrument and assessed the feasibility and acceptability of the ICECAP-O wellbeing and SF-12 questionnaire in older people with ESKD.

The dialysis group reported 0.05 lower SF-6D utilities compared with the conservative care group reflecting a potentially clinically meaningful difference related to treatment, however,

BMJ Open

this difference was not statistically significant. Meaningful differences or the minimal important difference (MID) in utility-based HRQoL reported in 11 studies using the SF-6D utilities ranged from 0.011 to 0.097, with a mean MID of 0.041,[28]. It is therefore likely our study has detected a meaningful difference. In addition, a 0.05 difference in ICECAP-O wellbeing for dialysis patients may also represent a clinically meaningful difference, however, MIDs for ICECAP-O have not yet been published. Similarly, the KDQOL-36TM instrument identified a higher burden of disease, and greater effects of the disease for those on dialysis. This finding needs to be explored further in a larger sample size to investigate the potential detrimental effects of dialysis on HRQoL.

In our study, with the exception of a strong correlation between the "control" and "role" domain of the ICECAP-O with the "pain" domain on the SF-6D, most of the ICECAP-O domains were found to have weak to moderate correlations with the SF-6D corresponding domains. This indicates the newly developed capability instrument does measure different aspects of quality of life or wellbeing, and offers additional information when compared to measures of health, such as the SF-6D used in the conventional QALY approach. In addition, we observed a higher score for the feasibility and acceptability of the ICECAP-O questions indicating it to be acceptable and as relevant as SF-12 (an established HRQoL measure).

There is debate in the health economics literature concerning the ways to apply the capability approach in economic evaluations with some suggesting that QALYs alone are adequate, while others argue this approach is too narrow, and that direct measures of capability or wellbeing provide a more extensive application of Sen's paradigm,[29]. Capability is empirically distinct from functioning and the content of capability instruments is not subsumed by the content of instruments used to capture changes in HRQoL for QALYs,[29].

BMJ Open

Health economic analyses would benefit from the inclusion of individual capability measures; whether the focus should be only upon people's *achievements*—their "functioning"—or people's *capability to achieve* is contested,[29]. Sen's example of the fasting man versus the starving man serves as a key example for focusing on capability: two people, one of whom is starving and the other, who is fasting, have comparable functioning in terms of nourishment, but their capabilities to be nourished are notably different,[29]. The argument is that focusing on functioning alone would miss important distinctions, such as differences in freedom and choice between individuals,[29].

There are some limitations to this study. First, we were only able to recruit 129 of the 194 patients outlined in the protocol sample size, as some of the study sites were unable to participate. Hence, the sample size may not have been sufficient to detect a statistically significant difference in mean scores if one existed. Second, our observational study of older patients with end-stage kidney disease may not have perfectly matched the two groups with respect to co-morbid conditions or rate of renal decline. We did not have complete data on comorbidities and this may have impacted our ability to explore the associations between treatment type, HRQoL or wellbeing. Third, considering the cross-sectional nature of the data, we were unable to analyse any changes relating to individuals' HRQoL or wellbeing over time, which might be captured in a longitudinal study. The strengths of our study include a prospective assessment of HRQoL in people over 75 years of age, and the use of a novel measure to value wellbeing. This information is essential for doctors to discuss the relative benefits of dialysis compared with conservative care.

In conclusion, we observed lower quality of life and wellbeing for older patients with ESKD managed on dialysis compared to comprehensive conservative care. Furthermore, measuring wellbeing using a capability index provides additional insights into the impact of dialysis on older people than HRQoL measurement alone and has potential to improve the economic evaluation of treatment for ESKD.

to beet terien only

Acknowledgements

The authors gratefully acknowledge the patients who participated in this study; the research nurses from the UK and Australian renal units; and Dr Sherilyn Goldstone for proof reading the final version of the manuscript.

Authors' Contributions

Authors FM, KM, SC, AB, and RM designed the study. RM, SC and AB led the data collection. KS conducted the analysis and drafted the first version of the manuscript. RM, AT and KM supported the data analysis and interpretation of the results, and all authors revised the final version of the manuscript.

Funding

This work was supported by the NHMRC Early Career Researcher Fellowship and Sidney Sax – Public Health Overseas Fellowship (1054216) grant awarded to Rachael Morton for the conduct of the ICECAP-O study. Karan Shah is employed at the NHMRC Clinical Trials Centre, University of Sydney, and is fully funded by the institution. The remaining authors declare that they have no other relevant financial interests.

Competing interests

None of the authors declare a conflict of interest. The results presented in this paper have not been published previously elsewhere, either in whole or part, except in abstract format.

Ethics approval

The study was performed in accordance with the NHMRC National Statement on Ethical Conduct in Human Research (Commonwealth of Australia, 2007), and relevant guidance in the

UK. Each renal unit participating in the study obtained the approval of the Institutional Health Research Ethics Committee to conduct the study. The study approval numbers are as follow: UK (IRAS project ID: 134360 & REC reference 14/LO/0291) and Australia (R20140203 HREC/14/RAH/36).

Data sharing statement

Data for the study can be provided for specific research questions that are available from the corresponding author on request.

Rectories only

REFERENCES

1. Morton RL, Turner RM, Howard K, et al. Patients who plan for conservative care rather than dialysis: a national observational study in Australia. Am J Kidney Dis. 2012;59(3):419-27.

2. Murtagh FEM, Burns A, Moranne O, et al. Supportive Care: Comprehensive Conservative Care in End-Stage Kidney Disease. Clin J Am Soc Nephrol. 2016;11(10):1909-14.

3. Coast J, Flynn TN, Natarajan L, et al. Valuing the ICECAP capability index for older people. Soc Sci Med. 2008;67(5):874-82.

4. Makai P, Beckebans F, van Exel J, et al. Quality of life of nursing home residents with dementia: validation of the German version of the ICECAP-O. PLoS One. 2014;9(3):e92016.

5. Weinstein MC, Torrance G, McGuire A. QALYs: the basics. Value Health. 2009;12:S5-S9.

6. Whitehead SJ, Ali S. Health outcomes in economic evaluation: the QALY and utilities. Br Med Bull. 2010;96(1):5-21.

7. Walker RC, Howard K, Tong A, et al. The economic considerations of patients and caregivers in choice of dialysis modality. Hemodialysis International. 2016;20(4):634-42.

8. Murtagh FE, Marsh JE, Donohoe P, et al. Dialysis or not? A comparative survival study of patients over 75 years with chronic kidney disease stage 5. Nephrol Dial Transplant. 2007;22(7):1955-62.

9. Ware Jr JE, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996;34(3):220-33.

10. Wyld ML, Chadban SJ, Morton RL. Improving Our Understanding of Quality of Life in CKD. Am J Kidney Dis. 2016;67(6):820-1.

11. Chen G, Ratcliffe J, Kaambwa B, et al. Empirical Comparison Between Capability and Two Health-Related Quality of Life Measures. Soc Indic Res.1-16.

12. Al-Janabi H, Flynn TN, Coast J. Development of a self-report measure of capability wellbeing for adults: the ICECAP-A. Qual Life Res. 2012;21(1):167-76.

13. Coast J, Smith RD, Lorgelly P. Welfarism, extra-welfarism and capability: the spread of ideas in health economics. Soc Sci Med. 2008;67(7):1190-8.

14. Sen A. Choice, welfare, and measurement: Harvard University Press; 1997.

15. Grewal I, Lewis J, Flynn T, et al. Developing attributes for a generic quality of life measure for older people: preferences or capabilities? Soc Sci Med. 2006;62(8):1891-901.

16. Makai P, Koopmanschap MA, Brouwer WB, et al. A validation of the ICECAP-O in a population of post-hospitalized older people in the Netherlands. Health Qual Life Outcomes. 2013;11(1):57.

17. Vandenbroucke JP, von Elm E, Altman DG, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and Elaboration. PLoS Med. 2007;4(10):e297.

18. Sellars M, Clayton JM, Morton RL, et al. An Interview Study of Patient and Caregiver Perspectives on Advance Care Planning in ESRD. Am J Kidney Dis. 2018;71(2):216-24.

19. Walker RC, Howard K, Morton RL, et al. Patient and caregiver values, beliefs and experiences when considering home dialysis as a treatment option: a semi-structured interview study. Nephrol Dial Transplant. 2015;31(1):133-41.

BMJ Open

20. Morton RL, Tong A, Webster AC, et al. Characteristics of dialysis important to patients and family caregivers: a mixed methods approach. Nephrol Dial Transplant. 2011;26(12):4038-46.

21. Peipert JD, Bentler PM, Klicko K, et al. Psychometric properties of the kidney disease quality of life 36-item short-form survey (KDQOL-36) in the United States. Am J Kidney Dis. 2018;71(4):461-8.

22. Brazier JE, Roberts J. The estimation of a preference-based measure of health from the SF-12. Med Care. 2004;42(9):851-9.

23. Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ. 2002;21(2):271-92.

24. Kharroubi SA, Brazier JE, Roberts J, et al. Modelling SF-6D health state preference data using a nonparametric Bayesian method. J Health Econ. 2007;26(3):597-612.

25. Ware JE, Keller SD, Kosinski M. SF-12: How to score the SF-12 physical and mental health summary scales: Health Institute, New England Medical Center; 1995.

26. Hays R, Spritzer K. KDQOL-36[™] Scoring Program (v1. 0). 2000.

27. Flynn TN, Chan P, Coast J, et al. Assessing quality of life among British older people using the ICEPOP CAPability (ICECAP-O) measure. Appl Health Econ Health Policy. 2011;9(5):317-29.

28. Walters SJ, Brazier JE. Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D. Qual Life Res. 2005;14(6):1523-32.

29. Mitchell PM, Venkatapuram S, Richardson J, et al. Are Quality-Adjusted Life Years a Good Proxy Measure of Individual Capabilities? Pharmacoeconomics. 2017;35(6):637-46.



Patient Characteristics	Dialysis	Conservative	
	Dialysis	Care	Total
	n = 83	n = 46	n = 129
	n (%)	n (%)	n (%)
Dialysis			
Facility Haemodialysis	68 (82%)	-	68 (53%)
Home Haemodialysis	2 (2%)	-	2 (2%)
Peritoneal Dialysis	13 (16%)	-	13 (10%)
Median age (y)	81 [78-84]	83 [81-87]	81 [78-85]
Age group			
≤81 years	50 (60%)	19 (41%)	69 (53%)
>81 years	33 (40%)	27 (59%)	60 (47%)
Sex			
Males	57 (69%)	27 (59%)	84 (65%)
Females	26 (31%)	19 (41%)	45 (35%)
Country			
United Kingdom	58 (70%)	9 (20%)	67 (52%)
Australia	25 (30%)	37 (80%)	62 (48%)
Education			
Primary school	26 (31%)	19 (41%)	45 (35%)
Some high school	35 (42%)	17 (37%)	52 (40%)
Completed high school	8 (10%)	3 (7%)	11 (9%)
Completed diploma	6 (7%)	3 (7%)	9 (7%)
Completed university degree	7 (8%)	3 (7%)	10 (8%)
Private Health Insurance			
Yes	15 (18%)	14 (30%)	29 (22%)
No	65 (78%)	29 (63%)	94 (73%)
Unknown	1 (1%)	1 (2%)	2 (2%)

Table 1: Patients characteristics	according to treatment group
-----------------------------------	------------------------------

	Differences†	95 % Lower CI	95 % Upper CI	p value
SF-6D utilities	-0.05	-0.12	0.01	0.12
KDQOL-PCS	-3.17	-7.61	1.27	0.16
KDQOL-MCS	-2.41	-7.66	2.84	0.37
KDQOL-Burden of Disease	-28.59	-41.77	-15.42	<0.001*
KDQOL-Symptoms of Disease	-5.93	-14.61	2.73	0.18
KDQOL-Effects of Disease	-16.49	-25.98	-6.99	<0.001*
ICECAP-O capability index	-0.07	-0.16	0.02	0.12

Table 2: Adjusted Difference in SF-6D utilities, KDQOL-36 scores, and ICECAP-O capability index for dialysis compared with conservative care (fully adjusted)

 \dagger Difference in scores adjusted for age, gender, country, education, and health insurance status. * p < 0.001, statistical significance. CI - Confidence interval. KDQOL-36 - Kidney disease quality of life with 36 items. PCS - Physical Component Summary. MCS - Mental Component Summary.

Table 3: Convergent validity between ICECAP-O and SF-6D measures (n = 114)[†] using Pearson's correlation coefficient

		domain				
		Attachment	Security	Role	Enjoyment	Control
SF-6D overall	0.65**	-	-	-	-	-
SF-6D domain						
Physical health	0.43**	0.08	0.31*	0.40**	0.32*	0.40**
Role limitations	0.30*	0.05	0.21*	0.28*	0.14	0.31*
Social functioning	0.41**	0.18	0.25*	0.34*	0.30*	0.35*
Pain	0.56**	0.17	0.29*	0.51**	0.43**	0.53**
Mental health	0.39**	0.19*	0.35*	0.30*	0.27*	0.27*
Vitality	0.44**	0.17	0.21*	0.41**	0.28*	0.42**

[†] Observations with missing values on either SF-12 or ICECAP-O questions were removed from the analysis (n = 15). * p < 0.05, statistical significance. ** p < 0.001, statistical significance.

Figure Legends

Figure 1- *Title:* KDQOL-36 Burden of Kidney Disease score for Dialysis group (n = 83). *Explanatory text:* A higher score indicates lower burden of disease and better quality of life.
Figure 2- Title: KDQOL-36 Burden of Kidney Disease score for Conservative Care group (n = 44).

Explanatory text: A higher score indicates lower burden of disease and better quality of life.

Figure 3- *Title:* KDQOL-36 Effects of Kidney Disease score for Dialysis group (n = 82).


Explanatory text: A higher score indicates lower effects of disease and better quality of life.

Figure 4- Title: KDQOL-36 Effects of Kidney Disease score for Conservative Care group (n = 45).

Explanatory text: A higher score indicates lower effects of disease and better quality of life.

BMJ Open

2 3 4 5	Supplementary Material
6 7	Supplementary Table 1 (Table S1): SF-6D utilities, SF-12 PCS and MCS scores, and
8 9 10	ICECAP-O capability index according to patient characteristics
10 11 12	Supplementary Table 2 (Table S2): Mean scores and weights of SF-6D, KDQOL-36 and
13 14	ICECAP-O according to treatment group
15 16 17	Supplementary Table 3 (Table S3): KDQOL-36 Burden of Kidney Disease, Symptoms of
18 19	Kidney Disease, and Effects of Kidney Disease scores according to patient characteristics
20 21	Supplementary Item 1 (Item S1): STROBE Statement: checklist of items that should be
22 23 24	included in reports of observational studies
25 26	Supplementary Item 2 (Item S2): KDQOL-36 Questionnaire (SF-12: Questions 1 – 12
27 28 20	(converted to SF-utilities), KDQOL scores (PCS and MCS scores: Questions 1 – 12, burden
29 30 31	of kidney disease: Questions 13 – 16, effects of kidney disease: Questions 17 – 28, symptoms
32 33	of kidney disease: Questions 29 – 36)
34 35 36	Supplementary Item 3 (Item S3): ICECAP-O Questionnaire
30 37 38	Supplementary Item 4 (Item S4): Background Questions
39 40	Supplementary Item 5 (Item S5): SF-6D domains
41 42 43	
44 45	
46 47	
48 49	
50	
51 52	
53	
54	
55	
56 57	
58	
59	






Figure 1: KDQOL-36 Burden of Kidney Disease score for Dialysis group (n = 83). A higher score indicates lower burden of disease and better quality of life.

84x63mm (300 x 300 DPI)





Figure 2: KDQOL-36 Burden of Kidney Disease score for Conservative Care group (n = 44). A higher score indicates lower burden of disease and better quality of life.

80x60mm (300 x 300 DPI)







Figure 3: KDQOL-36 Effects of Kidney Disease score for Dialysis group (n = 82). A higher score indicates lower effects of disease and better quality of life.

84x63mm (300 x 300 DPI)






Figure 4: KDQOL-36 Effects of Kidney Disease score for Conservative Care group (n = 45). A higher score indicates lower effects of disease and better quality of life.

84x63mm (300 x 300 DPI)

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Characteristics	SF-6D $(n = 116)$	$PCS (n = 115) \dagger \dagger$	MCS (n = 115)	ICECAP-O $(n = 126)$	
	Mean (95 % CI)	Mean (95 % CI)	Mean (95 % CI)	Mean (95 % CI)	
Age					
\leq 81 years	0.63 (0.60-0.67)	32.71 (30.31-35.10)	48.35 (45.51-51.19)	0.73 (0.69-0.78)	
>81 years	0.62 (0.58-0.65)	32.08 (29.33-34.84)	46.04 (42.89-49.20)	0.72 (0.67-0.77)	
Gender					
Males	0.65 (0.62-0.68)*	34.31 (32.00-36.62)*	47.92 (45.44-50.40)	0.73 (0.68-0.77)	
Females	0.58 (0.53-0.62)*	28.85(26.31-31.39)*	45.98 (42.03-49.93)	0.72 (0.67-0.78)	
Treatment**					
Dialysis	0.61 (0.57-0.64)	31.22 (29.02-33.43)	47.67 (45.03-50.30)	0.71 (0.66-0.75)	
Conservative Care	0.65 (0.61-0.70)	34.32 (31.27-37.38)	46.56 (42.98-50.15)	0.76 (0.70-0.82)	
Country					
United Kingdom	0.60 (0.56-0.63)*	30.76 (28.30-33.22)	49.62 (46.66-52.58)*	0.72 (0.67-0.76)	
Australia	0.65 (0.61-0.69)*	33.98 (31.38-36.57)	44.99 (42.06-47.92)*	0.73 (0.68-0.79)	В
Education §					M) C
Attended some high school	0.62 (0.59-0.65)	31.87 (29.84-33.91)	46.98 (44.43-49.53)	0.72 (0.68-0.76))pen
Completed high school or	$0.63\ (0.58-0.69)$	34.19 (30.22-38.17)	48.09 (44.21-51.97)	0.73 (0.66-0.80)	
tertiary education					
Private Health Insurance ¶					
Yes	0.68 (0.62-0.73)*	33.03 (29.55-36.50)	49.50 (44.82-54.18)	0.79 (0.73-0.85)	
No/Unknown	061 0 58 064)*	37 75 /30 00 37 70)	12 1 10 40 40 13)	0 71 (0 67-0 75)	

Specific SF-6D algorithms were used to convert the SF-12 scores to preference based SF-6D utilities for the UK and the Australian population. 13 out of 129 observations had missing values on SF-12 questionnaire and their SF-6D utilities were not calculated; the remaining had 2 observations missing value for education variable; 3 observations missing value for health insurance variable. 77 14 out of 129 observations had missing values on SF-12 questionnaire and their PCS score were not calculated; the remaining had 1 observation missing value for education variable; 2 observations missing value for health insurance variable. ‡ 14 out of 129 observations had missing values on SF-12 and their MCS score were not calculated; the remaining had 1 observation missing value for education variable; 2 observations missing value for health insurance variable. ‡‡ 3 out of 129 observations had missing values on ICECAP-O questionnaire and their capability index were not calculated; the remaining had 2 observations missing value for education variable; 4 observations missing value Completed A- levels/ University degree were merged into one category as "Completed high school or tertiary education". ¶ Individual responses to "No" and "Unknown" were merged into one category as "No/Unknown". CI - Confidence interval. SF-12 - Short form survey with 12 items. PCS - Physical Component Summary. MCS - Mental Component Summarg. responses to Primary school/Some high school were merged into one category as "Attended some high school" and the responses to GCSEs/Completed high school/Diploma/TARE/ for health insurance variable. * p < 0.05, statistical significance. ** The dialysis group consist of Facility Haemodialysis, Home Haemodialysis and Peritoneal dialysis. § Individual

For peer review only - http://bmjopen_bmj.com/site/about/guidelines.xhtml

Mean (SI) <	Instrument	Score	Weights	Score	Weights
SF-GD: Pysical functioning 247 (104) -0.02 (0.02) 226 (0.68) -0.018 (0.02) Role imitations 3.32 (1.44) -0.06 (0.02) 2.84 (1.28) -0.06 (0.03) Role imitations 3.33 (1.62) -0.06 (0.03) 2.66 (1.37) -0.06 (0.03) Printing 3.33 (1.62) -0.06 (0.03) 2.66 (1.37) -0.06 (0.03) Printing 3.33 (1.62) -0.06 (0.03) 2.66 (1.37) -0.06 (0.03) Printing 3.33 (1.72) -0.09 (0.02) 2.66 (1.37) -0.06 (0.03) Printing 3.34 (1.72) -0.09 (0.02) 2.56 (1.37) -0.06 (0.03) Virating 3.34 (1.72) -0.09 (0.02) 2.37 (1.13) -0.06 (0.01) Virating 3.34 (1.72) -0.09 (0.02) 2.37 (1.13) -0.06 (0.01) Virating -1.32 (1.32) -1.32 (1.32) -2.36 (1.32) -0.06 (0.01) Virating -1.32 (1.12) -1.32 (1.12) -2.46 (1.13) -0.06 (0.01) Virating -1.32 (1.12) -1.32 (1.13) -2.46 (1.13) -2.46 (1.13) Virating -1.32 (1.12) -1.32 (1.13) -2.46 (1.13) -		Mean (SD)	Mean (SD)	Mean (SD)	Mean (SD)
Physical functioning $247(1,0,0)$ $0.02(0,0)$ $2.56(0,5)$ $-0.018(0,0)$ Role luminations $3.32(1,5)$ $0.06(0,0)$ $2.84(1,28)$ $0.05(0,0)$ Social functioning $3.32(1,5)$ $0.06(0,0)$ $2.56(1,3)$ $0.06(0,0)$ Numinal health $3.32(2,1)$ $0.05(0,0)$ $2.66(1,3)$ $0.06(0,0)$ Numinal health $3.32(2,1)$ $0.05(0,0)$ $2.57(1,1)$ $0.06(0,0)$ Numinal health $3.36(1,7)$ $0.09(0,0)$ $2.37(1,1)$ $0.09(0,0)$ Numinal health $3.36(1,7)$ $0.09(0,0)$ $3.57(1,1)$ $0.09(0,0)$ Numinal health $3.36(1,7)$ $0.09(0,0)$ $3.37(1,1)$ $0.09(0,0)$ Numinal health $3.36(1,7)$ $0.09(0,0)$ $3.37(1,1)$ $0.09(0,0)$ Numinal health $3.36(1,7)$ $3.37(1,1)$ $3.37(1,1)$ $0.09(0,0)$ Numinal health $3.37(1,1)$ $3.37(1,1)$ $0.09(0,0)$ $0.06(0,0)$ Numinal health $3.37(1,1)$ $3.37(1,1)$ $0.09(0,0)$ Numinal health <td< td=""><td>SF-6D‡</td><td></td><td></td><td></td><td></td></td<>	SF-6D‡				
Role immations $3.21 (1.4)$ $0.06 (0.02)$ $2.84 (1.28)$ $0.65 (0.03)$ Secial functioning $3.31 (1.6_1)$ $0.06 (0.03)$ $2.66 (1.25)$ $0.06 (0.03)$ Pain $3.29 (2.13)$ $0.06 (0.03)$ $0.05 (0.04)$ $2.66 (1.25)$ $0.06 (0.03)$ Memal health $3.29 (2.13)$ $0.05 (0.04)$ $2.66 (1.2)$ $0.06 (0.03)$ Memal health $2.90 (1.92)$ $0.05 (0.04)$ $2.56 (1.2)$ $0.06 (0.01)$ Viaily $3.35 (1.12)$ $2.00 (0.02)$ $3.35 (1.13)$ $0.09 (0.01)$ KDOOL-SC $3.12 (9.32)$ $3.12 (9.32)$ $2.00 (0.02)$ $3.35 (1.12)$ $0.05 (0.03)$ KDOOL-SC $3.12 (2.73)$ $4.16 (71.12)$ $-0.06 (0.02)$ $3.32 (1.12)$ $0.00 (0.01)$ KDOOL-SC $3.71 (2.77)$ $-0.05 (0.02)$ $3.32 (0.13)$ $0.05 (0.13)$ $0.00 (0.01)$ KDOOL-SC $3.71 (2.77)$ $-0.00 (0.02)$ $3.32 (0.13)$ $0.02 (0.04)$ $0.05 (0.13)$ KDOOL-SC $3.71 (2.77)$ $-0.23 (0.23)$ $3.27 (0.13)$ $0.02 (0.03)$ $0.02 $	Physical functioning	2.47 (1.04)	-0.02 (0.02)	2.26 (0.68)	-0.018 (0.02)
	Role limitations	3.22 (1.44)	-0.06 (0.02)	2.84 (1.28)	-0.05 (0.03)
Pain 3.29 (2.13) -0.05 (0.05) 2.06 (1.37) -0.04 (0.05) Merral health 2.90 (1.92) -0.05 (0.04) 2.33 (1.10) -0.06 (0.01) Virality 2.90 (1.72) -0.09 (0.02) 3.57 (1.13) -0.09 (0.01) KDOL-36 3.86 (1.72) -0.09 (0.02) 3.57 (1.13) -0.09 (0.01) KDOL-36 3.86 (1.72) -0.09 (0.02) 3.57 (1.13) -0.09 (0.01) KDOL-36 3.12 (3.23 (3.23) 3.77 (1.13) -6.06 (0.01) -6.66 (0.01) Plysical Component Summary (MCS) 3.71 (1.771) -6.33 ($3.29.45$) -6.23 ($3.29.45$) -6.23 ($3.29.45$) Symptom of Kidney Disease 70.71 ($1.8.74$) -6.23 (2.027) -6.23 (2.027) -6.23 (2.027) Symptom of Kidney Disease $6.1.8$ (2.027) -70.71 ($1.8.74$) -756 ($1.9.19$) -6.23 (2.192) -6.23 (2.192) -6.23 (2.192) -756 (1.191) -756 (1.012) -6.23 (2.025) Symptom of Kidney Disease $-6.1.8$ (2.027) -2.2 (0.93) -2.2 (0.92) -2.2 (0.92) -2.2 (0	Social functioning	3.33 (1.62)	-0.06 (0.03)	2.65 (1.25)	-0.06 (0.03)
	Pain	3.29 (2.13)	-0.05 (0.05)	2.60 (1.37)	-0.04 (0.05)
Vitality $3.6 (1.72)$ $0.09 (0.02)$ $3.57 (1.13)$ $0.09 (0.01)$ KDOU36 $3.12 (9.32)$ $3.46 (1.72)$ $0.09 (0.02)$ $3.57 (1.13)$ $0.09 (0.01)$ Physical Component Summary (PCS) $31.22 (9.32)$ $3.12 (0.05)$ $3.12 (0.05)$ <t< td=""><td>Mental health</td><td>2.90 (1.92)</td><td>-0.05 (0.04)</td><td>2.33 (1.10)</td><td>-0.05 (0.04)</td></t<>	Mental health	2.90 (1.92)	-0.05 (0.04)	2.33 (1.10)	-0.05 (0.04)
KDQOL-36Physical Component Summary (PCS) $31.22 (9.32)$ $ 34.32 (10.05)$ $-$ Menal Component Summary (MCS) $47.67 (1.1.2)$ $ 45.66 (1.7.8)$ $-$ Menal Component Summary (MCS) $37.1 (27.77)$ $ 46.56 (1.7.8)$ $-$ Burden of Kidney Disease $34.71 (27.77)$ $ 62.83 (29.45)$ $-$ Sympton of Kidney Disease $70.71 (18.74)$ $ 70.71 (18.74)$ $-$ Sympton of Kidney Disease $70.71 (18.74)$ $ 70.71 (18.74)$ $-$ Sympton of Kidney Disease $70.71 (18.74)$ $ 81.29 (21.92)$ $-$ Sympton of Kidney Disease $ 64.18 (20.27)$ $ 81.29 (21.92)$ $-$ Attachment (low and friendship) $3.25 (0.87)$ $0.22 (0.06)$ $3.27 (0.81)$ $0.22 (0.05)$ Recurity (thinking about future without concern) $2.42 (0.99)$ $0.09 (0.05)$ $0.11 (0.02)$ Security (thinking about future without concern) $2.32 (0.94)$ $0.13 (0.04)$ $2.20 (0.05)$ Role (doing things that make you feel valued) $2.51 (0.94)$ $0.13 (0.04)$ $2.20 (0.05)$ Role (doing things that make you feel valued) $2.31 (0.03)$ $0.14 (0.04)$ Control (independence) $2.51 (0.94)$ $0.13 (0.04)$ $2.80 (0.97)$ $0.14 (0.04)$ Control (independence) $2.51 (0.94)$ $0.13 (0.04)$ $2.80 (0.97)$ $0.14 (0.04)$ Control (independence) $2.51 (0.94)$ $0.13 (0.04)$ $2.80 (0.97)$ $0.14 (0.04)$ Control (independence) $2.51 ($	Vitality	3.86 (1.72)	-0.09 (0.02)	3.57 (1.13)	-0.09 (0.01)
Physical Component Summary (PCS) $31.2 (9.32)$ $3.12 (9.32)$ $3.12 (9.32)$ $3.12 (9.32)$ $3.12 (9.32)$ $3.12 (9.32)$ $3.12 (9.32)$ $3.12 (9.32)$ $3.12 (9.32)$ $3.12 (9.32)$ $3.12 (9.37)$ $3.12 (9.37)$ $3.12 (9.37)$ $3.12 (9.37)$ $3.12 (9.37)$ $3.12 (9.37)$ $3.12 (9.37)$ $3.12 (9.37)$ $3.12 (9.37)$ $3.12 (9.37)$ $3.12 (9.37)$ $3.12 (9.37)$ $3.12 (9.37)$ $3.12 (9.37)$ $3.12 (9.37)$ $3.12 (9.37)$ $3.12 (9.37)$ $3.12 (9.18)$ $3.12 (9.19)$ $3.12 (0.16)$ $3.22 (0.16)$ $3.27 (0.81)$ $3.22 (0.91)$ $3.21 (0.91)$ $3.22 (0.05)$ $3.21 (0.91)$ $3.22 (0.05)$ $3.21 (0.05)$ $3.21 (0.05)$ $3.21 (0.05)$ $3.21 (0.05)$ $3.21 (0.05)$ $3.21 (0.05)$ $3.21 (0.05)$ $3.21 (0.05)$ $3.21 (0.05)$ $3.21 (0.05)$ $3.21 (0.05)$ $3.20 (0.97)$ $3.16 (0.05)$ $3.21 (0.05)$ $3.20 (0.97)$ $3.16 (0.05)$ $3.20 (0.97)$ $3.16 (0.05)$ $3.20 (0.97)$ $3.16 (0.05)$ $3.20 (0.97)$ $3.16 (0.05)$ $3.20 (0.97)$ $3.16 (0.05)$ $3.20 (0.97)$ $3.16 (0.05)$ $3.20 (0.97)$ $3.16 (0.05)$ $3.20 (0.97)$ $3.16 (0.05)$ $3.20 (0.97)$ $3.16 (0.05)$ $3.20 (0$	KDQOL-36				
Mental Component Summary (MCS) $47.67 (11.12)$ - $46.56 (11.78)$ -Burden of Kidney Disease $34.71 (27.77)$ - $62.83 (29.45)$ -Symptom of Kidney Disease $70.71 (18.74)$ - $62.83 (29.45)$ -Symptom of Kidney Disease $70.71 (18.74)$ - $76.61 (19.18)$ -Effects of Kidney Disease $64.18 (20.27)$ - $70.71 (18.74)$ -Effects of Kidney Disease $70.71 (18.74)$ - $76.61 (19.18)$ -Effects of Kidney Disease $64.18 (20.27)$ $0.22 (0.06)$ $3.27 (0.81)$ $0.22 (0.05)$ Attachment (love and friendship) $3.25 (0.87)$ $0.22 (0.06)$ $3.27 (0.81)$ $0.22 (0.05)$ Security (thinking about future without concern) $2.42 (0.99)$ $0.09 (0.05)$ $2.71 (0.92)$ $0.10 (0.05)$ Role (doing things that make you feel valued) $2.51 (0.82)$ $0.15 (0.04)$ $2.69 (0.85)$ $0.14 (0.04)$ Enjoyment (enjoyment and pleasure) $2.51 (0.82)$ $0.13 (0.04)$ $2.80 (0.7)$ $0.14 (0.04)$ Control (independence) $2.51 (0.94)$ $0.13 (0.04)$ $2.80 (0.7)$ $0.14 (0.04)$ Control (independence) $2.51 (0.94)$ $0.13 (0.04)$ $2.80 (0.7)$ $0.14 (0.04)$ Control (independence) $2.51 (0.94)$ $0.13 (0.94)$ $2.80 (0.7)$ $0.14 (0.94)$ Control (independence) $2.51 (0.94)$ $0.13 (0.94)$ $2.80 (0.7)$ $0.14 (0.94)$ Control (independence) $2.51 (0.94)$ $0.13 (0.94)$ $2.80 (0.7)$ $0.16 (0.94)$ Control (Physical Component Summary (PCS)	31.22 (9.32)	-	34.32 (10.05)	1
Burden of Kidney Disease $34.71 (27.77)$ $62.83 (29.45)$ $62.83 (29.45)$ $62.83 (29.45)$ $62.83 (29.45)$ $62.83 (29.45)$ $62.83 (29.45)$ $62.83 (29.45)$ $62.83 (29.45)$ $62.83 (29.45)$ $62.83 (29.45)$ $62.81 (20.2)$ $76.61 (19.18)$ $76.71 (10.92)$ $70.10 (10.05)$ $76.71 (10.92)$ $70.10 (10.05)$ $76.71 (10.92)$ $70.10 (10.05)$ Role (doing things that make you feel valued) $2.51 (0.94)$ $0.13 (0.04)$ $2.80 (0.97)$ $0.15 (0.05)$ $2.80 (1.97)$ $0.16 (0.05)$ Role (doing things that make you feel valued) $2.51 (0.94)$ $0.13 (0.04)$ $2.80 (0.97)$ $0.14 (0.04)$ Control (independence) $2.51 (0.94)$ $0.13 (0.04)$ $2.80 (0.97)$ $0.14 (0.04)$ Control (independence) $2.51 (0.94)$ $0.13 (0.04)$ $2.80 (0.97)$ $0.14 (0.04)$ $10 $ observations missing values on SF-6D Role limitation domain: 12 observations missing SVDOL-36 PCS, MCS, Burden of Kidney Disease, an	Mental Component Summary (MCS)	47.67 (11.12)	-	46.56 (11.78)	1
Symptom of Kidney Disease $70.71 (18.74)$ $76.61 (19.18)$ $-$ Effects of Kidney Disease $64.18 (20.27)$ $ 81.29 (21.92)$ $-$ Effects of Kidney Disease $64.18 (20.27)$ $ 81.20 (21.92)$ $-$ ICECAP-O ^{‡‡} $1226 (0.6)$ $3.25 (0.87)$ $0.22 (0.06)$ $3.27 (0.81)$ $0.22 (0.05)$ Attachment (love and friendship) $3.25 (0.87)$ $0.22 (0.06)$ $3.27 (0.81)$ $0.22 (0.05)$ Sccurity (thinking about fruture without concern) $2.42 (0.99)$ $0.09 (0.05)$ $2.71 (0.92)$ $0.10 (0.05)$ Role (doing things that make you feel valued) $2.51 (0.82)$ $0.15 (0.04)$ $2.69 (0.85)$ $0.15 (0.05)$ Role (doing things that make you feel valued) $2.51 (0.94)$ $0.13 (0.04)$ $2.69 (0.85)$ $0.14 (0.04)$ Control (independence) $2.51 (0.94)$ $0.13 (0.08)$ $2.80 (0.97)$ $0.14 (0.04)$ Control (independence) $2.51 (0.94)$ $0.13 (0.08)$ $2.80 (0.97)$ $0.14 (0.04)$ control (independence) $2.51 (0.94)$ $0.13 (0.08)$ $2.80 (0.97)$ $0.14 (0.04)$ control (independence) $2.51 (0.94)$ $0.13 (0.08)$ $2.80 (0.97)$ $0.14 (0.04)$ choservations missing values on SF-6D Role limitation $2.51 (0.94)$ $0.13 (0.08)$ $2.80 (0.97)$ $0.14 (0.04)$ choservations missing Effects of Kidney Disease core; 1 observation missing KDQOL-36 Effects of Bool Annoine 4 Stenden core; 1 observation missing VDOL-36 Effects of Kidney Disease, and Symptoms of Kidney Disease, and Symptoms of Kidney Disease, and Symptoms of Kidney Disease, and Symptom	Burden of Kidney Disease	34.71 (27.77)	2	62.83 (29.45)	ı
Effects of Kidney Disease $64.18(20.27)$ $ 81.29(21.92)$ $-$ ICECAP-O‡ $1000000000000000000000000000000000000$	Symptom of Kidney Disease	70.71 (18.74)	(76.61 (19.18)	1
ICECAP-O‡; Attachment (love and friendship) 3.25 (0.87) 0.22 (0.06) 3.27 (0.81) 0.22 (0.05) 0.10 (0.05) Security (thinking about future without concern) 2.42 (0.99) 0.09 (0.05) 0.15 (0.04) 2.71 (0.92) 0.10 (0.05) Role (doing things that make you feel valued) 2.51 (0.82) 0.15 (0.04) 2.69 (0.85) 0.15 (0.05) 0.14 (0.04) Enjoyment (enjoyment and pleasure) 2.51 (0.94) 0.13 (0.04) 2.69 (0.85) 0.15 (0.05) 0.14 (0.04) For the four third pleasure) 2.51 (0.94) 0.13 (0.08) 2.80 (0.97) 0.14 (0.04) 0.15 (0.09) 0.14 (0.04) For the formation and pleasure 2.52 (0.94) 0.13 (0.08) 2.82 (1.01) 0.15 (0.09) 0.14 (0.04) For the formation and pleasure 2.51 (0.94) 0.13 (0.08) 2.82 (1.01) 0.15 (0.09) 0.14 (0.04) For the formation and pleasure 2.51 (0.94) 0.13 (0.08) 2.82 (1.01) 0.15 (0.09) 0.14 (0.04) For the formation and pleasure 2.50 servations missing values on ICECAP-O Attachment domain. †† 1 observation missing value on SF-6D Role limitation domain; 2 observations missing KDQU-36 PCS, MCS, Burden of Kidney Disease, and Symptoms of Kidney Disease score; 1 observation missing KDQU-36 Effects of Kidney Disease score; 2 observations missing values on ICECAP-O Attachment domain. †† 1 observation missing VDQU-36 Ffects of Kidney Disease score; 1 observation missing VDQU-36 Effects of Kidney Disease score; 1 observations missing VDQU-36 Ffects of Kidney Disease score; 1 observation missing KDQU-36 Effects of Kidney Disease, and Symptoms of Kidney Disease score; 1 observation missing KDQU-36 Ffects of Kidney Disease, and Symptoms of Kidney Disease score; 1 observation missing KDQU-36 Effects of Kidney Disease, and Symptoms of Kidney Disease score; 1 observation missing KDQU-36 Effects of Kidney Disease as a science of the observation missing VDQU-36 Effects of Kidney Disease score; 1 observation missing KDQU-36 Ffect Annota score; 2 observation missing KDQU-36 Effects of Kidney Disease score; 1 observation missing KDQU-36 Ffect Annota score; 2 observation missing KDQU-36 Ffect Annota score; 2 observation missing KDQU-36 Ffect A	Effects of Kidney Disease	64.18 (20.27)		81.29 (21.92)	1
Attachment (love and friendship)3.25 (0.87)0.22 (0.06)3.27 (0.81)0.22 (0.05)Security (thinking about future without concern)2.42 (0.99)0.09 (0.05)2.71 (0.92)0.10 (0.05)Role (doing things that make you feel valued)2.51 (0.82)0.15 (0.04)2.69 (0.85)0.15 (0.05)Enjoyment (enjoyment and pleasure)2.51 (0.82)0.13 (0.04)2.69 (0.85)0.15 (0.05)Control (independence)2.51 (0.94)0.13 (0.04)2.80 (0.97)0.14 (0.04)f o boservations missing values on SF-6D Role limitation domain. 12 observations missing PCS and MCS score; 2 observations missing symptoms of Kidney Disease score; 10.15 (0.09)observations missing Effects of Kidney Disease score; 2 observations missing values on ICECAP-O Attachment domain. 7† 1 observation missing value on SF-6D Role limitationdomain; 2 observations missing KDQOL-36 PCS, MCS, Burden of Kidney Disease, and Symptoms of Kidney Disease score; 1 observation missing KDQOL-36 PCS, MCS, Burden of Kidney Disease, and Symptoms of Kidney Disease score; 1 observation missing kDQOL-36 PCA Amonin score station score station for score st	ICECAP-O#				
Security (thinking about future without concern)2.42 (0.99)0.09 (0.05)2.71 (0.92)0.10 (0.05)Role (doing things that make you feel valued)2.51 (0.82)0.15 (0.04)2.69 (0.85)0.15 (0.05)Enjoyment (enjoyment and pleasure)2.52 (0.94)0.13 (0.04)2.80 (0.97)0.14 (0.04)Control (independence)2.51 (0.94)0.13 (0.08)2.80 (0.97)0.14 (0.04)† 6 observations missing values on SF-6D Role limitation domain; 12 observations missing PCS and MCS score; 2 observations missing values on SF-6D Role limitation2.82 (1.01)0.15 (0.09)observations missing Effects of Kidney Disease score; 2 observations missing values on ICECAP-O Attachment domain. †† 1 observation missing value on SF-6D Role limitationdomain; 2 observations missing KDQUL-36 PCS, MCS, Burden of Kidney Disease, and Symptoms of Kidney Disease score; 1 observation missing KDQUL-36 Effects of Kidney	Attachment (love and friendship)	3.25 (0.87)	0.22 (0.06)	3.27 (0.81)	0.22 (0.05)
Role (doing things that make you feel valued) 2.51 (0.82) 0.15 (0.04) 2.69 (0.85) 0.15 (0.05) Enjoyment (enjoyment and pleasure) 2.52 (0.94) 0.13 (0.04) 2.80 (0.97) 0.14 (0.04) Control (independence) 2.51 (0.94) 0.13 (0.08) 2.82 (1.01) 0.15 (0.09) † 6 observations missing values on SF-6D Role limitation domain; 12 observations missing PCS and MCS score; 2 observations missing symptoms of Kidney Disease score; 1 observations missing value on SF-6D Role limitation domain; 2 observations missing values on ICECAP-O Attachment domain. †† 1 observation missing value on SF-6D Role limitation domain; 2 observations missing values on ICECAP-O Attachment domain. †† 1 observation missing KDQU-36 Effects of Kidney Disease score; 1 observation missing KDQU-36 Effects of Kidney Disease score; 1 observation missing KDQU-36 Effects of Kidney Disease score; 1 observation missing KDQU-36 Effects of Kidney Disease score; 1 observation missing KDQU-36 Effects of Kidney Disease score; 1 observation missing KDQU-36 Effects of Kidney Disease score; 1 observation missing kDQU-36 Effects of Kidney Disease score; 1 observation missing kDQU-36 Effects of Kidney Disease score; 1 observation missing kDQU-36 Effects of Kidney Disease score; 1 observation missing kDQU-36 Effects of Kidney Disease score; 1 observation missing kDQU-36 Effects of Kidney Disease score; 1 observation missing kDQU-36 Effects of Kidney Disease score; 1 observation missing kDQU-36 Effects of Kidney Disease score; 1 observation missing kDQU-36 Effects of Kidney Disease score; 1 observation missing kDQU-36 Effects of Kidney Disease score; 1 observation missing kDQU-36 Effects of Kidney Disease score; 1 observation missing kDQU-36 Effects of Kidney Disease	Security (thinking about future without concern)	2.42 (0.99)	0.09 (0.05)	2.71 (0.92)	0.10 (0.05)
Enjoyment (enjoyment and pleasure) 2.52 (0.94) 0.13 (0.04) 2.80 (0.97) 0.14 (0.04) Control (independence) 2.51 (0.94) 0.13 (0.08) 2.82 (1.01) 0.15 (0.09) † 6 observations missing values on SF-6D Role limitation domain; 12 observations missing PCS and MCS score; 2 observations missing value on SF-6D Role limitation observations missing Effects of Kidney Disease score; 2 observations missing values on ICECAP-O Attachment domain. †† 1 observation missing value on SF-6D Role limitation domain; 2 observations missing KDQOL-36 PCS, MCS, Burden of Kidney Disease, and Symptoms of Kidney Disease score; 1 observation missing KDQOL-36 Effects of Kidney	Role (doing things that make you feel valued)	2.51 (0.82)	0.15(0.04)	2.69 (0.85)	0.15 (0.05)
Control (independence) 2.51 (0.94) 0.13 (0.08) 2.82 (1.01) 0.15 (0.09) † 6 observations missing values on SF-6D Role limitation domain; 12 observations missing PCS and MCS score; 2 observations missing symptoms of Kidney Disease score; 1 observations missing Effects of Kidney Disease score; 2 observations missing value on SF-6D Role limitation domain; 2 observations missing KDQOL-36 PCS, MCS, Burden of Kidney Disease, and Symptoms of Kidney Disease score; 1 observation missing KDQOL-36 Effects of Kidney	Enjoyment (enjoyment and pleasure)	2.52 (0.94)	0.13(0.04)	2.80 (0.97)	0.14 (0.04)
† 6 observations missing values on SF-6D Role limitation domain; 12 observations missing PCS and MCS score; 2 observations missing Symptoms of Kidney Disease score; 1 observation missing value on SF-6D Role limitation domain; 2 observations missing KDQOL-36 PCS, MCS, Burden of Kidney Disease, and Symptoms of Kidney Disease score; 1 observation missing KDQOL-36 Effects of Kidney Disease score; 1 observations missing works on all ICFCAD Annoine + SE-6D Annoine cores are weighted domaints. + 1 ICFCAD Annoine cores are weighted domaints.	Control (independence)	2.51 (0.94)	0.13(0.08)	2.82 (1.01)	0.15 (0.09)
observations missing Effects of Kidney Disease score; 2 observations missing values on ICECAP-O Attachment domain. †† 1 observation missing value on SF-6D Role limitation domain; 2 observations missing KDQOL-36 PCS, MCS, Burden of Kidney Disease, and Symptoms of Kidney Disease score; 1 observation missing KDQOL-36 Effects of Kidney Disease score; 1 observation missing value on all ICECAP-O Annalies + SE-6D Anna	† 6 observations missing values on SF-6D Role limits	ation domain; 1	2 observations missing PCS	and MCS score; 2 observations r	nissing Symptoms of Kidney Disease score; 1
domain; 2 observations missing KDQOL-36 PCS, MCS, Burden of Kidney Disease, and Symptoms of Kidney Disease score; 1 observation missing KDQOL-36 Effects of Kidney Disease scores 1 observation missing value on all ICECAD. Acquire + SE 6D Acquire scores are weighted decrements	observations missing Effects of Kidney Disease score;	; 2 observations	missing values on ICECAP-0	O Attachment domain. †† 1 obser	vation missing value on SF-6D Role limitation
Disasse scores 1 absenvation mission value on all ICECAD. Acmaine + SE-KD Acmain scores are weighted decrements ++ ICECAP. Acmain scores are weighted increments	domain; 2 observations missing KDQOL-36 PCS, MC	CS, Burden of K	idney Disease, and Symptom	ns of Kidney Disease score; 1 obse	rvation missing KDQOL-36 Effects of Kidney
	Disease score: 1 observation missing value on all ICE	CAP-O domair	is. ± SF-6D domain scores ar	re weighted decrements. ‡‡ ICEC	A P-O domain scores are weighted increments.

SD - Standard deviation. KDQOL-36 - Kidney disease quality of life with 36 items.

6 g g g g g g g g g g g g g h h h h h h	T-36 Burden of Kiturey Disease, Symposities	Supplementary fable 9 (fable 33); kD COL-36 Burden of Kitliney Disease, Symptoms 8f Kitliney Disease, and Effects of Ridfiey Disease scored of Kitliney Disease, Symptoms 8f Kitliney Disease, and Effects of Ridfiey Disease scored of scored of kitliney Disease, Symptoms 8f Kitliney Disease, and Effects of Ridfiey Disease scored of score	1 1 6 8 2 9 5 4 5 7 1 sescores according to patient
Characteristics	Burden of Kidney Disease $(n = 127)$	Symptoms of Kidney Disease $(n = 125)$ †	Effects of Kidney Disease (n = 127)‡
	Mean (95 % CI)	Mean (95 % CI)	Mean (95 % CI)
Age			
\leq 81 years	41.80 (34.47-49.12)	72.21 (67.15-77.27)	69.15 (63.05-75.25)
>81 years	47.16 (38.81-55.50)	73.35 (68.76-77.95)	71.35 (66.26-76.43)
Gender			
Males	44.43 (37.70-51.15)	74.00 (70.01-78.00)	71.48 (66.72-76.23)
Females	44.51 (34.62-54.39)	70.46 (64.13-76.79)	67.91 (60.77-75.05)
$Treatment^{**}$			
Dialysis	34.71 (28.65-40.78)*	70.71 (66.56-74.85)	64.18 $(59.72-68.63)$ *
Conservative Care	62.83 (53.88-71.78)*	76.61 (70.78-82.44)	81.29 (74.70-87.88)*
Country			
United Kingdom	37.81 (30.68-44.94)*	71.97 (67.37-76.58)	66.29 (61.31-71.28)*
Australia	51.88 (43.59-60.16)*	73.72 (68.64-78.81)	74.65 (68.52-80.77)*
Education§			Dper
Attended some high school	45.32 (38.85-51.79)	71.42 (67.21-75.63)	70.93 (66.29-75.57)
Completed high school or tertiary educa-	43.53 (32.44-54.61)	76.87 (72.15-81.59)	68.92 (61.06-76.79)
tion			
Private Health Insurance¶			
Yes	55.32 (41.82-68.83)*	73.33 (65.11-81.54)	75.85 (67.67-84.02)
No/Unknown	41.62 (35.62-47.63)*	72.88 (69.03-76.73)	69.32 (64.80-73.84)
† 2 out of 129 observations had missing value	es on burden of disease questions and their s	† 2 out of 129 observations had missing values on burden of disease questions and their score was not calculated; the remaining had 2 observations missing value for education variable;	rvations missing value for education variable;
4 observations missing value for health insura	ance variable. †† 4 out of 129 observations	4 observations missing value for health insurance variable. †† 4 out of 129 observations had missing values on symptoms of disease questions and their score was not calculated; the	ons and their score was not calculated; the
remaining had 2 observations missing value f	for education variable; 4 observations missir	remaining had 2 observations missing value for education variable; 4 observations missing value for health insurance variable. ‡ 2 out of 129 observations had missing values on effects	29 observations had missing values on effects
of disease questions and their score was not c	calculated; the remaining had 2 observations	missing value for education variable; 4 observati	ons missing value for health insurance
variable. * $p < 0.05$, statistical significance. ³	** The dialysis group consist of Facility Hae	smodialysis, Home Haemodialysis and Peritoneal	dialysis. § Individual responses to Primary
school/Some high school were merged into o University degree were merged into one cate;	me category as "Attended some high school" gory as "Completed high school or tertiary e	school/Some high school were merged into one category as "Attended some high school" and the responses to GCSEs/Completed high school/Diploma/TAFE/ Completed A- levels/ University degree were merged into one category as "Completed high school or tertiary education". ¶ Individual responses to "No" and "Unknown" were merged into one category as " w	ool/Diploma/TAFE/ Completed A- levels/ nknown" were merged into one category ക്റ്റ് ഗ
"No/Unknown". CI - Confidence interval. Kl	DQOL-36 - Kidney disease quality of life w	ith 36 items.	4 of 50
)

Supplementary Item 1 (Item S1): STROBE Statement: checklist of items that should be

included in reports of observational studies

	Item		Yes/No/NA,
	No	Recommendation	Page No.
Title and abstract	1	(<i>a</i>) Indicate the study's design with a commonly	Yes, page 1-
		used term in the title or the abstract	2
		(b) Provide in the abstract an informative and	Yes, Page
		balanced summary of what was done and what was	2-3
		found	
Introduction		0	
Background/rationale	2	Explain the scientific background and rationale for	Yes, Page
		the investigation being reported	4-7
Objectives	3	State specific objectives, including any pre-	Yes, Page 7
		specified hypotheses	
Methods		2	
Study design	4	Present key elements of study design early in the	Yes, Page 7
		paper	
Setting	5	Describe the setting, locations, and relevant dates,	Yes, Page
		including periods of recruitment, exposure, follow-	7-8
		up, and data collection	
Participants	6	<i>Cross-sectional study</i> —Give the eligibility criteria,	Yes, Page
		and the sources and methods of selection of	7-8
		participants	

Variables	7	Clearly define all outcomes, exposures, predictors,	Yes, Page
		potential confounders, and effect modifiers. Give	8-9
		diagnostic criteria, if applicable	
Data sources/	8*	For each variable of interest, give sources of data	Yes, Page
measurement		and details of methods of assessment	9-10
		(measurement). Describe comparability of	
		assessment methods if there is more than one	
Ċ),	group	
Bias	9	Describe any efforts to address potential sources of	Yes, Page
		bias	
Study size	10	Explain how the study size was arrived at	Yes,
			Protocol
		C.	Page 7
Quantitative variables	11	Explain how quantitative variables were handled in	Yes, Page
		the analyses. If applicable, describe which	10
		groupings were chosen and why	
Statistical methods	12	(a) Describe all statistical methods, including those	Yes, Page
		used to control for confounding	10-11
		(b) Describe any methods used to examine	Yes, Page
		subgroups and interactions	10-11
		(c) Explain how missing data were addressed	Yes, Page
			10-11
		Cross-sectional study—If applicable, describe	NA
		analytical methods taking account of sampling	
		strategy	

		(<u>e</u>) Describe any sensitivity analyses	NA
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—	No –
		e.g., numbers potentially eligible, examined for eligibility,	screening
		confirmed eligible, included in the study, completing	logs at eac
		follow-up, and analysed	site were
			not
	Ċ		available
		(b) Give reasons for non-participation at each stage	No
		(c) Consider use of a flow diagram	NA
Descriptive data	14*	(a) Give characteristics of study participants (e.g.,	Yes, Page
		demographic, clinical, social) and information on	7-8, 22
		exposures and potential confounders	
		(b) Indicate number of participants with missing data for	Yes, Page
		each variable of interest	12-14, 24
		(c) <i>Cohort study</i> —Summarise follow-up time (e.g.,	NA
		average and total amount)	
Outcome data	15*	Cross-sectional study—Report numbers of outcome events	Yes, Page
		or summary measures	11-14
Main results	16	(a) Give unadjusted estimates and, if applicable,	Yes, Page
		confounder-adjusted estimates and their precision (e.g.,	11-14, 23-
		95% confidence interval). Make clear which confounders	24
		were adjusted for and why they were included	

		(b) Report category boundaries when continuous variables	Yes, Page
		were categorised	11-14, 23-
			24
		(<i>c</i>) If relevant, consider translating estimates of relative	NA
		risk into absolute risk for a meaningful time period	
Other analyses	17	Report other analyses done—e.g., analyses of subgroups	Yes, Page
		and interactions, and sensitivity analyses	11-14
Discussion			
Key results	18	Summarise key results with reference to study objectives	Yes, Page
		P	15-16
Limitations	19	Discuss limitations of the study, taking into account	Yes, Page
		sources of potential bias or imprecision. Discuss both	17
		direction and magnitude of any potential bias	
Interpretation	20	Give a cautious overall interpretation of results considering	Yes, Page
		objectives, limitations, multiplicity of analyses, results	17
		from similar studies, and other relevant evidence	
Generalisability	21	Discuss the generalisability (external validity) of the study	Yes, Page
		results	17
Other information	on		
Funding	22	Give the source of funding and the role of the funders for	Yes, Page
		the present study and, if applicable, for the original study	18
		on which the present article is based	

 Supplementary Item 2 (Item S2): KDQOL-36 Questionnaire (SF-12: Questions 1 – 12 (converted to SF-utilities), KDQOL scores (PCS and MCS scores: Questions 1 – 12, burden of kidney disease: Questions 13 – 16, effects of kidney disease: Questions 17 – 28, symptoms of kidney disease: Questions 29 – 36)

Your Health – and – Well-Being

Kidney Disease and Quality of Life (KDQOL^{TM_36})

This survey asks for your views about your health. This information will help keep track of how you feel and how well you are able to do your usual activities.




Thank you for completing these questions!

Kidney Disease and Quality of Life™ (KDQOL™-36) English Version 1. Copyright © 2000 by RAND and the University of Arizona

Your Health

This survey includes a wide variety of questions about your health and your life. We are interested in how you feel about each of these issues.

1. In general, would you say your health is: [Mark an 🖂 in the one box that best describes your answer.]



The following items are about activities you might do during a typical day. <u>Does your health now limit</u> you in these activities? If so, how much? [Mark an 🔀 in a box on each line.]

		Yes, limited a lot	Yes, limited a little	No, not limited at all
2.	<u>Moderate activities</u> , such as moving a table, pushing a vacuum cleaner, bowling, or playing golf		2	🔲 3
3.	Climbing several flights of stairs		2	3

During the <u>past 4 weeks</u>, have you had any of the following problems with your work or other regular daily activities <u>as a result of your</u> <u>physical health</u>?

	[Yes	No
4.	Accomplished less than you would like	<u> </u>	1
5.	Were limited in the <u>kind</u> of work or other activities	1	2

During the past 4 weeks, have you had any of the following problems with your work or other regular daily activities as a result of any emotional problems (such as feeling depressed or anxious)?

		Yes	No
6.	Accomplished less than you would like	<u> </u>	2
7.	Didn't do work or other activities as <u>carefully</u> as usual	i	2

8. During the <u>past 4 weeks</u>, how much did <u>pain</u> interfere with your normal work (including both work outside the home and housework)?

5

These questions are about how you feel and how things have been with you <u>during the past 4 weeks</u>. For each question, please give the one answer that comes closest to the way you have been feeling.

How much of the time during the past 4 weeks ...

	Г						
		All of the time	Most of the time	A good bit of the time	Some of the time	A little of the time	None of the time
9.	Have you felt calm and peaceful?	1	2	3	4	5	🗌 ó
10.	Did you have a lot of energy?	1	2	🗌 3		5	🔲 6
11.	Have you felt downhearted and blue? .	i	2	🗌 3	4	🔲 s	🗌 6

12. During the <u>past 4 weeks</u>, how much of the time has your <u>physical</u> <u>health or emotional problems</u> interfered with your social activities (like visiting with friends, relatives, etc.)?

All of the time	Most of the time	Some of the time	A little of the time	I
ι	2	3	4	5

	How <u>true</u> or <u>fals</u>	e is each o	f the follow	ving staten	nents for y	you?
		Definitely true	Mostly true	Don't know	Mostly false	Definitely false
13.	My kidney disease interferes too much with my life					3
14.	Too much of my time is spent dealing with my kidney disease	1	2	3	4	
15.	I feel frustrated dealing with my kidney disease	i	2	2	4	5
16.	I feel like a burden on my family	1	2	2	4	5

2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
51
52
53
54
55
56
57
58
59

1

During the <u>past 4 weeks</u>, to what extent were you bothered by each of the following?

				P	Very much bothered	
17.	Soreness in your muscles?	1	2	3	4	5
18.	Chest pain?	1		3	d	5
19.	Cramps?	i		3	4	5
20.	Itchy skin?	<u> </u>		Е з	4	5
21.	Dry skin?	i	2	B 3	4	5
22.	Shortness of breath?	<u> </u>	2	3	4	5
23.	Faintness or dizziness?	i	2	3	4	s
24.	Lack of appetite?	1		в з	4	5
25.	Washed out or drained?	1	2	2	4	5
26.	Numbness in hands or feet?	1	2	3	4	5
27.	Nausea or upset stomach?	1	2	3	4	5
28 ^a .	(Hemodialysis patie	nt only)				
	Problems with your access site?		2	3	4	s
28 ^b .	(Peritoneal dialysis	patient only))			
	Problems with your catheter site?	1	2	2	4	s

Effects of Kidney Disease on Your Daily Life

Some people are bothered by the effects of kidney disease on their daily life, while others are not. How much does kidney disease <u>bother</u> you in each of the following areas?


		Not at all	Somewhat	Moderately	Very much	Extremely
		bothered	bothered	bothered	bothered	bothered
29.	Fluid restriction?	<u> </u>	2	3	↓	5
30.	Dietary restriction?	1	2	3	4	s
31.	Your ability to work around the house?	1	2	3	4	🚺 s
32.	Your ability to travel?	1	2	3	4	s
33.	Being dependent on doctors and other medical staff?	1	2	2	4	🗖 s
34.	Stress or worries caused by kidney disease?	1	2	8	4	5
35.	Your sex life?	1		3	4	5
36.	Your personal appearance?	<u> </u>	2	3	4	5

BMJ Open

Supplementary Item 3 (Item S3): ICECAP-O Questionnaire

ABOUT YOUR QUALITY OF LIFE

By placing a tick (\checkmark) in ONE box in EACH group below, please indicate which statement best describes your quality of life at the moment.





Q1.	What is your full name?	
Q2.	What is your date of birth?	(<i>dd/mm/yyyy</i>)
Q3.	Gender (please tick one)	
	Male 🗆	
	Female 🗆	
Q4.	What is your main residential po	stcode?
Q5.	What was your country of birth?	
Q6.	What is the highest level of educ	ation you have completed? (please
	box that best describes you)	
	Primary school	
	Some high school	
	Completed high school	
	Completed Diploma/ TAFE cour	rse 🗆
	Completed University Degree	
Q7.	Do you have private health insur	
	Yes 🗆	
	No 🗆	
	Don't know	
Q8.	What type of kidney treatment as	re you <i>currently</i> having? (<i>please tic</i>
	Hemodialysis (satellite or hospit	al) 🗆
	Hemodialysis at home	
	Peritoneal dialysis	
	Non-dialysis renal supportive ca	re 🗆

Q9. If you are currently on dialysis when did you first start dialysis?

_____(mm/yyyy)

Q10. Have you ever had a kidney transplant before? (*please tick one*)

 $Yes \quad \Box \quad No \ \Box$

Q11. The next two questions are about the **ICECAP-O survey.** On the scale below please rate how <u>easy</u> this survey was to complete *(circle a number between 1)*

and 5)

Very easy	Somewhat	Neutral	Somewhat	Very
	easy		difficult	difficult
1	2	3	4	5

Q12. Did this survey measure the things that you consider <u>important</u> to your quality of life? *(circle a number between 1 and 5)*

Somewhat	Neutral	Somewhat	Completely
agree	0	disagree	disagree
2	3	4	5

Q13. If you responded with 'somewhat disagree' or 'completely disagree,' would

you like to tell us what you think the ICECAP-O survey was missing?

BMJ Open

Q14. The next two questions are about the SF-12 survey. On the scale below please rate

how <u>easy</u> this survey was to complete (circle a number between 1 and 5)

Very easy	Somewhat	Neutral	Somewhat	Very
	easy		difficult	difficult
1	2	3	4	5

Q15. Did this survey measure the things that you consider <u>important</u> to your quality of life? *(circle a number between 1 and 5)*

Completely	Somewhat	Neutral	Somewhat	Completely
agree	agree		disagree	disagree
1	2	3	4	5
1	2	3	4	

Q16. If you responded with 'somewhat disagree' or 'completely disagree,' would

you like to tell us what you think the SF-12 survey was missing?

Supplementary Item 5 (Item S5): SF-6D domains

Level	SF-6D				
	Physical Functioning				
1	Your health does not limit you in vigorous activities				
2					
3	Your health limits you a little in vigorous activities				
	Your health limits you a little in moderate activities				
4	Your health limits you a lot in moderate activities				
5	Your health limits you a little in bathing and dressing				
6	Your health limits you a lot in bathing and dressing				
	Role limitations				
1	You have no problems with your work or other regular				
1	daily activities as a result of your physical health or any emotional problems				
2	You are limited in the kind of work or other activities as a				
-	result of your physical health				
3	You accomplish less than you would like as a result of				
3					
4	emotional problems				
4	You are limited in the kind of work or other activities as a				
	result of your physical health and accomplish less than				
	you would like as a result of emotional problems				
	Social functioning				
1	Your health limits your social activities none of the time				
2	Your health limits your social activities a little of the time				
3	Your health limits your social activities some of the time				
4	Your health limits your social activities <i>most of the time</i>				
5	Your health limits your social activities all of the time				
5					
	Pain				
1	You have no pain				
2	You have pain but it does not interfere with your normal				
	work (both outside the home and housework)				
3	You have pain that interferes with your normal work				
	(both outside the home and housework) a little bit				
4	You have pain that interferes with your normal work				
	(both outside the home and housework) moderately				
5	You have pain that interferes with your normal work				
- 00	(both outside the home and housework) quite a bit				
6	You have pain that interferes with your normal work				
0	(both outside the home and housework) <i>extremely</i>				
	Mental health				
1	You feel tense or downhearted and low none of the time				
2	You feel tense or downhearted and low a little of the time				
3	You feel tense or downhearted and low some of the time				
4	You feel tense or downhearted and low most of the time				
5	You feel tense or downhearted and low all of the time				
ĩ	Vitality Xon have a lot of anarow all of the time				
1	You have a lot of energy all of the time				
2	You have a lot of energy most of the time				
3	You have a lot of energy some of the time				
4	You have a lot of energy a little of the time				
5	You have a lot of energy <i>none of the time</i>				

Copyright © 2004 John Wiley & Sons, Ltd.